<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1810200222
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Inhixa
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENOXAPARIN SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Subcutaneous
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C Don't Freez
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        53.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Shenzhen Techdow Pharmaceutical Co Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Shenzhen Techdow Pharmaceutical Co Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Techdow Pharma Netherlands B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Inhixa contains the active substance called enoxaparin sodium that is a low molecular weight heparin (LMWH).</p><p>&nbsp;</p><p>Inhixa works in two ways.</p><p>1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stopping existing blood clots from getting any bigger. This helps your body to break them down and stop them causing you harm.</p><p>2) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stopping blood clots forming in your blood.</p><p><strong>&nbsp;</strong></p><p>Inhixa can be used to:</p><ul><li>Treat blood clots that are in your blood</li><li>Stop blood clots from forming in your blood in the following situations:<ul><li>Before and after an operation</li><li>When you have an acute illness and face period of limited mobility</li><li>When you have unstable angina (a condition when not enough blood gets to your heart)</li><li>After a heart attack</li></ul></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop blood clots forming in the tubes of your dialysis machine (used for people with severe kidney problems).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Inhixa</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to enoxaparin sodium or any of the other ingredients of this medicine (listed in section 6). Signs of an allergic reaction include: rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to heparin or other low molecular weight heparins such as nadroparin, tinzaparin or dalteparin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had a reaction to heparin that caused a severe drop in the number of your clotting cells (platelets) - this reaction is called heparin-induced thrombocytopenia - within the last 100 days or if you have antibodies against enoxaparin in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are bleeding heavily or have a condition with a high risk of bleeding (such as stomach ulcer, recent surgery of the brain or eyes), including recent bleeding stroke.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using Inhixa to treat blood clots in your body and going to receive spinal or epidural anaesthesia or lumbar puncture within 24 hours.</p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Inhixa</strong></p><p>Inhixa should not be used interchangeably with other medicines belonging to the group of low molecular weight heparins. This is because they are not exactly the same and do not have the same activity and instructions for use.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before using Inhixa if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a reaction to heparin that caused a severe drop in the number of your platelets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are going to receive spinal or epidural anesthesia or lumbar puncture (see Operations and Anaesthetics): a delay should be respected between Inhixa use and this procedure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a heart valve fitted</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have endocarditis (an infection of the inner lining of the heart)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have history of gastric ulcer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a recent stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have diabetes or&nbsp; problems with blood vessels in the eye caused by diabetes (called diabetic retinopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had an operation recently on your eyes or brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are elderly (over 65 years old) and especially if you are over 75 years old</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are underweight or overweight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have high level of potassium in your blood (this may be checked with a blood test)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are currently using medicines which affect bleeding (see section below &ndash; Other medicines).</p><p>&nbsp;</p><p>You may have a blood test before you start using this medicine and at intervals while you are using it; this is to check the level of the clotting cells (platelets) and potassium in your blood.</p><p><strong>&nbsp;</strong></p><p><strong>Taking o</strong><strong>ther medicines</strong><strong>, herbal or dietary supplements</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&middot;&nbsp; Warfarin &ndash; used for thinning the blood</p><p>&middot;&nbsp; Aspirin (also known as acetylsalicylic acid or ASA), clopidogrel or other medicines used to stop blood clots from forming (see also in section 3, &ldquo;Changing of anticoagulant medicine&rdquo;)</p><p>&middot;&nbsp; Dextran injection &ndash; used as a blood replacer</p><p>&middot;&nbsp; Ibuprofen, diclofenac, ketorolac or other medicines known as non-steroidal anti-inflammatory agents which are used to treat pain and swelling in arthritis and other conditions</p><p>&middot;&nbsp; Prednisolone, dexamethasone or other medicines used to treat asthma, rheumatoid arthritis and other conditions</p><p>&middot;&nbsp; Medicines which increase potassium level in your blood such as potassium salts, water pills, some medicines for heart problems.</p><p><strong>&nbsp;</strong></p><p><strong>Operations and anesthetics</strong></p><p>If you are going to have a spinal puncture or an operation where an epidural or spinal anaesthetic is used, tell your doctor that you are using Inhixa. See &ldquo;Do not use Inhixa&rdquo;. Also, tell your doctor if you have any problem with your spine or if you ever had spinal surgery.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>If you are pregnant and have a mechanical heart valve, you may be at an increased risk of developing blood clots. Your doctor should discuss this with you.</p><p><strong>&nbsp;</strong></p><p>If you are breast-feeding or plan to breast-feed, you should ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Inhixa does not affect the ability to drive and operate machinery.</p><p><strong>&nbsp;</strong></p><p>It is advised that the trade name and batch number of the product you are using are recorded by your healthcare professional.</p><p><strong>&nbsp;</strong></p><p><strong>Important information about some of the ingredients of</strong><strong> Inhixa</strong></p><p>This medicine contains less than 1 mmol sodium (23&nbsp;mg) per dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Having this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or nurse will normally give you Inhixa. This is because it needs to be given as an injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you go home, you may need to continue to use Inhixa and give it yourself (see instructions below on how to do this).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhixa is usually given by injection underneath the skin (subcutaneous).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhixa can be given by injection into your vein (intravenous) after certain types of heart attack or operation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhixa can be added to the tube leaving the body (arterial line) at the start of the dialysis session.</p><p>Do not inject Inhixa into a muscle.</p><p><strong>&nbsp;</strong></p><p><strong>How much will be given to you</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how much Inhixa to give you. The amount will depend on the reason it is being used.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have problems with your kidneys you may be given a smaller amount of Inhixa.</p><p>&nbsp;</p><p>1. Treating blood clots that are in your blood</p><ul><li>The usual dose is 150&nbsp;IU (1.5&nbsp;mg) for every kilogram of your weight each day or 100&nbsp;IU (1 mg) for every kilogram of your weight twice a day.</li><li>Your doctor will decide how long you should receive Inhixa.</li></ul><p>&nbsp;</p><p>2. Stopping blood clots forming in your blood in the following situations:</p><p>v&nbsp; <em>Operation or periods of limited mobility due to an illness</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose will depend on how likely you are to develop a clot. You will be given 2,000&nbsp;IU (20&nbsp;mg) or 4,000&nbsp;IU (40&nbsp;mg) of Inhixa each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are going to have an operation your first injection will be usually given 2&nbsp;hours or 12&nbsp;hours before your operation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have restricted mobility due to illness, you will normally be given 4,000&nbsp;IU (40&nbsp;mg) of Inhixa each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how long you should receive Inhixa.</p><p><em>&nbsp;</em></p><p>v&nbsp; <em>After you have had a heart attack</em></p><p>Inhixa can be used for two different types of heart attack called STEMI (ST segment elevation myocardial infarction) or Non STEMI (NSTEMI). The amount of Inhixa given to you will depend on your age and the kind of heart attack you have had.</p><p>&nbsp;</p><p>NSTEMI type of heart attack:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 100&nbsp;IU (1&nbsp;mg) for every kilogram of weight every 12&nbsp;hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will normally ask you to take aspirin (acetylsalicylic acid) as well.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how long you should receive Inhixa.</p><p>&nbsp;</p><p>STEMI type of heart attack if you are under 75&nbsp;years old:</p><p>&middot;&nbsp;&nbsp; An initial dose of 3,000&nbsp;IU (30&nbsp;mg) of Inhixa&nbsp; will be given as injection into your vein.</p><p>&middot;&nbsp;&nbsp; At the same time you will also be given Inhixa as an injection underneath your skin (subcutaneous injection). The usual dose is 100&nbsp;IU (1&nbsp;mg) for every kilogram of your weight, every 12&nbsp;hours.</p><p>&middot;&nbsp;&nbsp; Your doctor will normally ask you to take aspirin (acetylsalicylic acid) as well.</p><p>&middot;&nbsp;&nbsp; Your doctor will decide how long you should receive Inhixa.</p><p>&nbsp;</p><p>STEMI type of heart attack if you are 75&nbsp;years old or older:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 75&nbsp;IU (0.75&nbsp;mg) for every kilogram of your weight, every 12&nbsp;hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximum amount of Inhixa given for the first two injections is 7,500&nbsp;IU (75&nbsp;mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how long you should receive Inhixa.</p><p>&nbsp;</p><p>For patients have an operation called percutaneous coronary intervention (PCI):</p><p>Depending on when you were last given Inhixa, your doctor may decide to give an additional dose of Inhixa before a PCI operation. This is by injection into your vein.</p><p><strong>&nbsp;</strong></p><p>3. Stopping blood clots from forming in the tubes of your dialysis machine</p><p>&middot;&nbsp;&nbsp; The usual dose is 100&nbsp;IU (1&nbsp;mg) for every kilogram of your weight.</p><p>&middot;&nbsp;&nbsp; Inhixa is added to the tube leaving the body (arterial line) at the start of the dialysis session. This amount is usually enough for a 4-hour session. However, your doctor may give you a further dose of 50&nbsp;IU to 100&nbsp;IU (0.5 to 1&nbsp;mg) for every kilogram of your weight, if necessary.</p><p><u>&nbsp;</u></p><p><u>How to give yourself an injection of Inhixa</u></p><p>If you are able to give this medicine to yourself, your doctor or nurse will show you how to do this. Do not try to inject yourself if you have not been trained how to do so. If you are not sure what to do, talk to your doctor or nurse immediately.</p><p><strong>&nbsp;</strong></p><p><strong><em>Before injecting yourself with Inhixa</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the expiry date on the medicine. Do not use if the date has passed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the syringe is not damaged and the medicine in it is a clear solution. If not, use another syringe.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice any change in the appearance of the product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure you know how much you are going to inject.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check your abdomen to see if the last injection caused any redness, change in skin colour, swelling, oozing or is still painful, if so talk to your doctor or nurse.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decide where you are going to inject the medicine. Change the place where you inject each time from the right to the left side of your stomach. This medicine should be injected just under the skin on your stomach, but not too near the belly button or any scar tissue (at least 5 cm away from these).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The pre-filled syringe is intended for single use only.</p><p>&nbsp;</p><p><strong><em>Instructions on injecting yourself with Inhixa</em></strong></p><p><strong>1)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands and the area that you will inject with soap and water. Dry them.</p><p><strong>2)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sit or lie in a comfortable position so you are relaxed. Make sure you can see the place you are going to inject. A lounge chair, recliner, or bed propped up with pillows is ideal.</p><p><strong>3)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose an area on the right or left side of your stomach. This should be at least 5&nbsp;cm away from your belly button and out towards your sides.</p><p><strong>&nbsp;</strong></p><p><strong>Remember:</strong> Do not inject yourself within 5&nbsp;cm of your belly button or around existing scars or bruises. Change the place where you inject between the left and right sides of your stomach, depending on the area you were last injected.</p><p><strong>&nbsp;</strong></p><p><strong>4)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully pull off the needle cap from the syringe. Throw away the cap. The syringe is pre-filled and ready to use.</p><p><img alt="" width="314" height="284" src="data:image/jpeg;base64,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" /></p><p><strong>Do not</strong> press on the plunger before injecting yourself to get rid of air bubbles. This can lead to a loss of the medicine. Once you have removed the cap, do not allow the needle to touch anything. This is to make sure the needle stays clean (sterile).</p><p>&nbsp;</p><p><strong>5)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the syringe in the hand you write with (like a pencil) and with your other hand, gently pinch the cleaned area of your abdomen between your forefinger and thumb to make a fold in the skin.</p><p>&nbsp;</p><p>Make sure you <strong>hold the skin fold throughout the injection.</strong></p><p><strong>&nbsp;</strong></p><p><strong>6)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the syringe so that the needle is pointing downwards (vertically at a 90&ordm; angle). Insert the full length of the needle into the skin fold.</p><p>&nbsp;</p><p><img alt="" width="381" height="303" src="data:image/jpeg;base64,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" /></p><p><strong>&nbsp;</strong></p><p><strong>7)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press down on the plunger with your finger. This will send the medicine into the fatty tissue of the stomach. Make sure you hold the skin fold throughout the injection.</p><p>&nbsp;</p><p><strong>8)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the needle by pulling it straight out.</p><p><img alt="" width="393" height="386" src="data:image/jpeg;base64,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" /></p><p><strong>To avoid bruising, do not rub the injection site after you have injected yourself.</strong></p><p>&nbsp;</p><p><strong>9)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drop the used syringe with its protective sleeve into the sharps bin. Close the container lid tightly and place the container out of reach of children.</p><p><strong>&nbsp;</strong></p><p><strong>When the container is full, give it to your doctor or home care nurse for disposal. Do not put it in the household rubbish.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Changing of anticoagulant treatment</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from Inhixa to blood thinners called vitamin-K antagonists (e.g. warfarin)</em></p><p>Your doctor will request you perform blood tests called INR and tell you when to stop Inhixa accordingly.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from blood thinners called vitamin-K antagonists (e.g. warfarin) to Inhixa</em><em> </em><em>&nbsp;</em></p><p>Stop taking the vitamin-K antagonist. Your doctor will request you perform blood tests called INR and tell you when to start Inhixa accordingly.</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from Inhixa</em><em> </em><em>to treatment with </em><em>direct oral anticoagulant</em><em> </em>Stop taking Inhixa. Start taking the direct oral anticoagulant 0-2 hours before the time you would have had the next injection, then continue as normal.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from treatment with direct oral anticoagulant to Inhixa</em></p><p>Stop taking direct oral anticoagulant. Do not start treatment with Inhixa until 12 hours after the final dose of direct oral anticoagulant.</p><p><strong>&nbsp;</strong></p><p><strong>Use in children and adolescents</strong></p><p>The safety and efficacy of Inhixa has not been evaluated in children or adolescents.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more Inhixa than you should</strong></p><p>If you think that you have used too much or too little Inhixa, tell your doctor, nurse or pharmacist immediately, even if you have no signs of a problem. If a child accidentally injects or swallows Inhixa, take them to a hospital causualty department straight away.</p><p>&nbsp;</p><p><strong>If you forget to use Inhixa</strong></p><p>If you forget to give yourself a dose, have it as soon as you remember. Do not give yourself a double dose on the same day to make up for a forgotten dose. Keeping a diary will help to make sure you do not miss a dose.</p><p>&nbsp;</p><p><strong>If you stop using Inhixa </strong></p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.</p><p>It is important for you to keep having Inhixa injections until your doctor decides to stop them. If you stop, you could get a blood clot which can be very dangerous.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Inhixa can cause side effects, although not everybody gets them.</p><p>Like other similar medicines (medicines to reduce blood clotting), Inhixa may cause bleeding which may potentially be life-threatening. In some cases the bleeding may not be obvious.</p><p>&nbsp;</p><p>If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling), consult your doctor immediately.</p><p>Your doctor may decide to keep you under closer observation or change your medicine.</p><p>&nbsp;</p><p>Stop using Inhixa and talk to a doctor or nurse at once if you get any signs of a severe allergic reaction (such as difficulty breathing, swelling of the lips, mouth, throat or eyes).</p><p>&nbsp;</p><p>You should tell your doctor straight away</p><p>&middot;&nbsp; If you have any sign of blockage of a blood vessel by a blood clot such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cramping pain, redness, warmth,&nbsp;or swelling in&nbsp;one of your&nbsp;legs&nbsp;&ndash; these are&nbsp;symptoms of deep vein thrombosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness, chest pain, fainting or&nbsp;coughing up blood&nbsp;&ndash; these are&nbsp;symptoms of a pulmonary embolism</p><p>&middot;&nbsp; If you have a painful rash of dark red spots under the skin which do not go away when you put pressure on them.</p><p>Your doctor may request you perform a blood test to check your platelet count.</p><p>&nbsp;</p><p><strong>Overall list of possible side effects:</strong></p><p><u>Very common </u>( may affect more than 1 in 10 people)</p><ul><li>Bleeding.</li><li>Increases in liver enzymes.</li></ul><p>&nbsp;</p><p><u>Common</u> (may affect up to 1 in 10 people)</p><p>&middot;&nbsp; You bruise more easily than usual. This could be because of a blood problem with low platelet counts.</p><p>&middot;&nbsp; Pink patches on your skin. These are more likely to appear in the area you have been injected with Inhixa.</p><ul><li>Skin rash (hives, urticaria).</li><li>Itchy red skin.</li><li>Bruising or pain at the injection site.</li><li>Decreased red blood cell count.</li><li>High platelet counts in the blood.</li><li>Headache.</li></ul><p><u>&nbsp;</u></p><p><u>Uncommon</u> (may affect up to 1 in 100 people)</p><ul><li>Sudden severe headache. This could be a sign of bleeding in the brain.</li><li>A feeling of tenderness and swelling in your stomach. You may have bleeding in your stomach.</li><li>Large red irregularly shaped skin lesions with or without blisters.</li></ul><ul><li>Skin irritation (local irritation).</li><li>You notice yellowing of your skin or eyes and your urine becomes darker in colour. This could be a liver problem.</li></ul><p>&nbsp;</p><p><u>Rare</u> (may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp; Severe allergic reaction.&nbsp; The signs may include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.</p><p>&middot;&nbsp; Increased potassium in your blood. This is more likely to happen in people with kidney problems or diabetes. Your doctor will be able to check this by carrying out a blood test.</p><p>&middot;&nbsp; An increase in the number of eosinophils in your blood. Your doctor will be able to check this by carrying out a blood test.</p><p>&middot;&nbsp; Hair loss.</p><p>&middot;&nbsp; Osteoporosis (a condition where your bones are more likely to break) after long term use.</p><p>&middot;&nbsp; Tingling, numbness and muscular weakness (particularly in the lower part of your body) when you have had a spinal puncture or a spinal anaesthetic.</p><p>&middot;&nbsp; Lost of control over your bladder or bowel (so you cannot control when you go to the toilet).</p><p>&middot;&nbsp; Hard mass or lump at the injection site.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Store below 30&nbsp;&deg;C. Do not freeze.</p><p>After dilution the solution should be used within 8&nbsp;hours.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p><p>Do not use Inhixa if you notice any visible change in the appearance of the solution.</p><p>&nbsp;</p><p>The Inhixa pre-filled syringes are for single dose use only. Discard any unused medicine.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Inhixa contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is enoxaparin sodium.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each mL contains 100&nbsp;mg enoxaparin sodium<em>.</em></p><p>Each pre‑filled syringe of 0.2&nbsp;mL contains 2,000 IU (20&nbsp;mg) of enoxaparin sodium.</p><p>Each pre‑filled syringe of 0.4&nbsp;mL contains 4,000 IU (40&nbsp;mg) of enoxaparin sodium.</p><p>Each pre‑filled syringe of 0.6&nbsp;mL contains 6,000 IU (60&nbsp;mg) of enoxaparin sodium.</p><p>Each pre‑filled syringe of 0.8&nbsp;mL contains 8,000 IU (80&nbsp;mg) of enoxaparin sodium.</p><p>Each pre‑filled syringe of 1.0&nbsp;mL contains 10,000 IU (100&nbsp;mg) of enoxaparin sodium.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each mL contains 150&nbsp;mg enoxaparin sodium<em>.</em></p><p>Each pre‑filled syringe of 0.8&nbsp;mL contains 12,000 IU (120&nbsp;mg) of enoxaparin sodium.</p><p>Each pre‑filled syringe of 1&nbsp;mL contains 15,000 IU (150&nbsp;mg) of enoxaparin sodium.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection is 0.2 mL of solution in:
-	a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a blue polypropylene plunger rod. 

Supplied in packs of: 
-	2 pre filled syringes

Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection is 0.4 mL of solution in:
-	a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a yellow polypropylene plunger rod.

Supplied in packs of: 
-	2 pre filled syringes

Inhixa 6,000 IU (60 mg)/0.6 mL solution for injection is 0.6 mL of solution in:
-	a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and an orange polypropylene plunger rod. 

Supplied in packs of: 
-	2 pre filled syringes

Inhixa 8,000 IU (80 mg)/0.8 mL solution for injection is 0.8 mL of solution in:
-	a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a red polypropylene plunger rod. 

Supplied in packs of: 
-	2 pre filled syringes
-	
Inhixa 10,000 IU (100 mg)/1 mL solution for injection is 1 mL of solution in:
-	a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a dark polypropylene plunger rod. 

Supplied in packs of: 
-	2 pre filled syringes

Inhixa 12,000 IU (120 mg)/0.8 mL is 0.8 mL of solution in:
-	a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a purple polypropylene plunger rod.

Supplied in packs of:
-	2 pre filled syringes,

Inhixa 15,000 IU (150 mg)/1 mL is 1 mL of solution in:
-	a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a dark blue polypropylene plunger rod. 

Supplied in packs of:
-	2 pre filled syringes,

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Techdow Europe AB</p><p>K&aring;bov&auml;gen 32</p><p>75236 Uppsala</p><p>Sweden</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p><strong>&nbsp;</strong>Shenzhen Techdow Pharmaceutical Co., Ltd.</p><p>No. 19, Gaoxinzhongyi Road</p><p>Shenzhen</p><p>China</p><p>&nbsp;</p><p>Health-Med sp&oacute;łka z ograniczoną odpowiedzialnością sp.k.</p><p>Chełmska 30/34</p><p>00-725 Warsaw</p><p>Poland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2020, version number 001
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي إنهيكسا على المادة الفعالة التي تُدعى إنوكسابارين صوديوم وهي من الهيبارين منخفض الوزن الجزيئي (إل إم دبليو إش LMWH)</p><p dir="RTL">يعمل إنهيكسا بطريقتين:</p><p dir="RTL">1)&nbsp;&nbsp;&nbsp; يعمل على منع زيادة حجم الجلطات الدموية التي تشكلت بالفعل. وهذا يساعد الجسم في تفتيتها وبالتالي يمنعها من أن تسبب لك الأذى.</p><p dir="RTL">2)&nbsp;&nbsp;&nbsp; يعمل على منع تكوّن جلطات الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام إنهيكسا في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج جلطات الدم التي تشكلت في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع تكوّن جلطات الدم في دمك في الحالات التالية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل وبعد أي عملية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند إصابتك بمرض حاد يحدّ من حركتك</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذ كنت مصابًا بالذبحة الصدرية الغير مستقرة (حالة تنتج عن عدم حصول القلب على الدم بشكل كافٍ)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد التعرض لنوبة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع تكوّن جلطات الدم في أنابيب آلة غسيل الكلى (التي تُستخدم للأشخاص الذين يعانون من مشاكل شديدة في الكلى)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم إنهيكسا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية نحو إنوكسابارين صوديوم أو نحو أي من المكونات الأخرى في هذا الدواء (المدرجة في الفقرة رقم 6). تتضمن أعراض الحساسية: طفح جلدي، صعوبة في التنفس أو البلع، تورّم الشفتين، الوجه، الحلق أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية نحو الهيبارين أو نحو أيّ من أنواع الهيبارين منخفض الوزن الجزيئي مثل نادروبارين، تينزابارين، أو دالتيبارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق وتعرضت لرد فعل مع استخدام الهيبارين أدّى إلى انخفاض شديد في عدد الخلايا التي تعمل على تخثّر الدم لديك (نقص الصفائح الدّمويّة) -يُسمّى هذا التفاعل نقص الصفائح الدموية الناجم عن الهيبارين &ndash; خلال 100 يوم الماضية أو إذا كان لديك أجسام مضادة للإنوكسابارين في دمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنزف بشدة أو تعاني من حالة مرضية تُعرّضك لخطر كبير لحدوث النزيف (مثل قرحة المعدة، جراحة حديثة في الدماغ أو العينين)، بما في ذلك السكتة الدماغية النّزفيّة الحديثة العهد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم إنهيكسا لعلاج جلطات الدم في جسدك وتنوي الخضوع للتخدير الشوكي أو فوق الجافية أو للبزل القطني (سحب عيّنة من النخاع الشوكي) خلال 24 ساعة.</p><p dir="RTL"><strong>التزم العناية الشديدة أثناء استخدام إنهيكسا </strong><br />ينبغي تجنّب استخدام إنهيكسا بالتبادل مع أيّ من الأدوية الأخرى التي تنتمي إلى مجموعة الهيبارين منخفض الوزن الجزيئي. وذلك لأنهم لا يُعدّون نظائر متشابهة تماماً وهناك اختلافات بينهم تتعلق بنطاق النشاط وتعليمات الاستخدام.</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل أن تستخدم إنهيكسا إذا:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>سبق وتعرّضت لرد فعل أثناء استخدام الهيبارين أدى إلى انخفاض شديد في عدد الصفائح الدموية لديك</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كنت ستخضع للتخدير الشوكي أو فوق الجافية أو للبزل القطني (أنظر العمليات والتخدير): يجب احتساب فترة زمنية بين استخدام &nbsp;إنهيكسا وهذا الإجراء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>سبق وخضعت لعملية تركيب صمام للقلب</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كان لديك التهاب الشغاف (عدوى البطانة الداخلية للقلب)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كان لديك تاريخ من الإصابة بقرحة المعدة</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تعرّضت مؤخرًا لسكتة دماغيّة</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كنت تعاني من ضغط الدم المرتفع</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كنت مصابًا بمرض السكري أو لديك مشاكل في الأوعية الدموية في العين بسبب مرض السكري (يسمى اعتلال الشبكية السكري)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>خضعت مؤخراً لجراحة في العينين أو الدماغ</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كنت من كبار السن (تتجاوز 65 سنة من العمر) وخاصة إذا تجاوزت 75 سنة من العمر</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كان لديك مشاكل في الكلى</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كان لديك مشاكل في الكبد</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كان لديك نقص أو زيادة في الوزن</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كان مستوى البوتاسيوم مرتفع لديك في الدم (يمكن الكشف عن ذلك من خلال فحص الدم)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كنت تستخدم حاليًّا أدوية تؤثر على النزيف (أنظر الفقرة أدناه &ndash; أدوية أخرى)</p><p dir="RTL">قد تخضع لفحص الدم عند البدء باستخدام هذا الدواء ثم خلال فترات منتظمة أثناء الاستخدام؛ وذلك للتحقق من عدد خلايا التخثر (الصفائح الدموية) ومستوى البوتاسيوم في دمك.</p><p dir="RTL"><strong>استخدام أدوية أخرى، والمكمّلات الغذائيّة والعشبية </strong><br />أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تتناول، تناولت مؤخرًا أو قد تتناول/تستخدم أي دواء آخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوارفارين &ndash; يعمل على سيولة الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسبرين (يُعرف أيضا بأسيتيل ساليساليك أسيد أو ASA)، كلوبيدوجريل أو أدوية أخرى تعمل على منع تكوّن جلطات الدم (أنظر أيضاً الفقرة 3، &quot;تغيير الأدوية المضادة لتخثر الدم&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقن ديكستران &ndash; يعمل كبديل عن الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيبوبروفين، ديكلوفيناك، كيتورولاك أو أدوية أخرى تُعرف بمضادات الالتهاب غير الاستيرودية والتي تُستخدم في تسكين الألم والحد من التورم الناجم عن التهاب المفاصل وغير ذلك من الحالات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بريدنيزولون، ديكساميثازون أو أدوية أخرى تُستخدم في علاج الربو، التهاب المفاصل الروماتويدي وحالات أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تسبب ارتفاع في مستوى البوتاسيوم في دمك مثل أملاح البوتاسيوم، الأقراص المُدرّة للبول، وبعض الأدوية التي تُعالج مشاكل في القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العمليّات والتخدير</strong><br />أخبر طبيبك أنك تستخدم إنهيكسا إذا كنت ستخضع لإجراء البزْل القَطَنيّ (سحب عينة من النخاع) &nbsp;أو لعملية يُستخدم لأجلها التخدير الشوكي أو فوق الجافية. أنظر &quot;لا تستخدم إنهيكسا&quot;. أخبر طبيبك أيضًا إذا كان لديك أي مشكلة في العمود الفقري أو إذا أُجريت لك عملية في العمود الفقري في السابق.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong><br />استشيري طبيبك أو الصيدلي قبل استخدام هذا الدواء إذا كنت حاملًأ، تعتقدين أنك ربما تكونين حاملا أو تخططين للإنجاب.</p><p dir="RTL">إذا كنت حاملاً ولديك صمام ميكانيكي للقلب، قد تكونين أكثر عرضة لخطر حدوث جلطات الدم. سيناقش طبيبك هذا الأمر معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت ترضعين طفلك من ثديك أو تنوين القيام بذلك، عليك استشارة الطبيب قبل البدء باستخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />لا يُؤثر إنهيكسا على القدرة على القيادة وتشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُنصح أن يتم تسجيل الإسم التجاري ورقم التشغيلة للمنتج الذي تستخدمه من قبل القائم على رعايتك الصحية.<br />&nbsp;</p><p dir="RTL"><strong>معلومات مهمة حول بعض مكونات إنهيكسا</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 مجم) في كل جرعة، أي أنّه &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">3.&nbsp; استخدم هذا الدواء تبعًا لإرشادات الطبيب أو الصيدلي دائمًا. تحقق من الطبيب أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>معلومات عامة عن طريقة الاستخدام </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم الطبيب أو الممرض بإعطائك إنهيكسا عادة. ذلك لأنه يُعطى عن طريق الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند عودتك إلى المنزل، قد تحتاج إلى الاستمرار في استخدام إنهيكسا وأن تحقنه بنفسك (أنظر الارشادات أدناه عن كيفية القيام بذلك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعطى إنهيكسا عادة عن طريق الحقن تحت الجلد (تحت الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن حقن إنهيكسا داخل الوريد لديك (حقن وريدي) بعد الإصابة بأنواع معينة من النوبات القلبية أو بعد العمليات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن إضافة إنهيكسا إلى الأنبوب الخارج من الجسم (الخط الشرياني) عند البدء بعملية غسيل الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تحقن إنهيكسا في العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي كمية الدواء التي ستُعطى لك</strong></p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;سيقرر لك الطبيب جرعة إنهيكسا التي ستحتاجها. وتعتمد الكمية على السبب الذي ستُستخدم<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من أجله.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;يمكن أن تُعطى جرعة أقل من إنهيكسا إذا كان لديك مشاكل في الكلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp; علاج جلطات الدم المتشكلة في دمك<br />- &nbsp;&nbsp;الجرعة المعتادة هي 150 وحدة دولية (1,5 مجم) لكل كيلوجرام من وزنك يوميًّا أو 100 وحدة<br />&nbsp;&nbsp;&nbsp;&nbsp; دوليّة (1 مجم) لكل كيلوجرام من وزنك مرتان يوميًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;سيقرر لك الطبيب المدة الزمنية التي تحتاجها للعلاج بحقن إنهيكسا.<br />&nbsp;</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp; منع تكوّن جلطات الدم في دمك في الحالات التالية:<br />* <em>عملية جراحية أو محدودية الحركة بسبب المرض</em><br />&nbsp;&nbsp; - ستعتمد الجرعة على مدى احتمال تعرضك لحدوث الجلطة. سيتم إعطاؤك 2000 وحدة دولية (20<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجم) أو 4000 وحدة دولية (40 مجم) من حقن إنهيكسا يومياً.&nbsp;</p><p dir="RTL">&nbsp;&nbsp; - إذا كنت ستخضع لعملية جراحية، سيتم إعطاؤك الحقنة الأولى قبل العملية بمدة ساعتين أو 12<br />&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ساعة.</p><p dir="RTL">&nbsp;&nbsp; - إذا كانت حركتك محدودة بسبب المرض، سيتم إعطاؤك عادة 4000 وحدة دولية (40 مجم) من<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقن إنهيكسا يوميًا.</p><p dir="RTL">&nbsp;&nbsp; - سيقرر لك الطبيب المدة الزمنية للعلاج بحقن إنهيكسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>* بعد تعرضك لنوبة قلبية&nbsp; </em></p><p dir="RTL">يمكن استخدام إنهيكسا في علاج نوعين مختلفين من أنواع النوبات القلبية تدعى STEMI (احتشاء عضلة القلب الناجم عن ارتفاع مقطع ST) أو NSTEMI (احتشاء عضلة القلب غير المرتبط بمقطع ST)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">. وستعتمد جرعة إنهيكسا التي ستُعطى لك على عمرك ونوع النوبة القلبية التي أصابتك.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">النوبة القلبية NSTEMI</p><p dir="RTL">&middot;&nbsp;&nbsp; الجرعة المعتادة 100 وحدة دولية (1 مجم) لكل كيلوجرام من وزنك كل 12 ساعة.</p><p dir="RTL">&middot;&nbsp;&nbsp; سيطلب منك الطبيب بالعادة أن تتناول الأسبرين (أسيتيل ساليسيلاك أسيد) معه كذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp; سيقرر لك الطبيب المدة الزمنية التي تحتاجها للعلاج بإنهيكسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">النوبة القلبية STEMI إذا كنت أقل من 75 سنة من العمر</p><p dir="RTL">&middot;&nbsp;&nbsp; الجرعة الابتدائية 3000 وحدة دولية (30 مجم) من إنهيكسا ستُعطى لك في الوريد (حقنة وريدية)</p><p dir="RTL">&middot;&nbsp;&nbsp; ستُعطى في الوقت نفسه إنهيكسا كحقنة تحت جلدك (تحت الجلد). الجرعة المعتادة 100 وحدة دولية (1 مجم) لكل كيلوجرام من وزنك كل 12 ساعة.</p><p dir="RTL">&middot;&nbsp;&nbsp; سيطلب منك الطبيب بالعادة أن تتناول الأسبرين (أسيتيل ساليسيلاك أسيد) معه كذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp; سيقرر لك الطبيب المدة الزمنية التي تحتاجها للعلاج بإنهيكسا.<br />&nbsp;</p><p dir="RTL">النوبة القلبية STEMI إذا كنت تبلغ 75 سنة من العمر أو أكثر</p><p dir="RTL">&middot;&nbsp;&nbsp; الجرعة المعتادة 75 وحدة دولية (0,75 مجم) لكل كيلوجرام من وزنك كل 12 ساعة.</p><p dir="RTL">&middot;&nbsp;&nbsp; الكمية القصوى التي يمكن إعطاؤها من إنهيكسا لأول حقنتين هي 7500 وحدة دولية (75 مجم)</p><p dir="RTL">&middot;&nbsp;&nbsp; سيقرر لك الطبيب المدة الزمنية التي تحتاجها للعلاج بحقن إنهيكسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للمرضى الذين يخضعون لإجراء يسمى التدخل التاجي عبر الجلد &quot;القسطرة&quot; (بي سي أي PCI):</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong>من المحتمل أن يقرر الطبيب إعطاءك جرعة إضافية من إنهيكسا قبل إجراء القسطرة، تبعاً للوقت الذي تلقيت فيه آخر جرعة. تُعطى هذه الجرعة بالحقن الوريدي.</p><p dir="RTL">3. منع حدوث الجلطات داخل أنابيب جهاز غسيل الكلى<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الجرعة المعتادة 100 وحدة دولية (1 مجم) لكل كيلوجرام من وزنك.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - يضاف إنهيكسا إلى الأنبوب الخارج من الجسم (الخط الشرياني) عند بدء الغسيل الكلوي. تكون<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذه الجرعة عادة كافية لدورة غسيل مدتها 4 ساعات. ولكن قد يقرر الطبيب إعطاءك جرعة<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إضافية بين 50 &ndash; 100 وحدة دولية (0,5 &ndash; 1 مجم) لكل كيلوجرام من وزنك عند الضرورة.</p><p dir="RTL"><strong>تعليمات استخدام الحقنة<br />كيف تحقن نفسك بحقن انهيكسا</strong><br />إذا كنت قادراً على أن تحقن نفسك بإنهيكسا، سيوضح لك الطبيب أو الممرض كيف تقوم بذلك. لا تحاول أن تحقن نفسك إذا لم تتدرب على ذلك. إذا لم تكن متأكداً مما ينبغي عليك فعله، تحدث إلى طبيبك أو الممرض فوراً.<br /><strong>قبل أن تحقن نفسك بإنهيكسا </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق من تاريخ انتهاء الصلاحية للدواء. لا تستخدمه إذا تجاوز ذلك التاريخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق من أن المحقنة غير تالفة وأن المحلول بداخلها صافٍ. إذا لم يكن كذلك استخدم غيرها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم المنتج إذا لاحظت أي تغيير في شكله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من أنك تعرف تمامًا الكمية التي يجب أن تحقنها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق من بطنك إذا كان الحقن الأخير سبب لك أي احمرار، أو تغير في لون الجلد، تورّم، نزح، أو انه ما زال مؤلمًا. إذا كان الأمر كذلك تحدث مع طبيبك أو الممرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدد المنطقة التي ستحقن فيها. قم بتغيير موضع الحقن كل مرة بين الجانبين الأيمن و الأيسر من بطنك. يجب حقن إنهيكسا تحت الجلد مباشرة في منطقة البطن، ولكن ليس بالقرب من السرة أو أي ندبة (اترك مسافة 5 سم عنها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحقنة مخصصة لإستخدام واحد فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات حول حقن نفسك بحقن إنهيكسا:</strong></p><p dir="RTL">1) اغسل يديك ومنطقة الحقن بالصابون والماء. ثم جففها.<br />2) اجلس أو استلق في وضع مريح بحيث تكون مسترخيًا. تأكد من أنك تستطيع أن ترى موضع الحقن.<br />&nbsp;&nbsp;&nbsp; &nbsp;يمكن أن تحقق ذلك باستخدام كرسي مخصص للتمدد أو الاستلقاء، أو مقعد قابل للبسط، أو سرير<br />&nbsp;&nbsp;&nbsp;&nbsp; مدعوم بالوسائد.<br />3) حدد منطقة للحقن في الجانب الأيمن أو الأيسر من بطنك. يجب أن تترك مسافة 5 سم على<br />&nbsp;&nbsp;&nbsp; الأقل بين موضع الحقن والسرة باتجاه أحد الجانبين.</p><p dir="RTL"><strong>تذكر:</strong> لا تحقن نفسك في موضع يقع ضمن 5 سم حول السرة أو حول الندبات أو الكدمات الموجودة. قم بتغيير موضع الحقن بين الجانب الأيمن والأيسر من الجسم حسب آخر موضع للحقن</p><p dir="RTL"><strong>4</strong>) اسحب بعناية غطاء الإبرة عن محقنة إنهيكسا وتخلّص منه. المحقنة مسبقة التعبئة وجاهزة للاستخدام.</p><p dir="RTL"><img alt="" width="314" height="284" src="data:image/jpeg;base64,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" /></p><p dir="RTL"><strong>لا تضغط</strong> على مكبس المحقنة قبل الحقن لتحاول التخلص من فقاعات الهواء. يمكن أن يؤدي ذلك إلى فقدان كمية من الدواء. بعد إزالة الغطاء، لا تسمح للإبرة بلمس أي شيء. وذلك للتأكد من أن تبقى الإبرة نظيفة (معقمة).</p><p dir="RTL">5) امسك المحقنة بيدك التي تكتب بها (كما تمسك القلم)، ثم قم بطيّ المنطقة المُنظّفة من بطنك بين السبابة والإبهام لعمل طيّة في الجلد بينهما.</p><p dir="RTL"><strong>تأكد من الحفاظ على طيّة الجلد خلال مدة الحقن</strong></p><p dir="RTL">6) امسك المحقنة بحيث تتوجه الإبرة إلى الأسفل (بشكل عامودي بدرجة 90 درجة مئوية). ادخل الإبرة بأكملها داخل طيّة الجلد.&nbsp;</p><p dir="RTL"><img alt="" width="381" height="303" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEA3ADcAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAEvAX0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorxD9pz4+XPwj0PTNB8KWSa98UPFUpsfDei5yDJj57mYfwwRD5mJwDgDIySADiv2lfiVrvxK8Zx/AP4bX72Wu6hALjxZ4it+RoGltwVU9rmYHai9QpLcZDD2XwD4F0b4ZeC9G8K+HrQWWi6TbLa2sAJJCqOpJ5JJySTySST1rjP2e/gdbfA/wAGy2k96+u+K9WnbUfEPiC4GZtSvX5eQk8hRnaqjAVQOMkk+pVQBRRRTAKKKKAOgoooqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqGsaxZeHtJvdU1K7isdOsoXuLm6uHCxxRqCzOxPQAAkn2oA5T40/GDw/wDAn4c6p4w8STsljZqFit4Rumu52OI4Il6s7tgAD3JwASPGv2c/hT4guNc1T4w/E6JT8S/E0QjisM7o/D+m53RWEWejDIaRgAWYnPQk8x8NLG+/a6+KFn8YPElrNb/DbQJnHgPQrpCv2xxlW1eZD3bkRAjKgbgAcE/U1NAFFFFUAUUUUAFFFFAHQUUUVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVna34g0zw3Yve6vqVppVkn3rm9nSGNfqzEAfnXm11+1l8FrK6+zy/FXwf5uQDs1mBwPxDkD86APWqKw/Cvjjw746sTe+G9f0vxBZjj7Rpd5Hcx59N0ZI/WtygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr46+JWrXH7ZvxSvPhro08ifB3wndqPGGp27FRrd8hDLpkTA8xIQGlYdSAoI4J6z9pv4sa/wCIvE1n8Dvhhem38ca5B52ta3ENy+G9LOA87EHiaQErEuQcndkfKT6d8LPhjoHwc8B6R4Q8M2gs9I02IRxqTl5GPLyO3VnZiWYnqSegwKYHSWVnb6bZwWlpBHbWsEaxRQxKFSNFACqoHAAAAAHAAqeiiqAKKKKACiiigAooooAu6H4i0rxRY/bdH1Kz1WzLtH9osZ0mTcDgjcpIyD1HatOvjbxl+yW/hvWrnxf8DvEk/wAKPGMsnnT21pl9G1M5JK3NocoMn+JQCMk4J5E3gn9u288A67aeD/2ivC5+GmvzOIrXxLbbp9A1E9mSYZ8knqVckKOWK9BNgPsOiqmn6ja6vYwXtjdQ3lnOgkiuLeQPHIpGQysCQQR3HFW6QBRRRQAUUUUAFFFFABRRRQAUUUUAFIc4OOtLRQB+KM1p8Uf2ifiT4ju/FaaPP4k03U7izng8UTyXQs2jcgxW1gpCLGowMsDuwTk5NdZcfCnxreapbeGpfGWgi9WMutrD4HtygGMld28MQQOmMAdAOlfcX7V/wV8D+PPGHw7l1rwxYXVzf6u8N3dxx+TcTRiBiFaWMq5A2jGW4xxXgt5+zX4Htf2iIvC8elXD+G2t0820k1C4YkNGxxvMm8DK9AenFO1wvY+dbfwj8S/g98VvCF14Xn8Pv4qutVtrWJvDJaxvJFaQB1uLQEpJEy5ByBjOc4Br9pK+Yf2T/hR4O+H3j/4pW/h/w3Y6a9jqVtDBMkIaaONrVWKiRsvgkkkE96+nqQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeNftMfHz/hSXhWyg0ex/4SD4geIp/7N8M+H0PzXd0w++4yCIYwQ0jEgAADIJFdp8Wfin4e+Cvw/wBX8Y+KLwWej6ZEZHI5eVjwkUa/xOzEKo7k9hk14R+zv8NvEPizxXffHD4nWf2fxxrkHkaPoch3L4c0snKW6A8CZxhpGwDkkccggHXfs6/A4/Bzwze3Os358QePvEU/9o+JfEEg+e8umH3F/uxRg7UUYAAzgEkV61RRVgFFFFABRRRQAUUUUAFFFFAGDWT4r8I6J460G60TxDpVnrek3SlJrO+hWWJx7gg8jqCOQeQQa1qKCD5Pb9nH4l/sz302tfs7eJ/tGhFzNc/DbxRO02ny5OSLaUkNCx7AkZOMsQAK9Y+CP7cvhD4leIV8GeMLG7+F3xLjISXwz4j/AHXnMeAbaYgLMpI4HDHsCOa9Yrg/i98C/A/x28PnR/Gvh+21iBQfJnYFLi2Y/wAUUq4ZDwDwcHABBHFTYq571RXwzptp8ev2QwP+Efubr48fC2DromoSY8RabEO0EmP9JUDopBJwAFUZNfTHwJ/aI8E/tFeGZdY8H6k8slrJ5F/pd7GYL7T5e8c8ROVPBAIypwcE4NIZ6dRRRQAUUUUAFFFFABRRRQAUUUUAeS/GyzS88VfDrd9+LU5pUA9RA2f0yfwrzfW7WNPj/ZT7FDtZw5YDnO5gCT344+lep/FpQ/jD4f5GcXl2fytnrzbxFHt+NWnSY5NvCM/9tDVxEzqPgSNnxX+MC9jfac4/GzUf0r3CvFPgqNnxg+LK45LaW/5wSD+le11AwooooAKKhmnjtYZJZpFiijUs0jkBVA5JJ7CvAvFX7enwO8J61LpUnjePWLyA4uP7As7jU44McEvJbxuq4PByeKAPoOivK/hv+1J8Jfi1JHD4U+IOg6reScLY/a1hus+nkybZP/Ha9ToAWiiigAooooAKKKKACiiigAqrfX1vpdjcXl5PHa2lvG0s08zBUjRQSzMTwAAMkn0q1Xx/8Y/EF5+1t8Tr34N+GbuW3+G3h+ZT491y1cr9slByukQuD1PBlI+6PlyDkMAVvBqXH7aPxUtfiPq8Ekfwc8KXbf8ACH6XcKVGtXqEq+qSoesanKxKR6tgHIP1TVTSdJs9B0u003TraKysLOJYLe2gUKkUagBVUDgAAAADoBVurAKKKKACiiigAooooAKKKKACvkXxV8WPjd8fPGmuRfs9XPh+x8HeGp/7Nu9f16LzItVvuTKtscHKQ4VSw4LOcZAro/jd401744+PpfgR8NtQk0+QxLL418VWvI0WxfP+jRt/z9TDIA6qpJI6lfpP4f8AgDQvhf4M0nwp4ZsI9K0LSoFt7W1h6Ko5JJ7sSSSTySSTyam4GLRRRVEBRRRQAV4v8Y/gPda3ryfET4b6ingz4sWEeItTjX/RtWjGCbW/jHEsbYADEFkOCCcAV7RRQBzf7N/7Qlp8dPDt9Bf2DeG/HegzfYfEfhm4YGawuB/Ev96Fx8yOOCOM5Br2Kvln4yfs9y+LvEFv498B65J4E+KmnxeXba7bLmG+jGCLa9j6TQnAHIJXAIzgA63wH/a0/wCEq8Tf8K5+KGkp8P8A4r264GnzSf6FrCjjz7CU8SKevl53L05wSJLPpCiiikAUUUUAFFFFABRRXkfx4/aAt/gf/YUcmg3WsT6xK8UEgnjtbWNl28STSHapO7IBHO1j2oAvfFtR/wAJV4AboRqFyM+xtZCR+OBXnfihNvxY0t/WO3BP/bRqi8UeJfib4z1Xw1qH/CNeGvD8VjcySxx3WszXbSB4Xj5MduFGA+eCemM9657xTp3xPk8S2Gpw2/hO6mjaP9zHPdKMKxIyWQdSSOKtaCZ6h8Jcx/Gn4lr0D22lNj1xHMM17RXyT4U8UfFnwn8QvEWtv8PtJ1waha2sLQWOuCBoxFv5BkiIOd/QkYx1rvv+GpJdFjZ/FXw18XaEiAmS5t7aO+t0A6kvG+cD121LGe8V4T8af2sNB+Guvp4N8N6Xd/EX4mXK5t/CegkNLEDjEl3LyttEMgln5wQQCOa831L4yfEL9rO6n0b4QteeAfhukjQah8RL+2Md9eFSVkh02BwCpBBUzuBg5wAV59e+DvwL8HfArw/JpnhTTPIkuG82+1K5czXt/KeTJPM2WkYkk8nAycADigDyWP8AZu8a/HqePVv2gfFLX2mswkh+HfhieS10e37hbiRSJLphxncQoOQAQcV9AeEfBfh/wDo0WkeGtEsNB02IAJaadbrBGMd8KACfc8mtqiqA86+Iv7Ovwy+LUbjxb4G0TW5X/wCXqa0Vbge4mUBwfcMDXmifsm+I/h3+8+EHxi8VeCok5j0TWnGu6UB/dEVwS6A8DKvkDpX0hRQB87L8cPj98KcL4++FFn8QdKj+/rfw3uy1xgdzYT4diRyQjkDtmu7+G/7Zfwk+JuojSbTxVDoXiTOx/D/iSNtM1BX/ALnlTBdzeyFq9Orj/iJ8HvBHxc042PjLwppPiO32lV/tC1V3jz3RyNyH3Ugj1qbAenKwZQQcgjrTq+TV/ZP8R/DMmb4L/FnxD4KgQ5Tw7rjHWtHwOdixzHzIgehKOSB2NWY/2jvjH8KP3XxU+EUniHS4/v8Aif4bzG+jwP4nsZMTIB1JBYDnA45LAfVNFeV/Cj9p74X/ABsbyvCPjHT7/UV4k0mdjbX0RHUPbyhZBjpnbjjrXqlIAoorxr9ov9o7SfgZoEdpaxr4h+IGrn7L4e8J2r7rrULluEJUcpEpOWkOAADzkgUAcr+1B8ZNeXWNM+DnwxnX/hZniaIvNqCjcnh7Ts4lvpcdGwdsanG5iD2APd/B34S6B8Efh/pnhLw7AyWVmpaS4lO6a6nY5knlbqzu2SSfUAYAAHIfs4fA+7+Fuj6pr/iu9XX/AIm+KpRf+JNaI4aUj5LaL+7DEDsVRgYBOBkAex0wCiiiqAKKKKACiiigAooooAK8I/aI+NOuaPq2l/C/4Zxxal8WPEsZNt5g3QaLaA4k1C64ICKMhQfvtgAHGDu/tDfHeP4N6Fp9lpGnnxJ8QPEMxsfDfhuE/vb25IGXb+7DGCGdzgADGQSKvfs0fs+v8H9J1PXfEuoL4k+J3ieRbzxHr7D78mPlt4c8pBEDtVRjOM4GQBLA6L4B/AvRP2f/AADD4d0iSW/vJpWvNV1i6O651S8fmW5mYkksx6DJwAB2r0qiikBwNFFFWQFFFFABRRRQAVxPxY+DPhD43eG/7F8XaTHqNujeZb3Ckx3NpIOkkMq4aNgQOQRnGCCOK7aigD5z0e3/AGiP2d2MGiaja/HbwPDgRadr1yLPxBbxj+FLojy5yB3kAY8AYr0XwF+3J8L/ABZqqaF4gv7r4beLuBJoHjW3OnT5/wBiR/3UgJzgq5JHOBXo9YHjP4f+GfiLpR0zxT4f03xDYHn7PqVqk6g+oDA4PuMEetTYq56vBNHcwpLDIs0TqGWRCCrA9CD3qavjofsh/wDCv5zefBr4geIvhXcBtx0uGY6jpEhJyd1nOWUE9Mqy4Hate3+IX7UPgYbdS8KeA/idapws2jajNo17IBnl0mDxZPorAZPQUWA+rqK+ZbP9tC80TC+PPgx8QvCW3/WXllp8esWcYHUmS1dnwOudlek/DP8Aac+FnxgmFv4T8caRqeoZKnTXn8i8UjqDbyBZAR3+WkM9RrM17w/pvijR7rS9XsYdR066QxzW1wgdHU9iD/McjrWnRQB8Xaza/FP4afE6w+D/AIKl0O60u5t5NW0vxF4m825fT7QHYbYxqRvdWJ2sxIK9cHgP8ReBvjJpviCytLn43wfbbjYVS38F2nkKWYgDJlDYB9ia9M8bSZ/a+8MKOqeFJ2P0NwR/Sj4nXPl+ONIdRvkCxkLnHIkOPpVITPFPip8XvjB+ylaDXfFqeFviLoU8sNoG02Cew1JpJGZU2xDejHIxheSSBxnI3/hv8Mfil+0JGviX4yXtx4P8NzkS2HgHRpDC5jPKteygliSOfLBBB6kHK11vxu08yeIPh5f3+2e8j8R6aVAHyoDPIcAe2Bz14FfQNMZm+HfDuneE9Es9I0i0jsNNtE8uC3jB2oMk98kkkkkkkkkk81pUUUAFFFFABRRRQAUUUUAFFFFAHm3xR/Zv+GnxmxJ4u8Habql6mCmorGYLxMdNtxGVkAHoGx7V57H+xr/YeE8KfGb4reFrZf8AV2UPiM3dsg9AlwkhA+hr6LooA+d5f2VfFmqL5Wr/ALRPxSuLbo0djfWtixHoXigDD6gg+9dp8JP2Zfh98F7+51XQNHkufEd0CLrxDrFxJfajOD1DTyksAe4XAOBkcCvVKKACiiigAooooAKKKKACiiigArgfjd8Z9C+BPgW58Sa35tw5dbXT9MtV3XOo3b8RW8KDlnZsDgYAyTwDW18RfiJoHwp8F6r4r8T6hHpmiabEZp7iQ8+gVR1ZmJACjJJIA5NeM/AP4Y6/8aPHdr8dfijp0mnzpGw8FeEbnkaJaN/y9TKeDdSgAk/wKQOuNqYG9+zX8DddtNdvvi78UxHdfFPX4RHHZA74PDtiTlLG36gNgjzHHLNkZIyW+jKKKkAooooA4GiiirICiiigAooooAKKKKACiiigAooooAK4H4jfAP4d/Fxf+Kv8HaTrc+AFu5rcLcpjptmXDrjthhXfUUAeBr+zb4v8FDZ8Mvjd4w8H2Y4TS9W8rXrSIdljW6DOgxxjeafCf2sPCbf6N4u+HHj6Bev9s6Vc6ZOw9jAzID9Rj6V7zXAfHH4xaZ8D/h/d+I7+GS/u2dbTTNKt+Z9RvJDthtowASWZuuAcAE4IBpWGeHeC/iX8SvFX7XVtZeP/AAtofhvXLXws6wx6Pqn22N4mmciRwQGTLAgBgCQMivWvG1r9j8VaW7yNNO4RpJGPJO89B2HGMV438DvhTrnw9/aAtNb8bXo1H4heKdAm1bXJVbMVvIZQsdrEMkCOFAEGM5IJzgjHs/xEk/4qLTH/AIti8/RzTQ2VvjnIG1bwAM8/8JFp36TN/jXvVfPnxum/4m3w/Yj5V8RWBZvbzj/U19B0AgoriLfWL3V/jJd6fBcumk6JoyG6hU/JLdXMpKA/7UcduTj0uAe4rt6BhRRVS61axsc/ab23t+cHzZVX+ZoAt0Vn2fiLStSbZaanZ3T5xthuFc5+gJrQoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqOua5p/hnRr3V9VvIdO0yxha4ubq4cJHFGoJZmJ4AABOatyypDG8kjrHGgLM7EAAAZJJPAAHevlOOG5/by8cvbxmaD9nrw5e7biVSU/4TC+ib/VqRjNnGwGSOHYYGcZVAWvhr4Y1D9s7x5p3xM8WWU1n8H9CufP8G+G7yMo2r3CkgapdIeqDnykI5B3EYJ3fYtQWttFZW8VvBEkNvEixxxRqFVFAAAAHQAYwB6VPUgFFFFABRRRQB4DZ/E688N6bbR/ELw/qXhTUY4lF1fC0afTGkAG90uITIsaE5IEzIwGMjINdfoPiTSPFNiL3RtUs9Ws2OBcWM6zJn0ypIz7V6dXA+KPgX4J8WXz6jdaFBZ6wf+Ytphazvf8Av/CVfHtup3FYWiuO1P4Z+OfBUL3HhbxPJ4it4wWGj+JVWXeByES6QLJGT03SecB3HetHwZ40s/GmmyTwRTWV5bSG3vtNu1C3FnMACY5ACRnBBDAlWUhlJUgmiToKKKKACiiigAooooAKKKKACiiigAr550XSIPir+3Brkmr7r3S/hroVk2mWTkGCHUr0yu9wV7yCFFVSfug5ABwa+hq8L/ZJX+3viF+0B4tIyb3xo2kRsQOY7G1hiGD6BncfUGgpG14xYL+1VohPH/FLTD/yOab8RJB/bGnn/Y/9mqPxs3/GVGlf9iw3/o9yf5VH8QZM6hZH/YP86aEzN+PmpW2nt4Iu7ueK0toddtJJZ5nCIirMCWZiQAAMkknAp2s/t1+Dr6+n074d6B4k+K9/E5iaTw1YH7AjjjD3cpWPHupYe9cT+0tpdh8QtJ8IafqkC3eiXGu28EtpJnZcL5qZD+qnkY7jrXs2l6XZ6Lp8Fhp1pBYWVuojitraMRxxqBgBVAAAHoBikO54tZeLP2jtd8Va9rei+FfBvw4tdaS2E1vr2oS6tcRyRK6GULAEj3MhjUgsQPKHJzxdm+GPxj8Uc+J/j/rUETZLW3hTSLXTAuSOBIRI+B0ySDXs1FAjw6T9kfw1qzBvEvi3x94wfJJ/trxXdupz1G1HUAewGKdb/sU/BOGNUfwFZ3WOc3dxcTnPqS8hNe30UBdnidz+xb8E7hCB8PtNtGIwJLN5YHHuGjcEH6Gj4a6hrv7NXxu8I+B38R6n4k+GvjQ3Flp1vrdw1zc6LfxRmVI45mJZoZEVlCMSVYAg4Jz7ZXj/AImsJ/iF+1h8JtAsoXmtPCYu/FGsTqpK24aGS3tEJ6BpJDIQDyRGxxgUDR9cUUUUDCiiigAooooAKKKKACiiigAooooAKKK+bPjR8RPEXxj8ez/A74V37WWoeWr+MfF1vyvh+zb/AJYxkdbuUZCjOVGScEEqAZfj7WtV/bC8fal8KvBt9Pp/ww0WcQeN/FVlIVa8kGCdKtHHUkYErgkKpK98N9Y+GfDOleDPD+n6HodhBpej6dAtta2dsgWOKNRgKAPb/OayPhb8MfDnwb8C6V4Q8K6emm6JpsXlxRryznq0jt/E7HLMx5JJNdbUAFFFFABRRRQAUUUUAFFFFABXk/xh8FXVnKvj7wxatJ4l0qLF5YwDH9sWKks9sw7yqCzRMeQ+VyFkfPrFFAHmuj6vZ+INIsdU0+dbqwvYI7m3njOVkjdQyMPYggj61crhvAdr/wAIX4m8T+A5B5cWm3H9paSp6Np1y7Oij2imE8IA+6scefvCu5qyAooooAKKKKACiiigAooooAZPMltDJLKwSONSzN2AAyT+AFeK/sB2zzfs1aRr06FLrxNqWp69MSMEm4vJWUn/AICE59AK6j9ozxP/AMIb8A/iJrQfa9noN68bf7ZhYJ/48RW/+zn4V/4Qn4BfDrQinlyWOgWMUi4x+8ECl8jsdxJoKRwHjptv7U+lf9iww/8AI0lV/iBJ+/tT32N/MUvj47f2qNNP/UuL/wCjpareO33SWg9QR+oqtQZy3xnQQ6F4DTuNatgfr5kRP8zXsleNfHBw2l+BiO+vwj8nhr2WpJOPuNQub74tWWnQzyJZafo8l3dRKxCvJNKqQEjocCC4xnoTn6dhXEeCV+2+PPiDqD/6yK+tdLT18qK0imA/77u5T+Oe9dvQAUVDdXUFjbS3FzLHb28SmSSWVgqooGSSTgAADJJ4Feaaf4x8V/G+4ew+FkEdnoG4x3Hj7VIC1kuDgixhODduOQHyIgR95uVoA3PiD8UbLwRLaaXa2k/iHxbqQK6X4c04Brq7YcFiOkcSnlpXwqgEkk4B7v4BfCi9+G+g6nqPiK5h1Dxv4juRqGt3duD5SuFCxW8JPPkwoAi55J3MQCxFaHwn+B/hz4R293Pp63GqeINQw2p+ItUk86/v2HQvIQMKP4Y0Coo4Cjv6FQUFFFFAwooooAKKKKACiiigAooooAKKK8v+Pnx60r4GeG7aWS2m13xTq0ostA8NWPzXeqXbYCxooyQoJBZyMKD3JAIBzP7Sfxb17R7zw/8ADL4dPFJ8UPGLtFZySLvTSLNf9fqEwHRUGQoP3mwADgg+n/An4H+H/gB4Bt/DehiW5ld2utS1a7O661K7fmW4mfqzMcn2GAOlcZ+zL8B9W8AtrPj34gXUOs/FjxXtk1a8i5hsIBzFYW392KMYBI++wyc4Br3qpAKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAeUfHbSzpNnp3xAs43a98Ll3vEjGTPpkm0XSEDk7AqzqByWgAHDHOvDMlxCksTrJFIoZXU5DAjIII4II5zXdyRpNG8ciq6MCrKwyCDwQR6V4X8N1fwbd6j8O73KXOgYbTGf/l50pifszqe5jAMDd90WTgOpLQmd3RRRVEhRRRQAUUUUAFFFFAHz7+3Y7X37PN74ciOLjxRq+l6FFjOSZ72IMOOeUD19OwxJbwpEgCoihVUDAAAwAK+QP2hvFyeNv2lPgX8MrKA3MUHiYa7qNyCdkclpayTxwccFtpDsP4Q0RP3xX2FQUj5h+MWrnQ/2mNNuhH5u3w+mUzjI82bPP61lax4otdXuo42kWGeJSwhB3NgkDJ5BAyPSvAv+CrjS/wBqu8Vks8sWl2RW9kZQtnm5mBkOTk7vuDAP3ueK/M59U1dWz/a1oSRjh4/8KL2Dc/Yj4r6tcapp/hb/AEZo4rXW7V1kKnBLSRjqRj+AYHua+ga/GT9kW6urv4oWovLX+1wlxamO7idSLFjcxjeRkcMMoMAnLDjGSP2H8TeKdI8F6Jc6xrupW2kaXbLuluruQIijsMnqSeABkk8AE0XuSc3ov/Eo+LniWyHyQarp9pqiD+9Mhe3mP4IloPxo8b/FrTPCeq2+gWNpd+KPGN2u608N6Oolu5B0DyZIWGIHrJIVUepPB5ax8L+O/wBoTxTpmu+Hft3w28H29rcWg8QahbganqUMzRMxtbWQHyVzCpWaYbsMSIzkGvoX4Y/B/wALfCHS5bPw5p3kz3Lebe6jcyGe9vpO8lxOxLyMeeSSBnAAGBQVY8r8Pfs6az8SLqDWPjFeQXtorCW28C6XITpduQcg3TkBrxxgEhgIgQcIeDX0HbWsVnbxQW8SQQRIEjjjUKqqBgAAcAADAA4FS0UDCiiigAoorzLxl+0d4C8Ga0dDfV5Nc8SjgaB4ctZdTv8AP+1DArNGPd9o96APTaK8cP7RGozKDZ/Br4nXinOGbRoLfpjqJrhCM59OxpF/aC8QFgG+BnxMA7kWdgf0+2UgPZKK8c/4aOmhUG6+EfxQtMjJH/COicjr18mV/TtnrTD+1h4KtMDVdM8aaESM51HwZqqKvsXFuVH4nFAHs1FeP2f7X3wYvJlif4j6FYTtnEOqXH2KTjr8kwU/pVy9/as+DOnw+bP8U/CKpnHy6zAxz6ABySfYCmB6pRXi/wDw1Z4Y1s+V4J0PxV8RLs5Cr4e0Of7PnkDN1OI4ACe+84HPply+F/jV8Wjs1m9svg94bkGHtNFnTUdclU9Qbgr5FsSOpjWUjswOCFoBznj79qDXfB2vy/D7TfBM/i34sz5fTtJ0iUNYy2zEhLu4mJzbRrgBkkAIPCllIeuq+Av7Nd14R8SXPxH+JOrReNPizqMXlSagsZFppMB5+y2EZ/1aDJBfAZ+ScZIPpPwx+D/hP4P6XPZeGdLW0e6k868v5nae8vpe8lxcOS8rH1YnHQYHFdtSAKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXAfFf4eXHjCxstU0OeKw8X6KzTaXeTZEb7gBJbTY5MMoADAdCqOBuRa7+igDyHwT4yt/Gmlyzrby6dqNpKbTUdLucCexuVALxSAcZAIIYZVlZWUlWBPQVmfE74dahNqi+M/B6Rp4rtohDdWMj+XDrNspJ+zyHosi5JilP3SSDlGYVB4R8W2HjTRU1GwMiAO0M9rcJsntZlOJIZUPKyKcgg/UEggmiTaooopiCiiigArlfHXi260f7Fo2hQR6h4u1gtFpllITsBGN9xMRysMQIZm6nKqMsygv8d+ItQ0eHSNO0RLeTXtc1CPTrH7UjPFGSGkkldVILLHDHLJtDLuKBdwzkdd8O/hja+BWvdQub2bXfEuo7ft+tXShZJQuSkUaD5YoVydsa8ckksxZiij5D8XeB7jRP2lNNsvD2uz2+q+BfDYupNXmgjmN3qmpzytcyTowOQ8dumQpUqrBVZQox9UfCzxnJ8QPh/omvTwJbXl1AVu7eMkrFcxsY5owTyQsiOATzgCvmvwlqH/CU/Er4ueKWO8X/AIqn0+F/+mNjHHZgA9x5kMxB/wBo17h+zapPwksJ8Yjur/UrqI9mjkvp3Rh7FWBHsRQg6nxR/wAFTtPXUL6/XbdyyR6NYvHBbhvLlIupjiYgcRgZbJKgMq89Afy+a0m7aLY/hO5/9q1+0P7Q0aa1+1ZoWiZBSXRLa4ul/wCmST3BAI9GIx+BrO8afss/C7x3qT6hqPhaCG9clpJdPlktfMJ6l1jZVJPckZ96YbH5lfsxx6za/EJpNMthZ3MKwzrGszrayss8ZVbgjzGK55CoC7NtVQxIB/Sjwz8D/EPxJ1y08UfETVLuWWJvNtbcr9neEnoLeEEi0X/bJe5IAJkiOUrjfh54Z8P/AAr+KkV7baRa6fpun6fbyTrDGAVVXubae7J5LGF5og7EkhLhmJwhr6+BDDI5HUEUbAcT/wAKV8DK5li8M2Ftf4/5CVsnlX2f7wuVIl3Z53bs55zmu4+EXijVLPXtR8Fa5fS6rLa2y3+l6ncEGe4tC2x45SAAzxPtBfALLJGTlgxLazfhWD4s+KWreIbT59G0bT30WK6UfJcXMkqSXAQ/xCIQwqSMjczr1UgAI9qorgPH3xz8IfDu5Fjf6g19rLSRRLpOlxG5ut8rrHEHRciIM7qoaUquSPmFZc2o/ETxlny/snw+0xuhwmoaqQfXObeFh6fvwfUGgZ33iTxVo3g3S31HXdVs9HsEIU3F9OsSZPQAsQCT0AGSTwAa8U+Jn7Vn/CJt4aTRvCmpTWXiHWINDtfEGtxtYWEVxMGMZZGHnspKkA+WqkkAOM5Ha6B8LdA0LVE1aSCbWdfUEf2zrEzXd2M9QjuSIgefljCqM8ADiuf/AGlPha/xk+CfinwxbfJqs1t9o0yYHa0V7ERLbsD2IkRQSOxPrQK5y3wN8P61+0gvxBk+KOu6heQeH/Fl54eg0PQppNL02aCGOFhJIkbedIWMjZWSZkIAwvc/Sfg3wB4a+HWkrpfhfQNN8Paepz9m0y1SBCfUhQMn1J5NeL/sPa5H40+EmoeM02xz+KNVOpXlqvDW14tpbW91Ew6gie3lODzgg96+ialjCiiikAUUUUAVbzTrXUIzHdW0NzGeqzRhx+RFU7HwrommSeZZ6PYWknXdDbIh568gVrUUAIBjpxS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeMfFrQ2+H2uv8SNLjYaeyrF4ps4lyJbVRhb4Af8ALSAfeI5aHcDkxxivZ6imhSaN45EWSNxtZGAIYEYIIPY0AcJDMlxEksbrJG6hldSCCCMggjqCOcinVxHgmzbwB4i1X4fzM32OwQX2hM5JLaa5IEQJ6m3cGLHJCGAnlue3qyAooooA5WONb79oDwdBIMx2ug6vfIp7SiWwhVgPUJNKM+jEdzXsVzI8dvK8S+ZIqEqnqQDgfnXi3iS4/wCEb+Jnw/8AEbcW7XE/h+6bH3I7wRmM/jcW9qmP+mme1e31LKR+dXwh1G8k+AfhS20iXzfFXiEtbw5X5l1K4lke4ZwecRMZpHB5CxN6V9k3F54b+CHwwWW/vI9J8L+GdMVHuLhuI4IYwoJPUkgAADJJIABJArzbxx+xXZal8QJfGfgPx54g+GWs3Ek81xDpccF1ZtLNtM0yQTowjkkKgsyEZOSRkkmK1/YktvEWrWF18TviX4v+KdlYzLcw6FrEsNvpbyqcq8tvBGolweQGJHYggkUXGfL3w31DxT4y/aE1L4g+LbaXTZ/F+mW+p6RpdwCJLDSxLNFaxuOzMsZlIHGZc8EkV9ImT3ry/wDa+0HxhqH7YngbRfD2v2vg+08TeGZYY9ZNmt3KjWcksskaRsQqkrMmGIPXAGRy6L9kI3W19S+NPxIu73OTJa6yLZMn0jjiC49iDTRPU5f4yS6n4dk/tnw/Bbz6/peqRSWlvdECC6huQI5raXIIMUoaRTkHGQRyAR6D8K/ihFZ6VLo0ukeIpksSEt7WLTJ769sVIyLO6SFGdXiOUWZgElQRuHYlseE/Hj4ZfED4L6t4Ht9M8cXHj7TfE+vWWkR2PiK1T7bA6uZQwuIyoYYV871yOOvb7B8QeB/D/iqeCfV9Hs7+5hBWK4miBljB6hXxuAPcAgGmI5nXp/tH2d/Ht7c+HNPugTaeCdHcza1qY/6bGElo06ZWMgAcvKASoseH9c1v4l+F7Aafj4e+BhGYrXQ9FKx3zxKSu2WdMCAcEbIPmGOJSCRXQ+H/AAboXhPz/wCxtHstMecgzSW0Co8pHQuwGWPuSTWJ8Hf+Sf2Q7C5vAB7C6lAH4Cgr0M34heG9K8G/CXXBo9lBpkFhGNTxAgBMkMizb3J5ZiYwSzEknkkmvoCvE/jOsb/B7x2Jf9UdBvg2Rnj7PJnj6V7BoupQ6xo9hf28gmt7qCOeORTwysoYEexBB/GgkuUUUUAeQfs0xL8Ofj18Y/h6CyWOoXFv430uMnjbdgxXaqOgC3EBOB/z1FfTtfMulodS/bg0d9OO86V4FvE1h1HCLcXtubRGP95jBcMB1wjHvz9NVLLCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeW/HjR7m30Ow8Z6Xbtcat4Vla9MESkvdWLALeQADkkxjzFXvJBEOmau2F9b6pY217aTJcWlxGs0U0ZyrowBVgRwQQQQfQ16IeeD0rwrwLZnwL4j13wDLlLbTmGoaL6HTZmYpGv/XGQSQ4HRFhJ+8KaEzuKKKKok5r4k+G7jxZ4H1bTrKRYtTaMT2Ez9IruJhLbufZZUjb8K7z4c+NrX4ieC9M162RoDcptntZOHtp1JWaFx2ZJFZCPVTWRXIeHbr/hW/xa8j7nh7xo5wvRbfVo4ycj0E8KHPQB4B1MhpMpHttFFFSM+Pv2vFFr+1J+zfdj70n/AAkFscjsbSIjn65ruVlK/wDLXZ6hSc/px+tVf20Pgfq/xG0DRPHPhvxP/wAIx4m+HsWoatYtJYLdxXO+3xJE6lhjcseARnG7OMgV83fDDXv2nfG/w/8ADviazi+Fuo2OtWEN9A10+oW86LIgYCRVDLkZwdpxkcU0Jm1+1Nr1vpHxB+AMtyCkDeM0XzG65aF4wcc8AyDJ6DrxX0jXyT4D+C/xK/a8n8V6x498S6LZS/DrVtS0nTdD8N2D+TNqS2gCzefK24KrSoQAoJK5wOK+mvBniyy8Z+HrTUrOVGZ0AuIM4ktpgBvikXqrq2QykAggggVRJq399BptjcXlzIsFtbxtLLIxwFVQSST6AAn8K5b4P2s9p8L/AAyLqNoruaxjup42GCsko8xwR2IZyD9K5jx94pt/HWuaV4IsFku9G1C+az1rVLcBrdfLiknaxD5wZZFiIcDJVC2cFlz6tQBxvxoYL8H/ABzuQyA6HfLsUZLEwOAB7kkAe5r2TS7GLS9NtLKCNYoLaJYY40GAqqAAAOwAAFeJfFbVLSceGfCUlwiXvijWLaxityfmkgjcT3WB1x5EUgJ6AsoPUA+7UAFDMFXJOABkknjFFeT/ALUniK80P4J67Z6XIY9c8QGLw7ppUkMLm8kW3Rhjn5RIznHICE9qAJv2L7i18d6R49+KsE8d2fGXiK4W0ljcNt0+yJtLZDjpny5JMf8ATbPevpCvlP8A4Jx+F7Pwf8G/GGl6YpXSrfxzrUFkpOSsMU4hQZ+kX619WVBYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXm3xk8Hajqlrpnibw5B5/ijw87y29tuC/b7ZwBcWhJ4HmKqspJAEkcZPAOfSaKAPLfDPiSw8XaDZ6vpkpnsrpNyllKspBIZHU4KurAqykAqwIIBBFZ/i/4haP4GmsF1gX8UV45RLm2024uYIyCAPNkiRliByMFyoODzwarXWnr4G+M17p1uoj0nxXaSavFGvCx30LRpdY7DzUlgfA6skrHJY1Z8WfEvwj4Dmgi8SeKNH0CWdGkij1K+igaRV6soYgkDuRwKsg6Sud+IXheTxh4Q1DTLef7HqBCz2N3jJtruJhJbyj/dlRGx3AIPBNReCfif4U+JH20+F9dtNdjs2VZ5bFi8algSAGA2nOD0Jx3xkV09AGv8NfGS/EDwHoniAQm1lvrZXuLUnLW04ys0Lf7Uciuh91NdPXkXwZnOg+MvHfhNuIUuo/EFivZYbzeJVHqRcwXLn0Eq+or12oLMfxhpv9teE9b089Luxng/76jZf618j/ALFuoHUv2V/hrIRgx6UtuQT3iZoz+qV9nMoZSCMgivh79jyZPDPwj1/wxdOIm8G+Jda0icMeUWO7llBPoNkgI9qaEz0D9gnNx4c+MF+3S7+Jetsh9VV40B/8dx+Fe3eKPgv4D8aao2pa54Q0bVNRZQj3VxZRtLIo6K7Yyw9iSK8d/wCCd9jJ/wAMwaPrcyMkviTVNU1whupWe9lKE+uUCkexFfS9IZ574++EOn+J/BunaLoht/C8+jXKXujTWlqvk2cyq6Y8kFQY2SWWNlBUlZGwVOCOEj+GXxTvGEMl34Q0pOhvY/tV6x9xCREAT6GQ49TXvtFAHzN4t+GGj/DXxV8Nr6/1STWfEupeIjFcazqTIjFBp95shhQAJFH5jIAqjLMy7izc163Xm/7QWi3vjzWrh9LgN3c+DLeHULO3Q83OoieG6EPbDCK2RQScEXZzjHPZeFfFGn+NPD9prOlSvLY3QJRpImicFWKsrIwDKysCCCAQQRVITNavE/ihIPGH7RHwq8JIfMt9GW88X38eeB5UZtbXP1luHYepiPpXthIUFicADOTXz38C7q/8da38Tfi7p9pFqkmtXY0jw3DcTmGOXTbItGjCTaxVZZ2uJMhSMFTg5pknWfsEwrb/AAr8ZxDKsnjzxArRn+Ai9fA/LB/Gvpavln9gy+1CbTfjRbarpy6PqEPxG1KWTT0uBOIPNgtpMBwq7gSzMDgZ3dK+pqgsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8o/aCgbS9C0TxiiEjwrqaahdlRk/YXje3uif9lI5jMQP+eAqSPwzoz67Jr6adaPq9xbpbNqHlKZWhUsyJvxnaC7EAHGWJr02eGO6hkiljWWKRSrxuAQwIwQQeoI9a+RdQ1DxD4B+Kq/B/R9ZfR9Ht7GbWdNv/s6XFwtiWiSG0BkDKBG5ulBKkmOKIAghiWhM+gVUKoAAA7ADApa4H4Z+MdV1LUtY8N+Ingn1rSlhuEvrWMxJeWspcRyFCTtcNHIrKCRlQwwGCjvqok5a3b+z/j94UnXgajoepWUuP4jHLayx5+g87HpuPrXTfF/48eBPgPoUeqeN/ENvo0U7bLa3IaW5un/uwwoC8hzgfKDjIzivAf2kPjqnwR+IHgq5s9ObxB4ovdO1O10HQ4shr2/kks44wxH3Y1VpGZiRhVODkisr4W/A+TSdcl8efEC+Xxl8UtRG661i4XdFYqckW1kh4hiXJAwAWySTzgTuyjbuP2xPiX4yYv8ADz4Fam2mv/q9V8a6pFpII7MLcCSUjvzjivkj4sfD39oDXPihrcdrqPhrwMfiekn9oaPoV9NJbXEtvEiyO0kkJaBpIiQzRgliBkc5H3xXlPxH/wCS4fCb66r/AOiI6dguVfBPxp+OXwf8KaN4ePwL8P6z4f0ezisrePwr4nETxQxoFUBLmMbjgD+IEnPU16Z8PP26fh14u8QW/hrxLFq3wx8WXB2w6R4ytDZ+e3TEM+TFJzgABgTngVqVgeNvAfh74j+H7jRPE+j2mt6XOMPb3cYcZ7Mp6qw7MCCDyCKVgufS1c18SPHumfC/wDr/AIt1hmXTtHs5LyVV+8+0EhFHdmOFA7lgK+R/hn8Qdd/ZD8a6N4M8U6vda/8ABrXLhLHRNc1KQyXPh66biO0uJDy1s3RHblDgEgDNe1ftL6gl1r3wk8Kz+W9jrnikSXdu/Pmx2lpcXaDHcCeG3Y/7oHekMsfCmx1W28Dafd+IECeItUDanqig52XMxMjxgnkrHuEa56LGo6AV11FDMFUknAAySasg+bf2g/jppvijVpPgZ4K1W4PxH8RSjTrh7e2lC6XZsA13cGYqELJBv2hWJDMuQK998J+F9N8E+GdK8P6PbLZ6VpdtHZ2sCdEjjUKo9zgDJPJOSeTXjHwNt2+KvxQ8W/GC5G/S3DeHPCmRx/Z8Mh8+6H/XecMQeCUiTsa98oA8l/ZE+f4kftESAtg+NUXaegI0+1BI+v8AQV9MV8kfsX+NNN8R/Gj9pG00xpWto/E1tcpJIhVZD9n+zSsh6FRNaSrkdSpr63qCwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5R/awtT4Y+Onwa8XAbLa6urjQbqQdWaVSLdD6jMkzexUH1r6ur57/bo8J6j4j/AGf9Q1HRrKbUNa8NXtvr1nBApZ98LEMygAklUd2wAT8vAJwCAYOuTf8ACN/ELwb4hT5IpbhtCvSOhhuceUT6kXEcCg9hI3qa9kr5T8c/Hz4deMPhDreqaV410QXFtZjU7aG4vY4p47iDFxCGiYhwweNOCAT2zxXQeLf2jm+KEdv4V+D8smq6hqKAXvi2GItp2i27D5pBIQFmnIJEaISN3LEBSDZBPHoFl8RP2hNV8ezBbm08L2p8N6KxGVE+4tfTofXcyW+R0MMg716XWX4Z8OWXhHw/p+jadGYrKxhWGJWJZjgcsxPLMTkljySSSSSTWpQAV5V8RBu+OHwn9v7VP/kCOvVa8l+Jd0Lf47fB+MgsZ31aNT2BFqrZPthCPqRQB61RRRQBz3xB8C6R8TfBeseFtdtxcaXqlu1vMvcZ6Mp7MpAYHsQD2r54+HvxM1fxl8VP2fvBPi278/xt4B1fxBouqySHDXax6cDaXeDyRLCwOT1YMa+qK+Tf2oPBs3wq+N3w/wD2hdKtJriz0K5Wz8UQWqFn+wsrRfado6lEkdT3xs6AEgKR91swVSSQABkknAxXyH8bfi542+PUE/gT4QbdP0fVhd2kvimQEzXsUETNdGwQdY1wIjcMQC8qKmc7xqfHD49eGvitp9l4N8JeMLD/AIRjULL+1PFXiWxvF2WWk5IMAcH5ZrghowPvKokOM4r3n9m74aroWmy+Lb3TBpV7qdtFaaXpZj2HStKj/wCPe3C/wO/+tkHBBZEOfKBpMEc/+y3qVtq37NvwwubWKO3iPhywjMMYwsbrAiuoHsysD3yDnmvQ9b1SLQ9Gv9Rn4gs7eS4kP+yilj+gNeNfBCX/AIVL488W/BrVh9ke1vrvXvC7Nwl7pNzO0uyM92t5ZHjZeoGw4weO6+Os01v8EPiHLbqTcR+HdRaMAZO4W0hHH1xTF1PD/wBiGOXwv4g+HMlwxWTxj4DkurpsHEl3FdR3QJJ5yRqNyeeymvuavjDwFjSb79mvUIgE2yx6cwHA8qbRrjj/AL7jiOPYV9n1LGgooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisHxd4ts/Bukm8uhJNI7+Vb2sIBluJSCRGgJAzgEkkgKASSACaANe4uIrOCSeeRIYY1LPJIwVVA5JJPQCuB1D4/eBrJikGsS6yw4P9h2NxqK59C0EbqPxIx3rz/WI73xpdC88TyJeBWDQ6UhJsrYjkYUgCRxx+8cE5yVCA7RcVQqgAYAGAAOKdhXNW7/aN3f8AIM+Hni7U0xkSlLK1U/UT3KOPxWsm4/aA8d3Azp/wsjjz0GreI4oCPqIYpv0Jp1FFguZs/wAYvjJeNi38HeCdMXP3rjX7u6P5LZxj9fzrPm8efHi8YhNS+HumIf4l0i+umH0Juox69RXRUU7CONkvPjrekmX4p+H7EHoun+DgCPxlu3z+VUZvDfxdvwwu/jxrkWf+gboOmQfluhkI+ua9AoosB5bcfBvxNqS/8TH43/E25Pf7Nq8Fln/vxAmPwrOuP2V/CWrZ/t/WfGnijd94a14t1CcH6gTAHP0r2OimB5Jov7JPwa0HYbT4beHXZWDB7uyW5bI5BzLuPXnrXqtnZ2+n28dvawR21vGAqRQoFVQOgAAAA9hU1FAgooooAK8d+Kilvj98EsDOLjVz+H2E17FXkfxLjd/j18GiASEk1hmI7D7HjJ/EgfjQB65RRRQAUyaGO4heKVFlidSrI4BVgRggg8EEcYNPooA+fvEn7Dfwv1PxND4k0CyvPA3iGCYXEV94cnEISUZIYQsrRggnIwo5rsrfQ/j54fwNK+OkWqwLkLD4k8K2s7EdgZYXiJ9zjJ616fRQM+ffjB4J+PHxd0WyttZvvhxc6npkpuNL16xt9S03UtOmIwZIJo5WCkjAKkFWHBBwKvWd5+0g3w51Dwx4ksPAPiu6u7GSwbVo9RurKRleMoXkQW7KzYOTtCg+gr3SigD5w8IeF/jp4fm8C/b9D8DataeELaEWVu2s3UXm3aW5gFzKRbHOEdyqAAAsSSxCke0/8Lc+Pk2FXwz8O7X1Z9WvpfxwLdfyzz6iumooA57/AIWR8eJN3y/DqDjgeRfyYPufMXI/AUq/ED477gWvPh2R3C6Xf598H7V/SugopWAy4/iR8aIz+8XwJcD0WC9i7cDJkbv3xWlb/GD4n2zAXPhDwpfJ3e31+5gb8FazYH/voU6iiwGxY/HjU4SF1jwFqkH96bS7y2u41Hr8zxufoEJ9Aa7nwn8R/D3jaSSHSr/feRruksbqGS2uUXONxhkVXC54DYwexNeXVT1HSoNS8p5N8VxA3mW91AxSaB+m5HHKnGQcHBBIIIJBVh3PoSivPPh/4+uL66TQ9ddf7U2k214qhUvVAycgcLKAMso4IBZQAGVPQ6QwooooAKKKKACiiigAooooAKKKKACiiigCveXkOn2s11cSLFbwoZJJGPCqBkk/gK8T1TUp/EmsyatdqUO0x2tu3W3hJBx/vMQCxHcAZIUGuz+J2rMzW+kocI2Lif8A2gCQi/TcpJ/3R2JriKaEwoooqiQooooAKKKKACiiigAooooAKKKKACiiigArzLx5AZPjZ8LJQeIxquR7G3Qfzx+dem1lah4bsdU1zStXnVmvdLEotmViAvmqFbI75AHWgDVooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIbq3F1HsLvG6sHSSM7XjYEFWU9iCAQfUV6r4F8VN4i094rramp2uFnC8BwfuyKPRsHjsQRzjJ8wqxpmpS6LqUGoQjLxZDLnHmIcblP1wCPQgHtikxnuFFV7S6jvbWG4iO6KVQ6NgjII447VYqSgooooAKKKKACiiigAooooAKKKKAP/2Q==" /></p><p dir="RTL">7) اضغط على مكبس المِحقنة بإبهامك. سيتم بذلك إطلاق الدواء داخل النسيج الدهني في بطنك. تأكد من<br />&nbsp;&nbsp;&nbsp; الحفاظ على طيّة الجلد خلال مدة الحقن .</p><p dir="RTL">8) انزع الإبرة بواسطة سحبها مباشرة إلى الخارج.</p><p dir="RTL"><img alt="" width="393" height="386" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEA3ADcAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAGCAYkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK4f4mfGzwJ8HNPW78aeKtN8PpJ/qorqYefMfSKEZeQ+yqTQB3FFfOn/DU/ifxh83w6+C3izxHaHlNU8RSReH7OQHoyeeTMynrnyelMbVP2mfFB+WP4a+AraT1N7rd1GDj2t4yRz6jinYD6OrF8T+MtA8E6a+oeItc07QLBeWutTu47aIY65ZyBXgr/AH4geKP+Rz+PXi+9jPW18LW1roUJ9RujRpsf9tc+9aHh39j/wCEfh7UU1OXwfb+IdYBBOqeJp5dWuSR333LSEH6YosAl5+2p4N1ieSz+HOj+Ifi1qQJQDwrpzNZI3QeZezbLdR7hz9Kyrvw/wDHX40DZ4l8QWfwd8MS/f0jwjP9t1mVT1WS/ZQkJ94UJHZu9e7W9tFZwJBbxJBBGAqxxqFVQOgAHAA9BUlFgOM+F3wd8IfBrRJNM8JaPFpsc8hmurlmaW5vJTkmSeZiXlckk5YkjOBgcV2dFFUAUquY2ypIPqDSUUAXYdSZcLIN4/vDirH9pQ/7X5VlUUrAdBRRRUgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeOfHD49TfD3U9M8HeEdIHi/wCJutxtLp2hiXy4beAHa15dyAHyrdTxn7zt8qgnJAB6V4o8XaL4H0S51nxFq9loek2w3TX2oXCQQoPd2IA/OvC5v2vZfG7GH4Q/DvxB8SFJwutzKNI0X0JF1cANIAf+eUbg9jUHhX9mODWtatvFvxe1X/hZ/jOM+bCl9HjSNLY87bKyOUXHAEjhpCQCWBOK9yVAihVAVVAAVRgADsKdgPC5PAvx0+Jmf+Ex+JNh8P8ASpOG0f4eWebllPOG1C6DMG7ExxJ04I611Hw5/Zt+Hnwv1BtV0jQEvPEcvM/iHWZXv9TmbuWuZizjPcKQPQCvTicDJ4HUk01WEihlIZWAIZTkEHoRVAOooooAKKKKACiiigAooooAKKKKACiiigDoKKKKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivP/jL8aPD3wP8Lrq+uPNc3V1KLXTNHsU8291O6b7kFvEOXYnGT0UckgDNAFf46fGjTfgj4KOrXFtLq2tXsy2Oi6FanNzql8/EcEY9zyzdFUEnpg8b8AfhHqHgWx1XxP4vuYtW+JnimUXuv6lGMohAxHaQE8iCFcIozyQWPLYGV8J/hX4j8ReM/wDhbHxVEL+NpoWg0fQYJPNtPDFo+CYYz0kuHGPNmxkkbVwo59vpgFFFFUBkeLtQOk+F9Vu1Xe8du+xf7zEEKPxJA/GtGzh+z2sEX/PNFX8gBWT4oH2r+y7ADP2q9jLD/ZjzKSfYmMD/AIEPWtygAooooAKKKKACiiigAopWXCg+tJQAUUUUAFFeefHT4tRfB3wHLqsVk2sa/ezx6boeixH97qOoSnbDAvoCeWP8Kqx7V86/8Ke/bb/6Kl4N/wDAE/8AxFAH3bRRRUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFfFuoeCvEH7cll4o1y68eeI/BPw8W8uNM8K2fhm7+zG7WCQxSahdEDMyySI4SMkKEUH7zbq8usfgH8W/hPG2n2el/Ee9ksWYL4k8CePlWC+jGdkj6dqMz4kwcMgyuclTggB2A/SOivzui+Nv7UPh3/RfDmmeL/GF0PljtPGngK1thkYADXltexR4/wBsqc9ea9z03w3+0j4/0ezPir4h+Gvh158KtdWXg3QzcXUZIBaMXF1LIisMkblQ8jIJ4NFgPQ/jn+0Ro3wZhtdMgtJvFHjvVVK6N4T00g3V23Te55EMKnlpnwqgHGSMHjfg98Hb1vEsnxJ+I+qW3iv4mXURiRrfP2HQYG5NpZRnJUY4aQ/O5BJIBxXU/Cn4D+FvhDJf3ulx3mqeI9TIOp+JNbumvNSviOnmTtztGBhFCqMcKK7a4ju0voZYhDLATtkVlw6KR1DZ5GcZBH40wL1FFFMAqO5uYrO3knmkWKCNS7yOQFUAZJJPAAHenswVck4AGSSeMV59Y38nxO8QGSL/AJFDTZcBu2o3Cnj6xIefRmA6gcAG/wCH/M13UZdelWSO2aPyLCKRSpERILSEHkGQgEA8hVXoSRXR0UUAFFFFABUVzdRWdvJPcSpBBGpZ5JGCqoHJJJ4AHqawfFPji08NywWaQzanrFwM2+m2gDSuOm49lUd2OAMHriqMPhO98UTQXvito3jjIki0W3Ym2jI5BkJx5rD3AUHoD1oA39A1ga/pq3yQSQW8rEwGQYaSMHAfGMgN1APOCCcE4GlQOOlFAC7vlx75FJRRQAU13WNC7kIigksx4AHUk06vBv2jdY1H4ga3oXwQ8MXUlrq/iyN7jXb+3OH0vQo2C3EuR915iRBHkcl2PG3NAEHwTs2/aJ+Ll38Yr9DJ4M8PtPpHgW3cfJOclLvVcHqZGBhiP9xGOAWzX1BWZ4b8Pad4R8P6domkWkdhpWnW8dpaWsIwkUSKFRQPQAAfhWnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMkTzEZTwGBFPooA+ZP2Mbg6H8J5/h3e4i1/wCH+p3Xh6/hbglVlaS3nAPJWWB43BPUk+hr3uvJvjD8GPE9v46X4o/Cu5s7Xxstslnq2iakxSw8RWsZJSOVwCYp0yRHNg4ztYFTx8gXH/BVXUdSujLZeGNK8OWe9oxFrQvLlyVJVj5kMQjxkHGC2B1PancD9GKK+Rvht/wUI0DX7OGfxPpUFlZscSap4f1BNSgh5wWmhAWeEcjqjYyMkA19V6Jrmn+JNItNU0q9g1DTruMSwXVtIHjkU8ggjgiqAvUUUUAFVtS1K00eyku725itLaMZaaZgqj8T6+nesS+8aRnz00fT7rX7iFtjLZ7VjVh1UyMQuR0IBJHcV5X4z0jxfrGtWmr+KtHmn8PQfMun6HdkzWh4IkOAC7DuRwB0x3AOy1KbU/ilJ/Z9ilzpHhUnF1fyoYpr1e8cSkAqhHViBkHAGM577TtPttJsYLOzgW3tYECRxoMBQOgFed+GPDuieJLcXOgeN/EDoOWjTUt7IfRkkQkH2Irpf+ENuYoznxXruAOWaSD8/wDVUAdPVHUtb07R499/f21knXdcTKg/UivN/EGj+cxgj1zxtrLnj7PYlYUPsZPLRQP+BVV0f4G22qTJPrFnFptn1+wQTGe4lPrNcNyc91TA9zQB1zfFvwxLc/ZrC9k1i87W+mQPOx/FRtA9yQKnZ/EviNcRovhiybrJIVnvGHsoykZ9yWI9Aa3dH0PT/D9oLbTbKCyt16RwRhR9Tjqfc81eoAx/D/hXTvDaym0iZ7mY5nu7hjJPMfV3PJ9hwB2ArYoooAKKKKACsvxN4p0fwXod3rOv6pZ6NpFqu+e+v51hhjHTJdiAMngc8kgDmqPxA8faH8L/AAbqnijxJfJp2jabEZZ52BJ6gBVA5ZmJCqoySSABk15H8O/g/rXx61/T/iV8YNOa206BhceF/h7dYaDTEP3bq9XpLdsCCFIKwg4A3ZIQCN+0prPxUkGn/A/wfdeMHkyG8Wa5DLpugWo6FvNdBJckH+GFTkc7gOa9D+BvwRu/hpeeIvEvibXv+Et8f+JZIX1XWBai2iSOJdsNrbxAny4Y8uQCSWZ2YnJwPWVRY1CqAqgYAAwBT6kAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvzR+LHhWDUfHnxNufh7cWL+CtDvhb32m6lai60/7cUDXAt3yGjkEkoG1SUBDZXgAfRfxs+KWvfFjxJ4h+HHgDVZdC8PaBEx8beNbU/vLMbCx0+ybp9qZfvydIQR/GQBwGlfD7TvCvwR8HeBNKs1sYdWlWRreMnIEr7iSTklghJJJJJXJJPNNK4j5xH7NeteJNK8NB/BUg1fVwX07VtL1GCKblS+7JKOgCjODlemRzivsn9kP4X+N/gL8GY9F8WQf2zq1zfTX7W+nzxkWiyBQIgGKpn5CzbCV3SNjI5PYeFdESb4n2qQoBYeHdIEUC/wBySZgo/wDHIiPxNer1Ww73RzMniLXZ1xZ+FrhW7NfXcMS/jtZz+lV18O674gY/8JBqMMFkeum6SGRXHpJMcMw9QoUHvkcV11FAGawfRoYYLPT0NhGoUR2xCtGB2CYAI+hz7Glt/EGn3EvlC5SOfvDNmN/++Wx/KtGqt9ptpqcPlXdvHcJ2WRQcfT0+ooA5nxR8LdE8S3Qv1SXStXU5XUdNfyZs+pI+9+IJ9xUMOk+N9DtPLttb0/XQv3f7StWilx6b42wT9VBPc1rR+FX0w79J1Ce0A5FvMxlh+mDyPqDmrtnrG6Zba9j+x3h4Ck5ST3Ru/rjgjuO9AFbTYNXvo1lvL9rRs4NvDaohBHYlmkBHuDj+VbSKVQAsXIGCzYyfrgAfkKdRQAUUUUAFFFFABTJpo7eF5ZnWKKNSzu5AVQBkkk8AAckmo72+t9Ns57u7nitbWBDJLPO4SONQCSzMSAAACSSQABXziv279tjWpbKxuLvTPgHYSGO81C3ZoZvF8ynDQQsMMtipBDyAgynKqdoJoAteCrc/tcfFOz8YzxmT4O+Dbtm8PxyKdniHVUJVr4g/et4DlYuMM+5skKBX1XVLSdJstA0u00zTbSGw0+0iWC2tbaMJHFGoAVFUDAAAAAHQCrtQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzp8WvjTr/jzxZf/AAq+EMyHxFDiPxF4uZd9n4ajYcqD0lvCM7YgcLwzkAYqp8evjBrvi3xFqfwt+G19Jp+oWNr9p8XeLoE80eHrQoWEUI6PeyqDsX+AfMR0xm/Br4heDvh38O9L0nwf8PvFsPh5VMkd3b2cd01y7HLzSukrM8rHJYkE5yDjAAYG3rHw30b4T/B3Svh54aSSKHUrtLOS4mkL3Fy0jGS5uJn6vI4VyzHqWwMDAFWGBdb+KsWxR9k0e3YqoHAbGxcfTMn5Vj+KPjz4W1L4gabcajLfaJZaTYzSRrq2nzW265kIXGWTHCKec4+birvgDXLOTwv4g8SWl3b6g8m5la3lV921SQuQTyWJAHqaonqenfDO38631nVSOb6+dY2/6ZxYiA+m5HI/3q7Ssvwto/8Awj/hvTNOJ3PbW6Ru395gBuJ9ycn8a1KCgooooAKKK8P+LX7V3h74e6pqOgaFYTeNfFOnxedf2VjcR29npadQ9/eyERWqn0YljxhTkUAe4VDdWcF9A0NxEssTdVYZH19j7jkV8weA/j/8XviJptxr/hXS/hZ480y2b/SNF8M+K5ZL6MHJ2iZoREXx0DBQcHDYOa9n+EXxo0L4x6ZfyadHeaVrOlzC11fQNVi8i+02cjISaPJ4I5VlJVhyCcHABvywaroXz2hbVbIdbeVsTIP9hz94D0PPvWhpWuWmsI5gdhKhxJBICskZ9Cp5H16e9aCnHB6d6p6hosF8yS4Mdwg/d3ER2uv49x7HIPcUAW6KwYvEDabfpp+r7YpJOILoDEU3sf7reoJx6HkCt6gArD8beN9C+HPhfUPEfiXVLfRtEsIzLcXd021VA6ADqWJwAoBJJAAJIFc38Xvjd4a+DOm20mryT3+s6g/kaV4f0yMz6jqc3aOCEcsckZY4VQckgVx/w9+A+vfEzxNZfET42RQz6pbSC40HwNDL52m6AP4JJP4bm7weZCCqnIQDANIDD8N/DnXP2tr6DxT8SdPvNC+FcbCXQ/AdyTFNqgBBS71RQeVOAUticAYL5PB+o7Gxt9Ms4LSzt4rW1gQRRQQIEjjQAAKqgYAA4AAwMVZoqQCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8k/aW+K2pfCv4dJ/wjkMd5428Q3sOg+HLWblHvpyQsjj+5EoeVv9mMjvXrdfOfxUUat+2P8H7G8OLPTvD+u6rZq3R7staW5IH95YppMegc0Adj8FPhDp/wa8B22g2csmoX0kjXmq6tcc3GpX0h3TXMpOSWZsnknAAA4Arivix4bn+D9hqnjzwULa2kUBtQ8P3BZbLUXZgqFQoJimLFRuUYbPIPJPuKsV6V5J8ebo6tq3gjwvFy2oaoL6ZexithvAI9DK0IqwPN9Y8WfF3RdPa/1n4d+FtRtb58C307xKyTEAcAedbhDwM8sBz1Gazrjxr8M9Ym+weMNEm+G3iSxhN3Lb65B9gumhjwd9tdQnbOqsFwEcnjlcZr07x5fLqfiTS9LtCssNlHuYKcgADJB+ioOPevNv2gPFWgeHfG2meI/E9n/btp4J0ibXPs0iCRpb24ZLe1hjUggOztheOCQe2aBaljwp8UPjRfTSyeD/CTeKfCjr/oeoeOLpdJuGHZlMaPI6EcgvEpIIO49+mm+O3xX8Jr9o8V/BKe802MZluvBuuxanKg7kW0iQyNj0XcfQGqn7PPxl8XeNPEninwl8RNN0nRvFulxWmpwW2lM5iksblCRguSWaKVJI3YYUkKQBkZ9zoDUz/ht8TPDnxb8K2/iHwtqK6jpkrtExKsksMqnDxSxsA0cingqwBB7YIJ6dmCqSTgAZJJwMV8iy/FvQP2eP2qPiJpV5aapev4w0nS9b0/Q/D+nS3l1d3im4t5zHFGCASkMRZmKj5QSc11kngXx3+07f8AmfEGwvvh98MI+YvBsV6BqOsk/wAWoSwsRHDjpbxsSxJ3tgAUDF8RfEnxH+0Z4gvvB3wr1STRvB1jKbfxD8Q7cAncDh7PTSQVebGQ0/KxZ4y2MeRfDz4c+H/ixJHFpOlxaZ8EPD+oSf2No4yzeJr6Jysmp3ztlp0EisI1cncV3tkbQPs6LwjYaP4Mfw5oFpbaHp8dm1paW9lEI4rYFCFCKoAABOeK+Tf2bfiJ4c8M/CPR/B+u6lYeGvE/g+1XSNZ0nUbhLeW2mhGwyEMRlJABIsgyrBgQSc4BM6jx78GRfaxaeMPAl3D4L+Immri01a2hAhuo+9reRrgTQtgAg/MpwykEYPEXH7QGi6b42+FXxo18Wvge41C71XwH41jMu6DzbeOWSM7wP3gSe3IjbG7bOV65FXPFfx0ufiFpmqwfDbULSw8OWKN/bXxN1T5dG0mMcObdjgXU4HCqhKAldzc4PiHgGzvvj98RPDulfCu81DwV8PPhLFJPpniDWLBbi61bWLkbzdTQzDDbwxk5AYCQEbTIoUBH6JfDf4z+BPjBazz+DvFeleIxAQJ0sLpXkhJ6B487kJ7bgM12O4xtjtXwx4uvdR8aawLHxP4btvAfx+02wudR8K+OfDrD7FrjWyCR4Gbh9rKMPbzBgFLFScV9dfCfx2nxQ+F3hHxekP2ca5pVtqPk5z5ZliVyue+CSM+1AzpdU0u01izeC7hWaJ+qsO/qD1BHqK8D8U/Ebxre+Obr4SfDBrHUPEtvEtzqPiPUgZbTw5aSf6szIMGa5bBMcORkDcxC8HR+K3xX8SeJfFl18K/hNFFd+NzAj6v4gnw1j4Yt5MhZZf8AnpcMMmOAcnAZsKDn1P4M/Bnw/wDA/wAHpoWhJLPLLIbrUdVvH8281K7bmS4uJDy7seeeAMAAAAVN7aAYXwf/AGb/AA58KdRufENxc3ni/wAe3ybL/wAXa84mvZh1McfAWCEHpFEFUADOcZr1uiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5B+0F8H9X+Ilt4c8R+D9RttH+IPhK7e+0W6vkZrWYSIY57S4C/N5MyYBK/MpVWHIwfX6KAPmWH9o7xpp8P9naz8A/iCnilf3ZttKhtbvTpH7FL3zlQIeuXCkDqueDyfw51Dxz8TPjl4h1Xx3pNh4X/AOEftY9OttF029N2YvMUTOJrgAKZQXhyIxtG0DJIJP1/d3UVjaz3M7iOCFGkkduiqASSfoM18qfCfVJW+HGu+L7gGO98SX1zqeG6qJXJjA9gjRj/AIBjtTV2JnXeB7WLWvE2s3gRVttpgjC8DDcDHvtH614Hf6T/AMNCaL8YU8L6haXXjfw/4h057HT7iQBS2nNHPbpICeEmIdQx4zk5+U17lp+qR+Bvhbq+uTEL5NtNdkk+ikL+oB/GsXwp+x34f8UfDnwVrv8AaOteCPiLHpqyy+JvDVyLa7czsZ3hnVlZJ0DyEbZFOMcEU3oCPBPH/wAavA/iSfR/FNt4ytPhN8XvDYdI7HxUrWrgNgzWN3GwBmgcgfMhOCA6nIIPsfwn/bX8FeNfhbqvjDxRNH4Lg0Wf7Hfz3Uwlsp5gCc2Uyj/SVIGQFG8ZAKgkE9Befsn/ABI1KVEv/wBoXW7m1X5Qf+EX0oXAX0EvknB6chc10ngz9if4ZeGb59U1uzvviH4ieNoTrXjS6OozojAgrGhAiiHJ/wBWinmlcLHD/sywXnxa+JHir463enSaZouuafbaL4Uhu123MmmRM8j3TL/CJpX3Kp52qpPUE/SlfMfwJ8af8M56la/Aj4h3A019PZofBviC7IS11zTtxMMQkOFW5iUiNoyQSFUrkHJ+m6oYteK/tLah8F/h/wCFpPHPxZ0Dw9qEdkvl20mpaZBdXc78lYYQ6lmYnOACAOSSACRsfGD9orwp8IGt9MuJJvEHjC/OzTPCeir9o1K+kPQLGOVXuZHwoAJzkYPyr+0H+z/r/j638A+IfjRMja/418Yad4eXQrGcmy8N6VIZJZLaGQfeuZvJRJLjqdxVMKOUBo/s43+qft3eJW8a+KtAi0L4LeF7hYvDPg5APIvrxMH7RcgALIIgQAgGwMxABKsW0PgX8Q/CngDR/GmkeLPEGmeHPFtp4n1a61u21a7jtpi0l1I8cwDkFkaEwlWGQVAAPGK+xPCPhHRvAfhvTvD/AIe0230jRtPiEFrZWqbY4lHYDuSSSSckkkkkkmqfiH4b+EvF2oQX+u+FtF1q9gA8q51DT4p5Y8dNrspIxk9CKYHxD4k8San4+h1P4mafBLJJqjN4H+FtjOjJ9pubtTHdasVIyECB9rEACOFjgbwa9sbVfEMLaN+z/wDBieG2u/DOk2llr/jK7iEsGgwCJVjVI84mvJFXcqEhVBDNkHFec/F74vXeuftdf8I34O05fEfjDwjo50zw1o6j/R4dVvFDXN9cMOI4La2EKknkmYqoJJx9a/Aj4P2XwR+HttoMV0+q6rPK9/rOsTL++1K/lO6e4c9csxwBk7VCqOBUgXPg/wDB3w98EvCKaF4fimcyStc3+pXrmW81G5bmS4uJTzJIx5JPA4AAAAruqKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeT/tReIpPD/wT1+K2fZfauI9HtsHkvcOIiR7hGdv+A15prdqui+FtA8PWw2COJECAYIwBgH6FiPwrZ/aPvR4l+KXw38Hg77e3kn8QXsfosa+VET9TJMR7rWVJMdY8cBicpbjJ9Mjn/wBCP6VaEyn8Y7Mat4b8L+B4D/yMerWmmOF6i3DBpj9Agcn6V9ULGI1CqAFAwAB0r5s8K2v/AAl37TmlRn57Xwpost6zdQLi4PlID6Ha03/fNfS1SwQUUUUhnN+PPh54Z+KHhy40DxdoVh4i0efl7PUIFlTI6MM/dYdmGCOxFeLL+wv4IswLbSfFXxG0HRhx/Yum+NL+Oz2/3QpkLAdsBhX0bRQB5z8KP2evh58EluD4N8L2ek3d0MXOosXuL257/vbiUtK4zzhmIp/x2+D9l8cvhvqHhe6vptJu2kivNO1a2GZtPvYXEkFwgyMlXUcZGQSMjOa9DooA+UNN/ae1b4QQrovx88O3vhXULYeWPGOl2Ut3oGpAcCVZY1Y27NjJjlVdvODjAE2tftwfD/Vbc6d8Mp5viv4zuV22OheHIJJQznhWnmKiOCIHBZ3YYAJwSMV9U1FFDHCpWONYwSWIUADJ6n607geDfsp/szp8EbHXvE/iKWHV/ih4xum1LxHq0eSiyOxcWsGeRDGWIHdiMngKF9+oopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVj+LfEVv4R8Laxrt2cWumWc15L2+WNC5/QUAfLs3iS38RfHz4i+IJZ1MWnCPQLHcecQjM2PbzHlHvke9a3gdRNNc3kxwJHwzegHzMfyOfwr8uta/bL8f+AvGmr2lharqGnLcNPcW2qWi+ZHdSHfcZaPa4Hms+AzHgA9DivV/hl/wUCuPGtxLo8nhy6h1Ka3lJmsbgbdqxkuzI2MKFBJ+ckjgAnAN6WsLU/RP9lG0fWW8feNJlxJrWtNawt1HkWw2DB9PNab8q9/rgPgL4RfwL8G/CGjzJsuorCOW6U9ftEo82b/yI7V39QMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvnr9ubxBe6f8Br7Q9LsrjUtU8SXcOlQ2dpKI5pUJMswRiRgmKJxnIxu4OcV9C18wfHjVv8AhIfj74b0lTut/DWkTalLjoLi5byowfcRxyH/AIH70wPwm17S9Yj1y9k1nT7v+1TO7XDiVxcmYsd5dXy27Oc5AOc5r6G/YZ+Fr/Ev4v6Ql3DLfWr39vYlrk7JoSW82Y4BJZTbxTA5IA3DgnBH6MeLPgl4A8fat/afiDwppup6hgK1xLFhnA4AcgjcAOBuzgcdKvfs2/Dnw7b/ALRmoXHh7QNO0fTfDWkn5dOtUgX7ROxiQMFAyQsVxgnJw/vRsI+zKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/OeH40a94s+LHxW1rQ/hn4r8ULD4km0eW8tBaxQxpZqsCovmzKxbhnIA48wZOSa/QjXtatfDeh6jq18/lWVhbyXU8n92NFLMfyBr40/ZRW9t/gdour6gmzV/E8tz4lvdx5eS9me4BB4OQsiD8BxTQmYGh/tC+HL3Vk0bWLXVfBviGRSYNJ8TWTWktwQOkLkmOU9gEck+le6fsY6KzeC/Eniub5pvEOsTNHL/AH7e3xboR7F0mb/gVeO/tdbPEXwhk8MHT7TUdZ8T6lZ6BpIvIFkMV3cyqglUkZDRp5jgjkbM8V9hfDnwLp/wx8B6D4T0oyyafo9pHZwyXDbpZAoALuQBlmOWJAGST0oYI6aiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoryzx1+0x8Ofh3q91per6+0l9YoZb+HS7G4vzp8YGS9yYI3EAA5/eFTjkDFejaXqlprmmWmo6fcxX1hdxLPb3Nu4eOWNgCrqw4IIIII9aALtFFFABRVDWNc07w7p8t/quoWumWUYzJc3kywxJ7lmIA/E15Xe/tYfDzzTFod7qPjJ843eF9LuNQgyP+niNDAPxkFAHsdFefeAfjb4b+IWsSaNbC/0jxBHb/bG0fWbRra5MAYKZEBysihiASjMFLAHGRn0GgAooooAw/GnhHT/H3g/XPDGrpJJpWs2M2n3iQyGNzDLGY3CsOQSrHkdK/PT4Gf8AC7m+GtlqPhWXw3468Fi4urbRbTXp3sNUWxhnkhtyZ4ozFJujjVssgPI5PWvuL9onxhJ8P/gL8Q/EcJK3Om6Be3Fvt6mYQt5YHuXKj8a+fNdvo/2dv2b9G07TrT7TqdnY2Og6XYwnDXF9L5dvEo9SZH3E+gY9qaEzF+Bfh74g/tAfFjwH438UeDrXwt4K8IT6lcQsurpejUNRXNpGUUIpCx5uCGIwSAR2z9xV45rXj7wJ+x78ENDHjHXYtL0zSrOO0WQoXmvZwoLmONQWd3YljgYBYkkDmvlr4L/8FYdI+L/7SumeDH8Or4c8EasGsdP1G+lzdveEjyTKAdkaPgoFG4hmUlsZANxn6EUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis3xB4h0zwnot7rGtahb6VpVlE09zeXkojihjAyWZiQAB6mgDSr5z+NnxW8SeMrjUfBPwqjmv7izmEHiPXrC4jhawUg5tbaSQhDdHjccnyVJJBcqtfMnxa/4KKyfFSTWLP4daJ4t1zwfYySRTnwrYTxXl+iA7mlvShFlAwyQYlaUryWi5FdH4N+H/7VXjrRbLTtO/4Q/wDZ18IQrsg0/T7ZdS1FIycnIO6Pcckk5RiSSRkk0wPVvh1+z2lpb6f/AMJJaWNlpVhKLiz8LaZK81qs2d32i7mcBrubd8wLKFDHJDsA47v4N/EDw94H+G+s3PiDxBpegaNa+JdZgtZtSvI7eNY1vpgUBcgYDbwAOgAA4xXz54j/AGbfDOjTRaf8Tv2hfiN4w1uVQ/8Awj2maq0L3I4BKWFqjTMORyMgZySOtdJ8NU+F/wALrlNF8E/DbQ9G1C0B2y+K9dsodRwWLEnfJPcqCxJw6qQSflBNPcD3D/hoceLI2X4ceE9V8aZ4XVLlW0vSc+v2mZN0i/7UEUoqk3hn4seLudf8f2XhK1brp/gvTVaYD+613diTd6ZWGM+mDzVuLxd491GHfpnhrwndjs3/AAlcuMc45Wxb2pZvEXxRjT934G8NSyHP3fFUwXPbJNgDj8KLAeba9+yL53idtbstftvEF2+0iX4gWk+vS2zAAE27tcRiJTjJUKOScEDAHV2PwH1q6Vf7b+IurOBgG10CxttPtseg3JNMB9JQR61haheftCeJvGkmgI3g3wJo5sxd/wBtWlvda1LnftMSmQW8YfGG+ZWGDkA84vt+zn4h8QY/4S340+PNajPDWulzWujQMO4zawpJj/tpn3pgc7dN8Mvgb+0F4enfUBa6rBoF815Ld3U+o6ndefNbi3hRSZJpATDcMEQEL5ecDIz3d7+0B4o15ivhPwDNb254XUfFl4LFT6MlvEssrf7sgiNcrov7Efw88J32o3fhq98VeG5dRcSXbWOv3DPMwGMvJKXcn6sefStiP9knwNKoXVL3xdryAkmPUvFupNG2ezRrOqMPYgj2pWA6b4Y/Gi71jxm3gjxZNo6+KJLKTUbR9JdliuII2RZAYXdnjZDInViHBJBG1gPYq+Xbj4a+CvAP7QHwe0fwR4Y0rQtVjm1PVL9tMtEjkOnrYyQM0zgbmDXFxagFiSSOOhx9RUgPJ/2pfBuq+P8A9n/xroeiW327VLizDw2m8J9o8uRJDECeAXVCozxlhkjrXi/w9gu/2mvjN4U8Tw6RqFl8L/BYOqWt3qVs0A1jVnjMcRiRwGaK3VpG34AMhUDO0mvff2gPFdz4L+DPi3VLFd+pixe2sY84L3UuIoVHuZHQfjXSeA/Cdv4D8EeH/DVo2+20ewgsI2IwWWKNUBPucZ/GgDT1KC0nsZkvooZbPYTKs6hk2gc5BGCMZ61+cX7LH7HPwz/au8JePPih4q0GWwfxF4uvp/Dtxo072LWNjE4WPy1TCZ3hwcqRlAR1NfWP7cvxKb4U/sq/ELWYJDHf3GnnTLPafm865IgUr7r5hb/gJrrP2afhqvwf+AfgPwf5Yin0vSYEuVHT7Qy75j+MrufxpAd7o9jJpek2VlNeXGoyW0CQteXW0zTlVAMj7QF3NjJwAMk4AHFX6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5f4kfETQfhL4E1vxh4nvRp+haRbtc3M5GTgcBVHVmYkKoHJJAHWgDz39o/9qzwb+zXplgutzrqPiXVpFh0nw7b3EUdxduTtDM0jBYogfvSuQoxxk8H5z8S/ESw/abvLa18VaRffEyy0+Rbn/hAvhzIL3RoJhyn9o6o7xQXMq9RErqikElX4auZ+Bv7Kcf7WHj7xB8fvjjokt3beIZg/hjwrfSOotNPU4gaZVIBygGEPByzEEsMfduh6DpnhfSbXS9H0+10rTLZRHBZ2UKwwxqOgVFAAHsBTA8F0vVvjVdaOmi+HPgv4M8DeH44vJhs/EGvq6pH02/Z7OB0AwT8ocj3rC+IFj4p8NaBP4h+OnxmXw/oDOIovDfgC3fTzdSHhYUuCWu5nboFiKE9emSO28eftF3Fz4nvfA3wq0P/AIT3xzbER3spkMWkaKx6G9uRkBh18mMNIcEEL1qz8Mf2dI9D8Tp478f6y/j/AOI7IVTVLqMJaaYp6xWFvkrAo6FuXbkluSKoDzv4W/AXUfGGmyOdDk+Dfw/vT5p8OaTIYtf1lT0fVL4EyJuHJhRy+CQ0nBWvbdO+APwz0rQ4tGtvh/4aTTIzkWz6VBIpPdm3ISzHuxJJPJJNd9RQB5XqH7Knwb1J/Ml+F3hKObp51to8EEmOuN8ahse2ar/8Ml/CPPHgixX0VZJQPyD4r1yigDx+T9kr4Wf8u/hy4045yG03V720bPrmKZeeKjH7Ot7oUnmeEvin478Pbfu215qa6zb/AEK3ySvj2Vx7EV7JVC712wsdWsNMmuAt/fiRra3ClmdYwC7cA4VdygscDLKM5YAgHhXgk/tMWGlSvrjeA9cube7ng+z3UVxp73EKSMIpkmhedR5iBW2tEpUkgjjJ5/4rftfeO/g3Jplt4g+BuqPc6lOLa1vbHW4JtOkkIJCGcJvVyRhVaIFycKCeD9SVwPxi8efDrwl4Xns/iPqej2+kaihgOn6oFlN4D1RIMFpT04VSc44oA+X/AIG/Fb4t3vjbxF4kn8E+E9Z8fa2FgNnqXi9tPn0+wiZmhtYrNrQyogLszM2S7sSTgAL7qnj79pCbJ/4Vz8PrbH8Mniu6cn8rIYxXzd4p0fxPr9v9m+DXgfxx4j0LIaPS/iFpkC6Nt7GGS9mivYxjpjcFGMKAMV6p8KvEX7SngvwVYaNrHwp0PW5bVpAl1ceNwswhMjNHESbeQsY0KpuZyWCgkkkkzYCP4oeJvj14s8Q+CvDGoeE/AUN3LqkeuQWtvrt46SLYkSnznNqCiCUw4KqxLFQQBk16EfHn7SEalv8AhXvw8nx/Anim7Un8TZVwNv8AEj4j6D8Xrrxl47+C/iO10mLRo9JsD4XurXWvs5adpbqR0jkWYhwlsAFiJAjORzXt3w3+NXgr4srcL4Y12G9vbXi602ZGt721PTEtvKFkj54+ZQCehNFgPJ/iBJ8Xviho9vpPjL4DeC/EenW13FfxQDxvKqrPESUcA2anIJPBJByQQRXUj44fG+33faP2fVnA/isPGtkxP0EiR/qRXs9FFgPGR+034508D+2P2efHcHPP9m3ul3wH/fN0Cfypy/tlaVaH/ib/AAv+KuiqD80k3hCe4jX6tbmQYr2SiiwHkEP7d3wR3Kl/4yk0CQ8FNe0i907aenJnhQD88V3vhf8AaE+F3jYoNA+I3hTWJG6R2WtW8r/QqHJB9iK35YknRkkVZEIxtYAjH0NcN4m+Anw08ab/AO3fh/4Z1Z3+9Jd6RA78/wC0Uz+OaLAesxyJMgdGDowyGU5B/Gn180N+xR8LLF2l8N2Gs+B7k5In8K6/e6dtJ7hI5Qn4FSPanr8C/ib4X58I/H3xMkY5Fr4u0601qM+xcpFLjoM7yfc0WYH0pRXzgnjL9pHwZzqPhHwN8SLReN+g6nPo14R3JiuFljJ9hKB9Knj/AG0vD/h1hH8RfBfjX4ZOvyyXWs6O11YBva7tDNHj3Yr68DmkB9EUVyvgP4peD/ihp/27wj4o0jxLaYBMml3sdwFz2YKSVPscV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8jeLJI/2xPjVc+GZLcz/B/wCHeog6m7cxa/rcfS2I/igticuDwzkAggZrt/j98UdZ8QeJYvgz8OtQWz8cataNcarraKXXw5pp+U3BAI/fvnbEmQckscBRnuPhf8NdD+EPgPR/CPhy3NvpWmQiKPedzyMSS8kjfxO7FmYnqWJ46U0B1CqI1AACqowABgACvn/xd408T/tAaxdeDvhpfzaH4St5Wt9f8fwgZ4JD2mmE8STZBVpxlIuQCzjA9i8Y+EY/G2nppt7e3MGkSE/bLW1cxtdrxiJpAQyoedwUgsMAnaWVtbTNLs9F062sNPtYbCwto1igtraMRxRIowFVQAAAAAAAABVAYvw8+HPh74VeE7Lw34X0yHStJtAQsUYJZ2PLSOxyzuxyWZiSSSSTXSUUUAFFFcN4q8SajresyeFPCs6wakoVtT1baHTSomGQADkNcOOUQghQd7AjasgBc1L4n6NpurXmnJFquo3Nmypc/wBl6Tc3aQOyhgjvFGyhtrKxXOQGUkAEZq/8LIv7r/kG+BvE1+D0kkit7RfxE80bAfRSfauj8M+GdP8ACOiwaZpkTRW0ZZi0jl5JJGJZ5JHJJZ2YlmYkkkkkkmtSgDhLi4+IuuW8sVvZaD4WEikJdzXUmozJkEAmERxICOD/AKxhkcgjrgeGfhj478L391qj+MdE8Qa3dKsc+o6poUoneNSSsSmO7CRICScRoASSSCSSfWqjuI3mt5I0kMTshUSKASpIwCM8ZHXmgDyFfEnxL8darqPh7TbbRvDdjaMIbrxfZ3T3vzjIkitreWFFMynALM0kaEkEOysg6bwL8EPCHgDUJdWs9OOo+JLgf6T4i1eQ3epTnvunfLBfRE2oOgUDArtNP0+30mxgs7SIQW0KhI416AD3PJPck8k5J5qxQAUUUUAFcT8QPg74W+JMltd6rYGDW7Pmx13T3NtqNm3YxXCYYD1Ukqw4ZSCQe2ooA888J654i8JapB4a8Z3CaoJjs0vxNFEIlvSBkRXEY+WO4ABIK4SQAlQpBQeh1V1TS7bWbCWzvIhNbygBlJIOQQQQRyCCAQQQQQCCCAamt43ht443kaZ1UKZGABYgYyQOMnqcADPYUASUUUUAFFFFABRRRQAUjAMCCMgjBBFLRQB5P44/ZW+F3j3UP7UvfCdrpmuglk1vQmfTb9G/vCeAo5I/2iR6g1gR/Df41fDD5/AvxOj8b6XH93QfiNb+dJjuF1GALKD2BkST3zXu9FAHitj+2DaeEbiKw+MHg7WPhTdMwjGq3WL/AESRug238IKpn0mWMjvXveja1p/iLS7fUdJvrbU9PuFEkN3ZzLLFIp6FXUkEfQ1k3VrDe28lvcRRzwSqUkhkUMrKRggg8EEdQa8O1T9le08L6lca78H/ABFefCbXZXMs1rpiCbRb1u/n6e58vnkbovLYZyDmpsB9LUV84aT+1Hqvw31C30T46+HovBcs0ggtvGOmO9x4evHJwA0pG+0Y9lmAHBw5r6ItbiK8t4riCVJoJVDpJGwZXUjIII4IIwQRSAnooooAKKKKACiiigAooooAKKKKACiiigAooooAK81/aC+LD/B34ZX2t2VmNU1+5lh0zRNMzj7ZqFw4jt4vpuO5j2VWPavSq+fP2rFS38TfAa9nUy2kPxBt4nhxkb5bC9SJyP8AZcqfxoA3fgb8IYvhL4VlS8uzrPi3WJjqPiLX5R++1G9YfOxPUIv3UQYCooAHUn0aiirAKKKKACq9/qFtpVlPeXtzDZ2cCGSW4uJAiRqBkszEgAAckkgCrFefeObo+NNctfBmnJ5ogubTUNZuyMx2kMcqzxxZ6GWUxgBRyqFnJHyBwBs3izWviCgtvB8E+maVLxJ4ovoNq7O5tIX+aVj/AAyOoiAIYGUDaet8L+F9P8H6SmnabE0cIZpJJJHLyzSMcvJI5JLuxJJYkkk1rUUAFFFFABRRRQAUUyaaO3heWV1iiRSzO5AVQBkkk8AAdzXEr8WrLVSf+EY0fVvGEYODdaTFGtqfdLid44pBng+WzY7igDuaK4lde8f3PzweENGt4j0TUPEDpN+Kx2sij8HNRSfEu58Nso8Y6DN4etyQDq1vOLzTVJ6B5gFeIerSxIg4G7JAoA7uimq4kUOhDIwBDKcg56EGnUAFFV7rULaxaBJ50heeQRRKxw0jEE4UdScAkgdACTwCasUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdS0yz1rT7ix1C0hvrK5jMU9tcxiSKRCMFWUgggjgggg14DJ8KfGf7N1xLrHwZLa54P3GW9+GepXJEKgklm0uZiTbv1PksTExJxtOK+iKKAMH4QfGnwx8bvDkmq+HLqUTWspttR0q+jMF9ptwPvQXEJ+aNwQevB6gkc131cn4f8ABeg6d4r1XxLa6PZ2/iDUYIra81KOELPPHGWKK7AZIG44z7DsK6yoAKKKKACiiigAooooAKKKKACiiigAooooAK8A/a9It7D4TX8o/wBGs/iJo7zMeihzLCp/77lT869/rwH9uy1ll/ZX8b6hbj/StFW11uBx1R7S6huMj8Ij+BoA9eoqCyukvrOC5iOY5o1kU+xAI/Q1PVgFFFFABXEfDJVjuvGkUg/09PEFwbpz1bdFE8JP0geBR7KB2rt68zh8WaX4B8eeL/7fnk0ex1O5trqDULyCRLNiLaOJs3BXy1OYlG1mBz2wQSAemUVFa3UN7bxz28sc8EihkkjcMrA9CCOCD6ipaACiiigArm/F3jq18LyW1lHbzavrt6CbPSLIAzzAYy5JIWONSRukchQSBkkgGr408Zz6VeW2haFbx6l4qvkLwW0hIitogcG5uCOViU8ADl2wq85K2vBvgm38Jx3NxLcSarrt8VbUNWuQPOuWGcAAcJGuSFjXCqCcAksSAYtv8PLvxZPHf+O54dUKsJIPD9sSdNtiDkFwQDcuDj55AFBAKxock96qhVAAAAGAAMDFLVWz1Sz1GS7jtLuG5ktJTb3CxSBjDIFVtjgH5W2upwcHDA9CKALVYfi7xfofg3S/tOvX0NpbSnykjkBd52IP7uOMAtIxGcKoJPYGsP4l+Ob7wy2maTolvBca/qvmtA13kwW0MQXzJ5ACCwUyRqEBBZpFGVAZh4x4k8VeFPhZdHWfFmutqfii7XYtxcATX0wJAEdvCo/dxbsAKgVc4LEsSxBGXH8dPGXw68fad4M8H/C6fW9A8RefP4et9V1qHTWtGij8yeAKUkKQkYeNGwygsoUKqqvpFmvx98YMovT4K+HFg/3jZtPrl8o9FLCCFW9ysgH901yvw78LeM/id8VPC/jfW/D0ng3wv4eju5LG01GQHUL6WaMRBpIwMQqqknBJYkDqDkfStAzk/Bvw4svCMz3s9/qHiHXZU2Ta1rMwluGBOSqBQscKEgEpEiKSASCea6yiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAvaV96T8P61pVm6V96T8P61pVLAKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFecftIaP8A8JD+z38TdM272uvDOpRKv+0bWTH64r0eqWtWUWpaPfWlwN1vcQSRSKe6spB/QmgDzT4F65/wkvwS+H+r795vvD+n3JY9ctbxsc++Sa7ivF/2L/M/4ZV+GCSuZDHokMas3UooKp/46BXtFWAUUUUAFIyhlIIBBGCCMjFLRQBxN38IfDwuJLvRoZ/CeouSzXfh+T7IXY/xSRgGKY/9dUYe1U5vE3iH4drv8VGHW/DqnDeILKLyprRem66gBI2D+KaIgDJLRooLD0KkIDAhhkEYINAGJJ488NQ2f2t/EOlJagZM7XsQTHru3Y/WucuvicfEoNn4Dtl8R3TnadWORpVsP77zjiYjn93CWYkAMYwSw6WPwT4dhvftiaBpaXnX7QtlGH/76xn9a2hwMDgdABQBzvg3wbD4Tt7mSS5k1TWL5xNqGqXAAluZAMDgcKijhUHCjgZJJPRUUUAYl74iltPGWkaINPllgvrK7umvlPyQtC9uqxkY5LidiDkYER4OeOXtdC1Xwx8Z7/UbHSpLvw94ns4TfXUM0aizvrdXVZZEZgzCWExx7kDEGBAQAdw9BkkSONndgiKCWZjgADkknsBXntvrGv8AxQXzdCvG8OeE2/1esLGr3uoL/et1cFIojxiR1ZnBJVVG12AMj4xaVH4/1rS/DWh3Mtt4rtw08mqWshUaTaSDa7S4+95pACREgsybwQIiw0fhn+z74O+F05v7Cyk1PX5OZ9d1aT7TeyMRgtvIwpI4O0DIAznrXZeF/Cel+DtONnpVt5CPIZZpZJGlmnkOMySSMS0jnAyzEkgAZwABsUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAXtK+9J+H9a0qzdK+9J+H9a0qlgFFFFIAooooAKKKKACiiigAooooAKKKKACs7xFMbbw/qcq8mO1lYD6ITWjVLWLb7bpN9b4z50EkePqpH9aAPDP2PbU2f7K/wnjc5Y+G7GQkerQq39a9grxn9jPUDqX7K3wudyC8OhW9qxHrEvlH9UNezVYBRRRQAUUUUAFFFFABRRRQAU1mCKWYgKASWbgYHc1X1TVLPQ9NutQ1G6hsrC1jMs9zcOESNAMlmY4AAAySa4FdOv/jAwn1a3n0vwRnMWk3CmOfVh2e6U4McB6iA4ZxjzAATGQCO6uH+NUn2K0DJ4ARsXd70/trB/wBRF62xPDydJANq5Usx9KVQihVACgYCgcY9BRHGkMaIiBI1AVVUYAA4AA7AelOoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAL2lfek/D+taVZulfek/D+taVSwCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABSUtZfifUF0nw3q165wttaSzH6KhP9KAPn/9iAo37L/gwxf6rdfeXn+59uuNv6Y6cV7pXi/7GFi2n/so/CqN12vJoFtOwwBzIokJ49S5PvmvaKsAooooAKKKKACiiigAqrqmq2eh6bd6jqFzFZ2FrE089xOwWONFBLMxPAAAJJq1Xnl1GPiV43ezf954X8Nzq1wv8F7qQwyIezJACrEcgyso4MRBAE0bRbv4k6lbeIvENtJbaJBIs2jaBcIVOQQUu7pD1lJAMcbDEQwSPM+56JRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAF7SvvSfh/WtKs3SvvSfh/WtKpYBRRRSAKKKKACiiigAooooAKKKKACiiigAryX9rDxV/whf7M/xQ1gPslg8O3qQt3814Wjjx77mXFetV82/tmTL40tPh98I4SJLnxx4ht2vYe40uyZbu7c+gPlwx88EygUAelfCvw2vg74Y+ENAQbV0vSLSyAA/55won/stdRSUtWAUUUUAFFFFABRRXO+LvHFn4TW2gMU2p6xellsdJswGuLkjGSASAiLkbpGIRQRkjIBAKfxC8T3mlW9po2hmN/FGsM0Fgsi7lgUAeZdSDvHEpBIJAZjGmQXBrY8LeG7Pwh4fs9IsPMNvbLgyStullcks8kjfxO7FmZjyWYk8msfwT4TvNPuLzX9flhufE+pKqzm3JMNpCpJS1hJAOxSSSxALsWYgAqq9dQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBe0r70n4f1rSrN0r70n4f1rSqWAUUUUgCiiigAooooAKKKKACiiigAooooASvlz4NSJ8Zvj98QPi6XW60LTh/whvhaReUaCB919cIehElz8gYdVg7giuo/au8Varc6V4d+F3he+fT/FHxAvG083kB/e6fpka77+7X0ZYv3anj55kwcivQ/B3hDSPAHhXS/DmgWUenaNplutra2sQwqIowB6knqSckkkkkkmmgNmiiiqAKKKKACiiuM8da9qEt9Y+FvD8/2bXNTVpZb4IG/s60UgSXGCCC5JCRqwILtkhlRhQA/xT48ez1I+H/Dtomt+KWQMbYsVgskbOJbqQA+WpwcKAXfBCqQGZbXg7wPF4Za5v7u5bV/EN8Ab7Vp1AeXGSsaLkiOFcnbGpwMkkszMzXvC/hPTPBuliw0u38mLcZJZHYvLPIcbpJJGJaR2xksxJPc1sUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAF7SvvSfh/WtKs3SvvSfh/WtKpYBRRRSAKKKKACiiigAooooAKKKKACiiigD5XuGaf/go3dLITItv8MYzCGORGX1I79vpnaucdcD0r6IooqkAUUUUwCiiigArgPBv7z4o/EiVvmkjmsIEc8lYxbBwgPZQ0jtjpl2PUmiigDv6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC9pX3pPw/rWlRRUsAooopAFFFFABRRRQAUUUUAf/9k=" /></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لتتجنب حدوث الكدمات، لا تدلك موضع الحقن بعد الانتهاء من الحقن.</strong></p><p dir="RTL">9) تخلّص من المحقنة مع الغطاء الواقي من خلال صندوق النفايات المخصص لذلك. أغلق غطاء الوعاء<br />&nbsp;&nbsp;&nbsp; بإحكام واحفظه بعيداً عن متناول الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عند امتلاء الصندوق، أعده إلى طبيبك أو ممرض الرعاية المنزلية للتخلص منه. لا تتخلص منه عبر النفايات المنزلية.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تغيير علاج مضادات التخثّر</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>تغيير من إنهيكسا إلى مُميعات الدم التي تدعى مضادات فيتامين-</em><em>K</em> <em>(على سبيل المثال الوارفارين)</em></p><p dir="RTL">سوف يطلب منك طبيبك إجراء فحص الدم الذي يسمى &quot;زمن البروثرومبين&nbsp; أي إن أرINR&quot; ويخبرك متى تتوقف عن استخدام إنهيكسا وفقا لذلك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تغيير من <em>مُميعات الدم التي تدعى مضادات فيتامين-</em><em>K</em> <em>(على سبيل المثال الوارفارين) إلى إنهيكسا.</em></p><p dir="RTL">توقف عن تناول <em>مضادات فيتامين-</em><em>K</em><em>.</em> سيطلب منك طبيبك إجراء فحص للدم يُسمى &quot;زمن البروثرومبين أي إن أر INR&quot; ويخبرك متى تبدأ العلاج بإنهيكسا وفقا لذلك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>تغيير من إنهيكسا إلى العلاج بمضاد التخثر المباشر عن طريق الفم</em><br />توقف عن استخدام إنهيكسا. ابدء في تناول مضاد التخثر المباشر عن طريق الفم قبل 0-2 ساعات من الوقت الذي كان مُقرراً للحقن المقبل، ثم استمر كالمعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>تغيير من العلاج بمضاد التخثر المباشر عن طريق الفم إلى إنهيكسا </em><br />توقف عن تناول مضاد التخثر. لا تبدأ العلاج بإنهيكسا إلا بعد مرور 12 ساعة عن آخر جرعة تناولتها من مضاد التخثر الفموي.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الاستخدام لدى الأطفال والمراهقين</strong><br />لم يتم تقييم فاعلية ومأمونية استخدام إنهيكسا لدى الأطفال والمراهقين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت أكثر مما يجب من إنهيكسا </strong><br />إذا اعتقدت أنك استخدمت أكثر أو أقل مما ينبغي من إنهيكسا، أخبر طبيبك أو الممرض أو الصيدلي فوراً، حتى وإن لم تظهر عليك أي أعراض. &nbsp;إذا قام طفل بطريق الخطأ بحقن أو ابتلاع محلول إنهيكسا، فقم بإحضاره إلى قسم الطوارىء بالمستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تستخدم إحدى الجرعات من إنهيكسا</strong><br />إذا نسيت أن تحقن نفسك إحدى الجرعات، قم بذلك في أقرب وقت تتذكرها. <strong>لا تعطي</strong> لنفسك جرعة مضاعفة في نفس اليوم للتعويض عن الجرعة المنسية. ويساعدك تسجيل موعد الجرعات في مذكرة على التأكد من أنك لن تنسى موعد الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام إنهيكسا</strong><br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.</p><p dir="RTL">من المهم بالنسبة لك الاستمرار في استخدام إنهيكسا حتى يقرر الطبيب إيقافه. إذا توقفت عن استخدامه من تلقاء نفسك، يمكن أن تتعرض لحدوث جلطة دموية والتي يمكن أن تكون خطيرة جدا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية قد يؤدي استخدام إنهيكسا إلى أعراض جانبية وإن كانت لا تحدث لدى جميع من يستخدمه.&nbsp;&nbsp;</p><p dir="RTL">وكما هو الحال مع الأدوية الأخرى المشابهة (الأدوية التي تقلل من تجلط الدم)، قد يسبب إنهيكسا نزيفًا يمكن أن يهدد الحياة. وفي بعض الحالات، قد يكون النزيف غير واضح للعيان.</p><p dir="RTL">إذا تعرضت لنزيف لا يتوقف من تلقاء ذاته أو إذا ظهرت لديك علامات تدل على نزيف مفرط (ضعف استثنائي، تعب، شحوب، دوخة، صداع أو تورم مجهول السبب)، استشر طبيبك فورا.<br />قد يقرر طبيبك إبقاءك تحت المراقبة أو تغيير الدواء.</p><p dir="RTL">توقف عن استخدام إنهيكسا وتحدث إلى طبيب أو ممرض فوراً إذا ظهرت لديك علامات تدل على رد فعل تحسسي شديد (مثل صعوبة في التنفس، وتورم في الشفتين والفم والحلق أو العيون).</p><p dir="RTL">يجب عليك أن تخبر طبيبك فورًا:<br />&bull;&nbsp; إذ ظهرت لديك علامات تدل على انسداد وعاء دموي بجلطة مثل:<br />&nbsp;&nbsp;&nbsp; - ألم تشنجي، احمرار، دفء، أو تورم في إحدى ساقيك - هذه أعراض تخثر الأوردة العميقة</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - ضيق التنفس، ألم في الصدر، إغماء أو سعال مصحوب بدم - هذه أعراض انسداد رئوي</p><p dir="RTL">&bull; إذا كان لديك طفح جلدي مؤلم من البقع الحمراء الداكنة تحت الجلد والتي لا تختفي عند الضغط عليها.</p><p dir="RTL">قد يطلب منك طبيبك إجراء فحص دم للتحقق من عدد الصفائح الدموية.</p><p dir="RTL"><strong>القائمة الشاملة للأعراض الجانبية المحتملة:</strong><br /><u>شائعة جدًا</u> (قد تؤثر في أكثر من شخص من بين 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp; نزيف</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتفاع في انزيمات الكبد</p><p dir="RTL"><u>شائعة</u> (قد تؤثر في ما يصل إلى شخص من بين 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp; التكدّم بسهولة أكثر من المعتاد. قد يحدث ذلك بسبب مشكلة في الدم تتعلق بانخفاض عدد الصفائح الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp; ظهور بقع وردية عل الجلد. يكثر احتمال ظهور هذه البقع في موضع الحقن بحُقن إنهيكسا.</p><p dir="RTL">&middot;&nbsp;&nbsp; طفح جلدي (الشرى، أرتيكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp; احمرار الجلد مع الحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp; تكدُّم أو ألم في موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض عدد كريات الدم الحمراء.</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة في عدد الصفائح الدموية في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp; صداع.</p><p dir="RTL"><u>غير شائعة</u> (قد تؤثر في ما يصل إلى شخص من بين 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp; صداع شديد مفاجىء. قد يكون ذلك علامة على حدوث نزيف في الدماغ.</p><p dir="RTL">&middot;&nbsp;&nbsp; الشعور بألم وانتفاخ في معدتك. قد يدل ذلك على وجود نزيف في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp; إصابات جلدية كبيرة غير منتظمة الشكل حمراء اللون مع أو بدون تقرح.</p><p dir="RTL">&middot;&nbsp;&nbsp; تهيج الجلد (تهيج موضعي)</p><p dir="RTL">&middot;&nbsp;&nbsp; قد تلاحظ اصفرار في الجلد أو العينين ويصبح لون البول داكناً . قد يدل ذلك على مشكلة في الكبد.</p><p dir="RTL"><u>نادرة</u> (قد تُؤثر على ما يصل إلى 1 من 1000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp; رد فعل تحسسي شديد. قد تشمل العلامات: طفح جلدي، مشاكل في البلع أو التنفس، وتورم شفتيك، ووجهك، وحلقك أو لسانك.</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتفاع مستوى البوتاسيوم لديك في الدم. يزداد احتمال حدوث هذا العرض لدى الأفراد الذين يعانون من مشاكل في الكلى أو مرض السكري. سيتمكن الطبيب من تحديد ذلك من خلال فحص الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتفاع في عدد الخلايا الحمضية في الدم. يمكن لطبيبك التحقق من ذلك من خلال إجراء فحص للدم.</p><p dir="RTL">&middot;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp; هشاشة العظام (حالة تصبح فيها العظام أكثر عرضة للكسر) مع الاستخدام المُطوّل.</p><p dir="RTL">&middot;&nbsp;&nbsp; وخز وخدر وضعف عضلي (خاصة في الجزء السفلي من الجسم) عندما تخضع لإجراء البزْل القَطني أو التخدير الشوكي.</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان السيطرة على المثانة أو الأمعاء (بحيث لا يمكنك التحكم بموعد قضاء الحاجة).</p><p dir="RTL">&middot;&nbsp;&nbsp; ظهور كتلة صلبة أو ورم في موقع الحقن.</p><p dir="RTL">إذا تفاقم لديك أيّ عرَض جانبي أو واجهت أي أعراض جانبيّة محتملة غير مُدرجة في هذه النشرة، أخبر طبيبك أو القائم على رعايتك الصحيّة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.<br />احفظ المحاقن في درجة حرارة أقل من 30 درجة مئوية. يجب عدم تجميده.</p><p dir="RTL">بعد تخفيف المحلول يجب استخدامه خلال 8 ساعات.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن في الملصق. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">لا تستخدم إنهيكسا إذا لاحظت أيّ تغيير واضح في شكل المحلول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حقن إنهيكسا مسبقة التعبئة مُعدّة للاستخدام الواحد فقط. تخلّص من أي محلول مُتبقّ غير مستخدم.</p><p dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تُستخدم. وستساعد هذه التدابير على حماية البيئة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا تحتوي حُقن انهيكسا</strong><br />- المادة الفعالة هي إنوكسابارين صوديوم</p><p dir="RTL">يحتوي كل 1 مل على 100 مجم إنوكسابارين صوديوم</p><p dir="RTL">&middot; &nbsp;تحتوي المحقنة 0,2 مل المسبقة التعبئة على 2000 وحدة دولية (20 مجم) من إنوكسابارين صوديوم.</p><p dir="RTL">&middot; &nbsp;تحتوي المحقنة 0,4 مل المسبقة التعبئة على 4000 وحدة دولية (40 مجم) من إنوكسابارين صوديوم.</p><p dir="RTL">&middot; &nbsp;تحتوي المحقنة 0,6 مل المسبقة التعبئة على 6000 وحدة دولية (60 مجم) من إنوكسابارين صوديوم.</p><p dir="RTL">&middot; &nbsp;تحتوي المحقنة 0,8 مل المسبقة التعبئة على 8000 وحدة دولية (80 مجم) من إنوكسابارين صوديوم.</p><p dir="RTL">&middot; تحتوي المحقنة 1 مل المسبقة التعبئة على 10000 وحدة دولية (100 مجم) من إنوكسابارين صوديوم.</p><p dir="RTL">يحتوي كل 1 مل على 150 مجم إنوكسابارين صوديوم</p><p dir="RTL">&middot; &nbsp;تحتوي المحقنة 0,8 مل المسبقة التعبئة على 12000 وحدة دولية (120 مجم) من إنوكسابارين صوديوم.</p><p dir="RTL">&middot; &nbsp;تحتوي المحقنة 1 مل المسبقة التعبئة على 15000 وحدة دولية (150 مجم) من إنوكسابارين صوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot; &nbsp;المكوّن الآخر هو الماء المخصص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف تبدو محاقن انهيكسا وما هي محتويات العلبة</strong></p><p dir="RTL">إنهيكسا 2000 وحدة دوليّة (20 مجم)/0,2 مل هو محلول للحقن حجمه 0,2 مل مُعبّأ في:</p><p dir="RTL">- محقنة ذات اسطوانه مصنوعة من الزجاج الصافي عديم اللون من النوع I المتعادل مع إبرة ثابتة وغطاء<br />&nbsp;&nbsp; إبرة مغلق بواسطة سدادة مطاطية من مادة كلوروبيوتيل ومكبس من مادة البولي بروبيلين الأزرق.</p><p dir="RTL">تتوفر في عبوات تحتوي على:<br />محقنتين مسبقتي التعبئة</p><p dir="RTL">&nbsp;</p><p dir="RTL">إنهيكسا 4000 وحدة دوليّة (40 مجم)/0,4 مل هو محلول للحقن حجمه 0,4 مل مُعبّأ في:</p><p dir="RTL">- محقنة ذات اسطوانه مصنوعة من الزجاج الصافي عديم اللون من النوع I المتعادل مع إبرة ثابتة وغطاء إبرة<br />&nbsp;&nbsp; مغلق بواسطة سدادة مطاطية من مادة كلوروبيوتيل ومكبس من مادة البولي بروبيلين الأصفر.</p><p dir="RTL">تتوفر في عبوات تحتوي على:<br />محقنتين مسبقتي التعبئة<br /><br />&nbsp;</p><p dir="RTL">إنهيكسا 6000 وحدة دوليّة (60 مجم)/0,6 مل هو محلول للحقن حجمه 0,6 مل مُعبّأ في:</p><p dir="RTL">- محقنة ذات اسطوانه مصنوعة من الزجاج الصافي عديم اللون من النوع I المتعادل مع إبرة ثابتة وغطاء إبرة<br />&nbsp;&nbsp; مغلق بواسطة سدادة مطاطية من مادة كلوروبيوتيل ومكبس من مادة البولي بروبيلين البرتقالي.</p><p dir="RTL">تتوفر في عبوات تحتوي على:<br />محقنتين مسبقتي التعبئة</p><p dir="RTL">&nbsp;</p><p dir="RTL">إنهيكسا 8000 وحدة دوليّة (80 مجم)/0,8 مل هو محلول للحقن حجمه 0,8 مل مُعبّأ في:</p><p dir="RTL">- محقنة ذات اسطوانه مصنوعة من الزجاج الصافي عديم اللون من النوع I المتعادل مع إبرة ثابتة وغطاء إبرة<br />&nbsp;&nbsp; مغلق بواسطة سدادة مطاطية من مادة كلوروبيوتيل ومكبس من مادة البولي بروبيلين الأحمر.</p><p dir="RTL">تتوفر في عبوات تحتوي على:<br />محقنتين مسبقتي التعبئة</p><p dir="RTL">&nbsp;</p><p dir="RTL">إنهيكسا 10000 وحدة دوليّة (100 مجم)/1 مل هو محلول للحقن حجمه 1 مل مُعبّأ في:</p><p dir="RTL">- محقنة ذات اسطوانه مصنوعة من الزجاج الصافي عديم اللون من النوع I المتعادل مع إبرة ثابتة وغطاء<br />&nbsp;&nbsp; إبرة مغلق بواسطة سدادة مطاطية من مادة كلوروبيوتيل ومكبس من مادة البولي بروبيلين الداكن.</p><p dir="RTL">تتوفر في عبوات تحتوي على:<br />محقنتين مسبقتي التعبئة</p><p dir="RTL">&nbsp;</p><p dir="RTL">إنهيكسا 12000 وحدة دوليّة (120 مجم)/0,8 مل هو محلول للحقن حجمه 0,8 مل مُعبّأ في:</p><p dir="RTL">- محقنة ذات اسطوانه مصنوعة من الزجاج الصافي عديم اللون من النوع I المتعادل مع إبرة ثابتة وغطاء<br />&nbsp;&nbsp; إبرة مغلق بواسطة سدادة مطاطية من مادة كلوروبيوتيل ومكبس من مادة البولي بروبيلين الأرجواني.</p><p dir="RTL">تتوفر في عبوات تحتوي على:<br />محقنتين مسبقتي التعبئة</p><p dir="RTL">&nbsp;</p><p dir="RTL">إنهيكسا 15000 وحدة دوليّة (150 مجم)/1 مل هو محلول للحقن حجمه 1مل مُعبّأ في:</p><p dir="RTL">- محقنة ذات اسطوانه مصنوعة من الزجاج الصافي عديم اللون من النوع I المتعادل مع إبرة ثابتة وغطاء<br />&nbsp;&nbsp; إبرة مغلق بواسطة سدادة مطاطية من مادة كلوروبيوتيل ومكبس من مادة البولي بروبيلين الأزرق الداكن.</p><p dir="RTL">تتوفر في عبوات تحتوي على:<br />محقنتين مسبقتي التعبئة<br /><br />قد لا تسوق جميع أحجام العلب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>حامل ترخيص التسويق </u><br />تيكدو الأوروبية إيه بي<br />كوبوفاغن 32<br />75236 أوبسالا<br />السويد<br /><br /><u>المُصنّع</u><br />شركة شنتشن تيكدو الصيدلانية ذات المسؤولية المحدودة<br />رقم 19، طريق غاوشينشونيي<br />شنتشن<br />الصين</p><p dir="RTL"><br />شركة هيلث-ميد ذات المسؤولية المحدودة إس بي.كيه.<br />تشيلمسكا 30/34<br />725-00 وارسو<br />بولند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             ٢٠٢٠/١٠، إصدار رقم ٠٠١
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhixa 8,000 IU (80 mg)/0.8 mL solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10,000 IU/mL (100 mg/mL) solution for injection:

Each pre-filled syringe contains enoxaparin sodium 8,000 IU anti-Xa activity (equivalent to 80 mg) in 0.8 mL water for injections.

For the full list of excipients, see section 6.1.

Enoxaparin sodium is a biological substance obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre filled syringe.
Clear, colourless to pale yellow solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inhixa is indicated in adults for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of thrombus formation in extra corporeal circulation during haemodialysis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute coronary syndrome:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients</em></p><p>Individual thromboembolic risk for patients can be estimated using validated risk stratification model.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients at moderate risk of thromboembolism, the recommended dose of enoxaparin sodium is 2,000&nbsp;IU (20&nbsp;mg) once daily by subcutaneous (SC) injection. Preoperative initiation (2&nbsp;hours before surgery) of enoxaparin sodium 2,000 IU (20&nbsp;mg) was proven effective and safe in moderate risk surgery.</p><p>In moderate risk patients, enoxaparin sodium treatment should be maintained for a minimal period of 7-10&nbsp;days whatever the recovery status (e.g. mobility). Prophylaxis should be continued until the patient no longer has significantly reduced mobility.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients at high risk of thromboembolism, the recommended dose of enoxaparin sodium is 4,000&nbsp;IU (40&nbsp;mg) once daily given by SC injection preferably started 12&nbsp;hours before surgery. If there is a need for earlier than 12&nbsp;hours enoxaparin sodium preoperative prophylactic initiation (e.g. high risk patient waiting for a deferred orthopaedic surgery), the last injection should be administered no later than 12&nbsp;hours prior to surgery and resumed 12&nbsp;hours after surgery.</p><p>o&nbsp;&nbsp; For patients who undergo major orthopaedic surgery an extended thromboprophylaxis up to 5&nbsp;weeks is recommended.</p><p>o&nbsp;&nbsp; For patients with a high venous thromboembolism (VTE) risk who undergo abdominal or pelvic surgery for cancer an extended thromboprophylaxis up to 4&nbsp;weeks is recommended.</p><p>&nbsp;</p><p><em>Prophylaxis of venous thromboembolism in medical patients</em></p><p>The recommended dose of enoxaparin sodium is 4,000 IU (40&nbsp;mg) once daily by SC injection.</p><p>Treatment with enoxaparin sodium is prescribed for at least 6 to 14&nbsp;days whatever the recovery status (e.g. mobility). The benefit is not established for a treatment longer than 14 days.</p><p><strong>&nbsp;</strong></p><p><em>Treatment of DVT and PE</em></p><p>Enoxaparin sodium can be administered SC either as a once daily injection of 150 IU/kg (1.5 mg/kg) or as twice daily injections of 100 IU/kg (1 mg/kg).</p><p>The regimen should be selected by the physician based on an individual assessment including evaluation of the thromboembolic risk and of the risk of bleeding. The dose regimen of 150 IU/kg (1.5 mg/kg) administered once daily should be used in uncomplicated patients with low risk of VTE recurrence. The dose regimen of 100 IU/kg (1 mg/kg) administered twice daily should be used in all other patients such as those with obesity, with symptomatic PE, cancer, recurrent VTE or proximal (vena iliaca) thrombosis.</p><p>&nbsp;</p><p>Enoxaparin sodium treatment is prescribed for an average period of 10&nbsp;days. Oral anticoagulant therapy should be initiated when appropriate (see &ldquo;Switch between enoxaparin sodium and oral anticoagulants&rdquo; at the end of section 4.2).</p><p>&nbsp;</p><p><em>Prevention of thrombus formation during haemodialysis </em></p><p>The recommended dose is 100&nbsp;IU/kg (1&nbsp;mg/kg) of enoxaparin sodium.</p><p>For patients with a high risk of haemorrhage, the dose should be reduced to 50&nbsp;IU/kg (0.5&nbsp;mg/kg) for double vascular access or 75&nbsp;IU/kg (0.75&nbsp;mg/kg) for single vascular access.</p><p>&nbsp;</p><p>During haemodialysis, enoxaparin sodium should be introduced into the arterial line of the circuit at the beginning of the dialysis session. The effect of this dose is usually sufficient for a 4-hour session; however, if fibrin rings are found, for example after a longer than normal session, a further dose of 50&nbsp;IU to 100&nbsp;IU/kg (0.5 to 1&nbsp;mg/kg) may be given.</p><p>&nbsp;</p><p>No data are available in patients using enoxaparin sodium for prophylaxis or treatment and during haemodialysis sessions.</p><p>&nbsp;</p><p><em>Acute coronary syndrome: treatment of unstable angina and NSTEMI and treatment of acute STEMI</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of unstable angina and NSTEMI, the recommended dose of enoxaparin sodium is 100&nbsp;IU/kg (1&nbsp;mg/kg) every 12&nbsp;hours by SC injection administered in combination with antiplatelet therapy. Treatment should be maintained for a minimum of 2&nbsp;days and continued until clinical stabilization. The usual duration of treatment is 2 to 8&nbsp;days.<strong> </strong></p><p>Acetylsalicylic acid is recommended for all patients without contraindications at an initial oral loading dose of 150&ndash;300&nbsp;mg (in acetylsalicylic acid-naive patients) and a maintenance dose of 75&ndash;325&nbsp;mg/day long-term regardless of treatment strategy.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of acute STEMI, the recommended dose of enoxaparin sodium is a single intravenous (IV) bolus of 3,000&nbsp;IU (30&nbsp;mg) plus a 100&nbsp;IU/kg (1&nbsp;mg/kg) SC dose followed by 100&nbsp;IU/kg (1&nbsp;mg/kg) administered SC every 12&nbsp;hours (maximum 10,000&nbsp;IU (100&nbsp;mg) for each of the first two SC doses). Appropriate antiplatelet therapy such as oral acetylsalicylic acid (75&nbsp;mg to 325&nbsp;mg once daily) should be administered concomitantly unless contraindicated. The recommended duration of treatment is 8&nbsp;days or until hospital discharge, whichever comes first. When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific), enoxaparin sodium should be given between 15 minutes before and 30&nbsp;minutes after the start of fibrinolytic therapy.</p><ul><li><ul><li>For dosage in patients &ge; 75 years of age, see paragraph &ldquo;Elderly&rdquo;.</li></ul></li></ul><p>o&nbsp;&nbsp; For patients managed with PCI, if the last dose of enoxaparin sodium SC was given less than 8&nbsp;hours before balloon inflation, no additional dosing is needed. If the last SC administration was given more than 8&nbsp;hours before balloon inflation, an IV bolus of 30&nbsp;IU/kg (0.3&nbsp;mg/kg) enoxaparin sodium should be administered.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of enoxaparin sodium in paediatric population have not been established.</p><p><em>Elderly</em></p><p>For all indications except STEMI, no dose reduction is necessary in the elderly patients, unless kidney function is impaired (see below &ldquo;renal impairment&rdquo; and section 4.4).</p><p>For treatment of acute STEMI in elderly patients &ge;75 years of age, an initial IV bolus must not be used. Initiate dosing with 75&nbsp;IU/kg (0.75&nbsp;mg/kg) SC every 12&nbsp;hours (maximum 7,500&nbsp;IU (75&nbsp;mg) for each of the first two SC doses only, followed by 75&nbsp;IU/kg (0.75&nbsp;mg/kg) SC dosing for the remaining doses). For dosage in elderly patients with impaired kidney function, see below &ldquo;renal impairment&rdquo; and section 4.4.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Limited data are available in patients with hepatic impairment (see sections 5.1 and 5.2) and caution should be used in these patients (see section 4.4).</p><p>&nbsp;</p><p><em>Renal impairment (see sections 4.4 and 5.2)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe renal impairment</p><p>Enoxaparin sodium is not recommended for patients with end stage renal disease (creatinine clearance &lt;15 mL/min) due to lack of data in this population outside the prevention of thrombus formation in extra corporeal circulation during haemodialysis.</p><p>&nbsp;</p><p>Dosage table for patients with severe renal impairment (creatinine clearance [15-30]&nbsp;mL/min):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><u>Indication</u></p></td><td style="vertical-align:bottom"><p><u>Dosing regimen</u></p></td></tr><tr><td style="vertical-align:top"><p>Prophylaxis of venous thromboembolic disease</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2,000&nbsp;IU (20&nbsp;mg) SC once daily</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of&nbsp; DVT and PE</p></td><td style="vertical-align:top"><p>100&nbsp;IU/kg (1&nbsp;mg/kg) body weight SC once daily</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of unstable angina and NSTEMI</p></td><td style="vertical-align:top"><p>100&nbsp;IU/kg (1&nbsp;mg/kg) body weight SC once daily</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of acute STEMI (patients under 75)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Treatment of acute STEMI (patients over 75)</p></td><td style="vertical-align:top"><p>1 x 3,000&nbsp;IU (30&nbsp;mg) IV bolus plus 100&nbsp;IU/kg (1&nbsp;mg/kg) body weight SC and then 100&nbsp;IU/kg (1&nbsp;mg/kg) body weight SC every 24&nbsp;hours</p><p>&nbsp;</p><p>No IV initial bolus, 100&nbsp;IU/kg (1&nbsp;mg/kg) body weight SC and then 100&nbsp;IU/kg (1&nbsp;mg/kg) body weight SC every 24&nbsp;hours</p></td></tr></tbody></table><p>The recommended dosage adjustments do not apply to the haemodialysis indication.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Moderate and mild renal impairment</p><p>Although no dose adjustment is recommended in patients with moderate (creatinine clearance 30-50&nbsp;mL/min) and mild (creatinine clearance 50-80&nbsp;mL/min) renal impairment, careful clinical monitoring is advised.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Inhixa should not be administered by the intramuscular route.</p><p>&nbsp;</p><p>For the prophylaxis of venous thrombo-embolic disease following surgery, treatment of DVT and PE, treatment of unstable angina and NSTEMI, enoxaparin sodium should be administered by SC injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For acute STEMI, treatment is to be initiated with a single IV bolus injection immediately followed by a SC injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the prevention of thrombus formation in the extra corporeal circulation during haemodialysis, it is administered through the arterial line of a dialysis circuit.</p><p>&nbsp;</p><p>The pre-filled disposable syringe is ready for immediate use.</p><p>&nbsp;</p><p>The use of a tuberculin syringe or equivalent is recommended when using ampoules or multiple-dose vials to assure withdrawal of the appropriate volume of drug.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SC injection technique:</p><p>Injection should be made preferably when the patient is lying down. Enoxaparin sodium is administered by deep SC injection.</p><p>&nbsp;</p><p>Do not expel the air bubble from the syringe before the injection to avoid the loss of drug when using pre-filled syringes. When the quantity of drug to be injected requires to be adjusted based on the patient&rsquo;s body weight, use the graduated pre-filled syringes to reach the required volume by discarding the excess before injection. Please be aware that in some cases it is not possible to achieve an exact dose due to the graduations on the syringe, and in such case the volume shall be rounded up to the nearest graduation.</p><p>&nbsp;</p><p>The administration should be alternated between the left and right anterolateral or posterolateral abdominal wall.</p><p>&nbsp;</p><p>The whole length of the needle should be introduced vertically into a skin fold gently held between the thumb and index finger. The skin fold should not be released until the injection is complete. Do not rub the injection site after administration.</p><p>&nbsp;</p><p>Note for the pre-filled syringes fitted with an automatic safety system: The safety system is triggered at the end of the injection (see instructions in section 6.6).</p><p>&nbsp;</p><p>In case of self-administration, patient should be advised to follow instructions provided in the patient information leaflet included in the pack of this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IV (bolus) injection (for acute STEMI indication only):</p><p>For acute STEMI, treatment is to be initiated with a single IV bolus injection immediately followed by a SC injection.</p><p>For IV injection, either the multidose vial or pre-filled syringe can be used.</p><p>Enoxaparin sodium should be administered through an IV line. It should not be mixed or co-administered with other medications. To avoid the possible mixture of enoxaparin sodium with other drugs, the IV access chosen should be flushed with a sufficient amount of saline or dextrose solution prior to and following the IV bolus administration of enoxaparin sodium to clear the port of drug. Enoxaparin sodium may be safely administered with normal saline solution (0.9%) or 5% dextrose in water.</p><p>&nbsp;</p><p>o&nbsp;&nbsp; Initial 3,000&nbsp;IU (30&nbsp;mg) bolus</p><p>For the initial 3,000&nbsp;IU (30&nbsp;mg) bolus, using an enoxaparin sodium graduated pre-filled syringe, expel the excessive volume to retain only 3,000&nbsp;IU (30&nbsp;mg) in the syringe. The 3,000&nbsp;IU (30&nbsp;mg) dose can then be directly injected into the IV line.</p><p>&nbsp;</p><p>o&nbsp;&nbsp; Additional bolus for PCI when last SC administration was given more than 8&nbsp;hours before balloon inflation</p><p>For patients being managed with PCI, an additional IV bolus of 30&nbsp;IU/kg (0.3&nbsp;mg/kg) is to be administered if last SC administration was given more than 8&nbsp;hours before balloon inflation.</p><p>&nbsp;</p><p>In order to assure the accuracy of the small volume to be injected, it is recommended to dilute the drug to 300&nbsp;IU/mL (3&nbsp;mg/mL).</p><p>To obtain a 300&nbsp;IU/mL (3&nbsp;mg/mL) solution, using a 6,000&nbsp;IU (60&nbsp;mg) enoxaparin sodium pre-filled syringe, it is recommended to use a 50&nbsp;mL infusion bag (i.e. using either normal saline solution (0.9%) or 5% dextrose in water) as follows:</p><p>Withdraw 30&nbsp;mL from the infusion bag with a syringe and discard the liquid. Inject the complete contents of the 6,000&nbsp;IU (60&nbsp;mg) enoxaparin sodium pre-filled syringe into the 20&nbsp;mL remaining in the bag. Gently mix the contents of the bag. Withdraw the required volume of diluted solution with a syringe for administration into the IV line.</p><p>&nbsp;</p><p>After dilution is completed, the volume to be injected can be calculated using the following formula [Volume of diluted solution (mL) = Patient weight (kg) x 0.1] or using the table below. It is recommended to prepare the dilution immediately before use.</p><p>&nbsp;</p><p>Volume to be injected through IV line after dilution is completed at a concentration of 300 IU (3 mg) /mL.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>Weight</p><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Required dose</p><p>&nbsp;30&nbsp;IU/kg (0.3&nbsp;mg/kg)</p></td><td colspan="3" style="vertical-align:top"><p>Volume to inject when diluted to a final concentration of</p><p>&nbsp;300 IU (3&nbsp;mg) / mL</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>[Kg]</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>IU</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>[mg]</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p>[mL]</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>45</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>1350</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>13.5</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p>4.5</p></td></tr><tr><td style="vertical-align:top"><p>50</p></td><td colspan="2" style="vertical-align:top"><p>1500</p></td><td colspan="2" style="vertical-align:top"><p>15</p></td><td colspan="3" style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>55</p></td><td colspan="2" style="vertical-align:top"><p>1650</p></td><td colspan="2" style="vertical-align:top"><p>16.5</p></td><td colspan="3" style="vertical-align:top"><p>5.5</p></td></tr><tr><td style="vertical-align:top"><p>60</p></td><td colspan="2" style="vertical-align:top"><p>1800</p></td><td colspan="2" style="vertical-align:top"><p>18</p></td><td colspan="3" style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>65</p></td><td colspan="2" style="vertical-align:top"><p>1950</p></td><td colspan="2" style="vertical-align:top"><p>19.5</p></td><td colspan="3" style="vertical-align:top"><p>6.5</p></td></tr><tr><td style="vertical-align:top"><p>70</p></td><td colspan="2" style="vertical-align:top"><p>2100</p></td><td colspan="2" style="vertical-align:top"><p>21</p></td><td colspan="3" style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>75</p></td><td colspan="2" style="vertical-align:top"><p>2250</p></td><td colspan="2" style="vertical-align:top"><p>22.5</p></td><td colspan="3" style="vertical-align:top"><p>7.5</p></td></tr><tr><td style="vertical-align:top"><p>80</p></td><td colspan="2" style="vertical-align:top"><p>2400</p></td><td colspan="2" style="vertical-align:top"><p>24</p></td><td colspan="3" style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>85</p></td><td colspan="2" style="vertical-align:top"><p>2550</p></td><td colspan="2" style="vertical-align:top"><p>25.5</p></td><td colspan="3" style="vertical-align:top"><p>8.5</p></td></tr><tr><td style="vertical-align:top"><p>90</p></td><td colspan="2" style="vertical-align:top"><p>2700</p></td><td colspan="2" style="vertical-align:top"><p>27</p></td><td colspan="3" style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>95</p></td><td colspan="2" style="vertical-align:top"><p>2850</p></td><td colspan="2" style="vertical-align:top"><p>28.5</p></td><td colspan="3" style="vertical-align:top"><p>9.5</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td colspan="2" style="vertical-align:top"><p>3000</p></td><td colspan="2" style="vertical-align:top"><p>30</p></td><td colspan="3" style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>105</p></td><td colspan="2" style="vertical-align:top"><p>3150</p></td><td colspan="2" style="vertical-align:top"><p>31.5</p></td><td colspan="3" style="vertical-align:top"><p>10.5</p></td></tr><tr><td style="vertical-align:top"><p>110</p></td><td colspan="2" style="vertical-align:top"><p>3300</p></td><td colspan="2" style="vertical-align:top"><p>33</p></td><td colspan="3" style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>115</p></td><td colspan="2" style="vertical-align:top"><p>3450</p></td><td colspan="2" style="vertical-align:top"><p>34.5</p></td><td colspan="3" style="vertical-align:top"><p>11.5</p></td></tr><tr><td style="vertical-align:top"><p>120</p></td><td colspan="2" style="vertical-align:top"><p>3600</p></td><td colspan="2" style="vertical-align:top"><p>36</p></td><td colspan="3" style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>125</p></td><td colspan="2" style="vertical-align:top"><p>3750</p></td><td colspan="2" style="vertical-align:top"><p>37.5</p></td><td colspan="3" style="vertical-align:top"><p>12.5</p></td></tr><tr><td style="vertical-align:top"><p>130</p></td><td colspan="2" style="vertical-align:top"><p>3900</p></td><td colspan="2" style="vertical-align:top"><p>39</p></td><td colspan="3" style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>135</p></td><td colspan="2" style="vertical-align:top"><p>4050</p></td><td colspan="2" style="vertical-align:top"><p>40.5</p></td><td colspan="3" style="vertical-align:top"><p>13.5</p></td></tr><tr><td style="vertical-align:top"><p>140</p></td><td colspan="2" style="vertical-align:top"><p>4200</p></td><td colspan="2" style="vertical-align:top"><p>42</p></td><td colspan="3" style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>145</p></td><td colspan="2" style="vertical-align:top"><p>4350</p></td><td colspan="2" style="vertical-align:top"><p>43.5</p></td><td colspan="3" style="vertical-align:top"><p>14.5</p></td></tr><tr><td style="vertical-align:top"><p>150</p></td><td colspan="2" style="vertical-align:top"><p>4500</p></td><td colspan="2" style="vertical-align:top"><p>45</p></td><td colspan="3" style="vertical-align:top"><p>15</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arterial line injection:</p><p>It is administered through the arterial line of a dialysis circuit for the prevention of thrombus formation in the extra corporeal circulation during haemodialysis.</p><p>&nbsp;</p><p><u>Switch between enoxaparin sodium and oral anticoagulants</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Switch between enoxaparin sodium and vitamin K antagonists (VKA) </em></p><p>Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized</p><p>Ratio (INR)] must be intensified to monitor the effect of VKA.</p><p>As there is an interval before the VKA reaches its maximum effect, enoxaparin sodium therapy should be continued at a constant dose for as long as necessary in order to maintain the INR within the desired therapeutic range for the indication in two successive tests.</p><p>For patients currently receiving a VKA, the VKA should be discontinued and the first dose of enoxaparin sodium should be given when the INR has dropped below the therapeutic range.</p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Switch between enoxaparin sodium and direct oral anticoagulants (DOAC)</em></p><p>For patients currently receiving enoxaparin sodium, discontinue enoxaparin sodium and start the DOAC 0 to 2 hours before the time that the next scheduled administration of enoxaparin sodium would be due as per DOAC label.</p><p>For patients currently receiving a DOAC, the first dose of enoxaparin sodium should be given at the time the next DOAC dose would be taken.</p><p>&nbsp;</p><p><u>Administration in spinal/epidural anaesthesia or lumbar puncture </u></p><p>Should the physician decide to administer anticoagulation in the context of epidural or spinal anaesthesia/analgesia or lumbar puncture, careful neurological monitoring is recommended due to the risk of neuraxial haematomas (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>At doses used for prophylaxis</em></p><p>A puncture-free interval of at least 12 hours shall be kept between the last injection of enoxaparin sodium at prophylactic doses and the needle or catheter placement.</p><p>For continuous techniques, a similar delay of at least 12 hours should be observed before removing the catheter.</p><p>For patients with creatinine clearance [15-30]&nbsp;mL/min, consider doubling the timing of puncture/catheter placement or removal to at least 24&nbsp;hours.</p><p>The 2&nbsp;hours preoperative initiation of enoxaparin sodium 2,000 IU (20&nbsp;mg) is not compatible with neuraxial anaesthesia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>At doses used for treatment</em></p><p>A puncture-free interval of at least 24 hours shall be kept between the last injection of enoxaparin sodium at curative doses and the needle or catheter placement (see also section 4.3).</p><p>For continuous techniques, a similar delay of 24 hours should be observed before removing the catheter.</p><p>For patients with creatinine clearance [15-30]&nbsp;mL/min, consider doubling the timing of puncture/catheter placement or removal to at least 48&nbsp;hours.</p><p>Patients receiving the twice daily doses (i.e. 75&nbsp;IU/kg (0.75&nbsp;mg/kg) twice daily or 100&nbsp;IU/kg (1&nbsp;mg/kg) twice-daily) should omit the second enoxaparin sodium dose to allow a sufficient delay before catheter placement or removal.</p><p>Anti-Xa levels are still detectable at these time points, and these delays are not a guarantee that neuraxial hematoma will be avoided.</p><p>Likewise, consider not using enoxaparin sodium until at least 4 hours after the spinal/epidural puncture or after the catheter has been removed. The delay must be based on a benefit-risk assessment considering both the risk for thrombosis and the risk for bleeding in the context of the procedure and patient risk factors.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enoxaparin sodium is contraindicated in patients with:
•	Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWH) or to any of the excipients listed in section 6.1;
•	History of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies (see also section 4.4 );
•	Active clinically significant bleeding and conditions with a high risk of haemorrhage, including recent haemorrhagic stroke, gastrointestinal ulcer, presence of malignant neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities;
•	Spinal or epidural anaesthesia or loco-regional anaesthesia when enoxaparin sodium is used for treatment in the previous 24 hours (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>General</em></p><p>Enoxaparin sodium cannot be used interchangeably (unit for unit) with other LMWHs. These medicinal products differ in their manufacturing process, molecular weights, specific anti-Xa and anti-IIa activities, units, dosage and clinical efficacy and safety. This results in differences in pharmacokinetics and associated biological activities (e.g. anti-thrombin activity, and platelet interactions). Special attention and compliance with the instructions for use specific to each proprietary medicinal product are therefore required.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>History of HIT (&gt;100 days)</em></p><p>Use of enoxaparin sodium in patients with a history of immune mediated HIT within the past 100 days or in the presence of circulating antibodies is contraindicated (see section 4.3). Circulating antibodies may persist several years.</p><p>Enoxaparin sodium is to be used with extreme caution in patients with a history (&gt;100 days) of heparin-induced thrombocytopenia without circulating antibodies. The decision to use enoxaparin sodium in such a case must be made only after a careful benefit risk assessment and after non-heparin alternative treatments are considered (e.g. danaparoid sodium or lepirudin).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Monitoring of platelet counts</em></p><p>The risk of antibody-mediated HIT also exists with LMWHs. Should thrombocytopenia occur, it usually appears between the 5<sup>th</sup> and the 21<sup>st</sup> day following the beginning of enoxaparin sodium treatment.</p><p>The risk of HIT is higher in postoperative patients and mainly after cardiac surgery and in patients with cancer.</p><p>Therefore, it is recommended that the platelet counts be measured before the initiation of therapy with enoxaparin sodium and then regularly thereafter during the treatment.</p><p>If there are clinical symptoms suggestive of HIT (any new episode of arterial and/or venous thromboembolism, any painful skin lesion at the injection site, any allergic or anaphylactoid reactions on treatment), platelet count should be measured. Patients must be aware that these symptoms may occur and if so, that they should inform their primary care physician.</p><p>In practice, if a confirmed significant decrease of the platelet count is observed (30 to 50 % of the initial value), enoxaparin sodium treatment must be immediately discontinued and the patient switched to another non-heparin anticoagulant alternative treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Haemorrhage</em></p><p>As with other anticoagulants, bleeding may occur at any site. If bleeding occurs, the origin of the haemorrhage should be investigated and appropriate treatment instituted.</p><p>Enoxaparin sodium, as with any other anticoagulant therapy, should be used with caution in conditions with increased potential for bleeding, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired haemostasis,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; history of peptic ulcer,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recent ischemic stroke,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe arterial hypertension,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recent diabetic retinopathy,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neuro- or ophthalmologic surgery,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant use of medications affecting haemostasis (see section 4.5).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Laboratory tests</em></p><p>At doses used for prophylaxis of venous thromboembolism, enoxaparin sodium does not influence bleeding time and global blood coagulation tests significantly, nor does it affect platelet aggregation or binding of fibrinogen to platelets.</p><p>At higher doses, increases in activated partial thromboplastin time (aPTT), and activated clotting time (ACT) may occur. Increases in aPTT and ACT are not linearly correlated with increasing enoxaparin sodium antithrombotic activity and therefore are unsuitable and unreliable for monitoring enoxaparin sodium activity.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Spinal/Epidural anaesthesia or lumbar puncture</em></p><p>Spinal/epidural anaesthesia or lumbar puncture must not be performed within 24 hours of administration of enoxaparin sodium at therapeutic doses (see also section 4.3).</p><p>There have been cases of neuraxial haematomas reported with the concurrent use of enoxaparin sodium and spinal/epidural anaesthesia or spinal puncture procedures resulting in long term or permanent paralysis. These events are rare with enoxaparin sodium dosage regimens 4,000&nbsp;IU (40&nbsp;mg) once daily or lower. The risk of these events is higher with the use of post-operative indwelling epidural catheters, with the concomitant use of additional drugs affecting haemostasis such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or spinal deformity.</p><p>&nbsp;</p><p>To reduce the potential risk of bleeding associated with the concurrent use of enoxaparin sodium and epidural or spinal anaesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of enoxaparin sodium (see section 5.2). Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of enoxaparin sodium is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. For patients with creatinine clearance [15-&shy;30&nbsp;mL/minute], additional considerations are necessary because elimination of enoxaparin sodium is more prolonged (see section 4.2).</p><p>&nbsp;</p><p>Should the physician decide to administer anticoagulation in the context of epidural or spinal anaesthesia/analgesia or lumbar puncture, frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), bowel and/or bladder dysfunction. Instruct patients to report immediately if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Skin necrosis / cutaneous vasculitis</em></p><p>Skin necrosis and cutaneous vasculitis have been reported with LMWHs and should lead to prompt treatment discontinuation.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Percutaneous coronary revascularization procedures</em></p><p>To minimize the risk of bleeding following the vascular instrumentation during the treatment of unstable angina, NSTEMI and acute STEMI, adhere precisely to the intervals recommended between enoxaparin sodium injection doses. It is important to achieve haemostasis at the puncture site after PCI. In case a closure device is used, the sheath can be removed immediately. If a manual compression method is used, sheath should be removed 6&nbsp;hours after the last IV/SC enoxaparin sodium injection. If the treatment with enoxaparin sodium is to be continued, the next scheduled dose should be given no sooner than 6 to 8&nbsp;hours after sheath removal. The site of the procedure should be observed for signs of bleeding or hematoma formation.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Acute infective endocarditis</em></p><p>Use of heparin is usually&nbsp;not recommended in patients with acute infective endocarditis due to the risk of cerebral haemorrhage.&nbsp; If such use is considered absolutely necessary, the decision must be made only after a careful individual benefit risk assessment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Mechanical prosthetic heart valves</em></p><p>The use of enoxaparin sodium has not been adequately studied for thromboprophylaxis in patients with mechanical prosthetic heart valves. Isolated cases of prosthetic heart valve thrombosis have been reported in patients with mechanical prosthetic heart valves who have received enoxaparin sodium for thromboprophylaxis. Confounding factors, including underlying disease and insufficient clinical data, limit the evaluation of these cases. Some of these cases were pregnant women in whom thrombosis led to maternal and foetal death.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pregnant women with mechanical prosthetic heart valves</em></p><p>The use of enoxaparin sodium for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied. In a clinical study of pregnant women with mechanical prosthetic heart valves given enoxaparin sodium (100&nbsp;IU/kg (1&nbsp;mg/kg ) twice daily) to reduce the risk of thromboembolism, 2 of 8 women developed clots resulting in blockage of the valve and leading to maternal and foetal death. There have been isolated post-marketing reports of valve thrombosis in pregnant women with mechanical prosthetic heart valves while receiving enoxaparin sodium for thromboprophylaxis. Pregnant women with mechanical prosthetic heart valves may be at higher risk for thromboembolism.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Elderly</em></p><p>No increased bleeding tendency is observed in the elderly with the prophylactic dosage ranges. Elderly patients (especially patients eighty years of age and older) may be at an increased risk for bleeding complications with the therapeutic dosage ranges. Careful clinical monitoring is advised and dose reduction might be considered in patients older than 75 years treated for STEMI (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Renal impairment</em></p><p>In patients with renal impairment, there is an increase in exposure of enoxaparin sodium which increases the risk of bleeding. In these patients, careful clinical monitoring is advised, and biological monitoring by anti-Xa activity measurement might be considered (see sections 4.2 and 5.2).</p><p>Enoxaparin sodium is not recommended for patients with end stage renal disease (creatinine clearance &lt;15 mL/min) due to lack of data in this population outside the prevention of thrombus formation in extra corporeal circulation during haemodialysis.</p><p>In patients with severe renal impairment (creatinine clearance 15-30&nbsp;mL/min), since exposure of enoxaparin sodium is significantly increased, a dosage adjustment is recommended for therapeutic and prophylactic dosage ranges (see section 4.2).</p><p>No dose adjustment is recommended in patients with moderate (creatinine clearance 30-50&nbsp;mL/min) and mild (creatinine clearance 50-80&nbsp;mL/min) renal impairment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Hepatic impairment</em></p><p>Enoxaparin sodium should be used with caution in patients with hepatic impairment due to an increased potential for bleeding. Dose adjustment based on monitoring of anti-Xa levels is unreliable in patients with liver cirrhosis and not recommended (see section 5.2).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Low weight</em></p><p>An increase in exposure of enoxaparin sodium with prophylactic dosages (non-weight adjusted) has been observed in low-weight women (&lt;45&nbsp;kg) and low-weight men (&lt;57&nbsp;kg), which may lead to a higher risk of bleeding. Therefore, careful clinical monitoring is advised in these patients (see section 5.2).</p><p>&nbsp;</p><ul><li><em>Obese Patients</em></li></ul><p>Obese patients are at higher risk for thromboembolism. The safety and efficacy of prophylactic doses in obese patients (BMI &gt;30&nbsp;kg/m2) has not been fully determined and there is no consensus for dose adjustment. These patients should be observed carefully for signs and symptoms of thromboembolism.</p><p>&nbsp;</p><ul><li><em>Hyperkalaemia</em></li></ul><p>Heparins can suppress adrenal secretion of aldosterone leading to hyperkalaemia (see section 4.8), particularly in patients such as those with diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, taking medicinal products known to increase potassium (see section 4.5). Plasma potassium should be monitored regularly especially in patients at risk.</p><p>&nbsp;</p><ul><li><em>Traceability</em></li></ul><p>LMWHs are biological medicinal products. In order to improve the LMWH traceability, it is recommended that health care professionals record the trade name and batch number of the administered product in the patient file.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concomitant use not recommended: </u></p><ul><li><em>Medicinal products affecting haemostasis (see section 4.4)</em></li></ul><p>It is recommended that some agents which affect haemostasis should be discontinued prior to enoxaparin sodium therapy unless strictly indicated. If the combination is indicated, enoxaparin sodium should be used with careful clinical and laboratory monitoring when appropriate. These agents include medicinal products such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic salicylates, acetylsalicylic acid at anti-inflammatory doses, and NSAIDs including ketorolac,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other thrombolytics (e.g. alteplase, reteplase, streptokinase, tenecteplase, urokinase) and anticoagulants (see section 4.2).</p><p>&nbsp;</p><p><u>Concomitant use with caution:</u></p><p>The following medicinal products may be administered with caution concomitantly with enoxaparin sodium:</p><ul><li><em>Other medicinal products affecting haemostasis such as:</em></li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Platelet aggregation inhibitors including acetylsalicylic acid used at antiaggregant dose (cardioprotection), clopidogrel, ticlopidine, and glycoprotein IIb/IIIa antagonists indicated in acute coronary syndrome due to the risk of bleeding,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dextran 40,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic glucocorticoids.</p><p>&nbsp;</p><ul><li><em>Medicinal products increasing potassium levels:</em></li></ul><p>Medicinal products that increase serum potassium levels may be administered concurrently with enoxaparin sodium under careful clinical and laboratory monitoring (see sections 4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>In humans, there is no evidence that enoxaparin crosses the placental barrier during the second and third trimester of pregnancy. There is no information available concerning the first trimester.</p><p>Animal studies have not shown any evidence of foetotoxicity or teratogenicity (see section 5.3). Animal data have shown that enoxaparin passage through the placenta is minimal.</p><p>Enoxaparin sodium should be used during pregnancy only if the physician has established a clear need.</p><p>Pregnant women receiving enoxaparin sodium should be carefully monitored for evidence of bleeding or excessive anticoagulation and should be warned of the haemorrhagic risk. Overall, the data suggest that there is no evidence for an increased risk of haemorrhage, thrombocytopenia or osteoporosis with respect to the risk observed in non-pregnant women, other than that observed in pregnant women with prosthetic heart valves (see section 4.4).</p><p>&nbsp;</p><p>If an epidural anaesthesia is planned, it is recommended to withdraw enoxaparin sodium treatment before (see section 4.4).</p><p><em>&nbsp;</em></p><p><u>Breast‑feeding </u></p><p>It is not known whether unchanged enoxaparin is excreted in human breast milk. In lactating rats, the passage of enoxaparin or its metabolites in milk is very low. The oral absorption of enoxaparin sodium is unlikely.&nbsp; Inhixa can be used during breastfeeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no clinical data for enoxaparin sodium in fertility. Animal studies did not show any effect on fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Enoxaparin sodium </strong>has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Enoxaparin sodium has been evaluated in more than 15,000 patients who received enoxaparin sodium in clinical trials. These included 1,776 for prophylaxis of deep vein thrombosis following orthopaedic or abdominal surgery in patients at risk for thromboembolic complications, 1,169 for prophylaxis of deep vein thrombosis in acutely ill medical patients with severely restricted mobility, 559 for treatment of DVT with or without PE, 1,578 for treatment of unstable angina and non-Q-wave myocardial infarction and 10,176 for treatment of acute STEMI.</p><p>&nbsp;</p><p>Enoxaparin sodium regimen administered during these clinical trials varies depending on indications. The enoxaparin sodium dose was 4,000&nbsp;IU (40&nbsp;mg) SC once daily for prophylaxis of deep vein thrombosis following surgery or in acutely ill medical patients with severely restricted mobility. In treatment of DVT with or without PE, patients receiving enoxaparin sodium were treated with either a 100&nbsp;IU/kg (1&nbsp;mg/kg) SC dose every 12&nbsp;hours or a 150&nbsp;IU/kg (1.5&nbsp;mg/kg) SC dose once a&nbsp;day. In the clinical studies for treatment of unstable angina and non-Q-wave myocardial infarction, doses were 100&nbsp;IU/kg (1&nbsp;mg/kg) SC every 12&nbsp;hours, and in the clinical study for treatment of acute STEMI enoxaparin sodium regimen was a 3,000&nbsp;IU (30&nbsp;mg) IV bolus followed by 100&nbsp;IU/kg (1&nbsp;mg/kg) SC every 12&nbsp;hours.</p><p>&nbsp;</p><p>In clinical studies, haemorrhages, thrombocytopenia and thrombocytosis were the most commonly reported reactions (see section 4.4 and &#39;Description of selected adverse reactions&#39; below).</p><p>&nbsp;</p><p><u>Tabulated summary list of adverse reactions</u></p><p>&nbsp;</p><p>Other adverse reactions observed in clinical studies and reported in post-marketing experience (* indicates reactions from post-marketing experience) are detailed below.</p><p>Frequencies are defined as follows: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt;1/1,000); and very rare (&lt; 1/10,000) or not known (cannot be estimated from available data). Within each system organ class, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><em>Blood and the lymphatic system disorders</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: Haemorrhage, haemorrhagic anaemia*, thrombocytopenia, thrombocytosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Eosinophilia*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Cases of immuno-allergic thrombocytopenia with thrombosis; in some of them thrombosis was complicated by organ infarction or limb ischaemia<strong> </strong>(see section 4.4).</p><p>&nbsp;</p><p><em>Immune system disorders</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: Allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Anaphylactic/Anaphylactoid reactions including shock*</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: Headache*</p><p>&nbsp;</p><p><em>Vascular disorders</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Spinal haematoma* (or neuraxial haematoma). These reactions have resulted in varying degrees of neurologic injuries including long-term or permanent paralysis (see section 4.4).</p><p>&nbsp;</p><p><em>Hepato-biliary disorders</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: Hepatic enzyme increases (mainly transaminases &gt; 3 times the upper limit of normality)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: Hepatocellular liver injury *</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Cholestatic liver injury*</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: Urticaria, pruritus, erythema&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: Bullous dermatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Alopecia*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Cutaneous vasculitis*, skin necrosis* usually occurring at the injection site (these phenomena have been usually preceded by purpura or erythematous plaques, infiltrated and painful).</p><p>Injection site nodules* (inflammatory nodules, which were not cystic enclosure of enoxaparin). They resolve after a few&nbsp;days and should not cause treatment discontinuation.</p><p>&nbsp;</p><p><em>Musculoskeletal, connective tissue and bone disorders</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Osteoporosis* following long term therapy (greater than 3 months)</p><p>&nbsp;</p><p><em>General disorders and administration site conditions</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: Injection site haematoma, injection site pain, other injection site reaction (such as oedema, haemorrhage, hypersensitivity, inflammation, mass, pain, or reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: Local irritation, skin necrosis at injection site</p><p>&nbsp;</p><p><em>Investigations</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: Hyperkalaemia* (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Haemorrhages</em></p><p>These included major haemorrhages, reported at most in 4.2&nbsp;% of the patients (surgical patients). Some of these cases have been fatal. In surgical patients, haemorrhage complications were considered major: (1) if the haemorrhage caused a significant clinical event, or (2) if accompanied by haemoglobin decrease &ge; 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial haemorrhages were always considered major.</p><p>As with other anticoagulants, haemorrhage may occur in the presence of associated risk factors such as: organic lesions liable to bleed, invasive procedures or the concomitant use of medications affecting haemostasis (see sections 4.4 and 4.5).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Prophylaxis in surgical patients</p></td><td style="vertical-align:top"><p>Prophylaxis in medical patients</p></td><td style="vertical-align:top"><p>Treatment in patients with DVT with or without PE</p></td><td style="vertical-align:top"><p>Treatment in patients with unstable angina and non-Q-wave MI</p></td><td style="vertical-align:top"><p>Treatment in patients with acute STEMI</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p><em>Very common</em>: <strong>Haemorrhage <sup>&alpha;</sup></strong></p><p>&nbsp;</p><p><em>Rare:</em> <strong>Retroperitoneal haemorrhage</strong></p></td><td style="vertical-align:top"><p><em>Common:</em></p><p><strong>Haemorrhage <sup>&alpha;</sup> </strong></p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p><strong>Haemorrhage <sup>&alpha;</sup></strong></p><p><strong>&nbsp;</strong></p><p><em>Uncommon:</em></p><p><strong>Intracranial haemorrhage, Retroperitoneal haemorrhage</strong></p></td><td style="vertical-align:top"><p><em>Common: </em><strong>Haemorrhage <sup>&alpha;</sup></strong></p><p><em>Rare: </em><strong>Retroperitoneal haemorrhage</strong></p></td><td style="vertical-align:top"><p><em>Common:<strong> </strong></em><strong>Haemorrhage <sup>&alpha;</sup></strong></p><p>&nbsp;</p><p><em>Uncommon: </em><strong>Intracranial haemorrhage, Retroperitoneal haemorrhage</strong></p></td></tr></tbody></table><p><strong><sup>&alpha;</sup></strong>: such as haematoma, ecchymosis other than at injection site, wound haematoma, haematuria, epistaxis and gastro‑intestinal haemorrhage.</p><p>&nbsp;</p><p><em>Thrombocytopenia and thrombocytosis</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Prophylaxis in surgical patients</p></td><td style="vertical-align:top"><p>Prophylaxis in medical patients</p></td><td style="vertical-align:top"><p>Treatment in patients with DVT with or without PE</p></td><td style="vertical-align:top"><p>Treatment in patients with unstable angina and non-Q-wave MI</p></td><td style="vertical-align:top"><p>Treatment in patients with acute STEMI</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p><em>Very common</em>: <strong>Thrombocytosis<sup>&beta;</sup></strong></p><p>&nbsp;</p><p><em>Common: </em><strong>Thrombocytopenia</strong></p></td><td style="vertical-align:top"><p><em>Uncommon: </em><strong>Thrombocytopenia</strong></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Very common</em>:&nbsp;&nbsp;&nbsp; <strong>Thrombocytosis</strong><em> </em><strong><sup>&beta;</sup></strong></p><p><em>&nbsp;</em></p><p><em>Common: </em><strong>Thrombocytopenia</strong></p></td><td style="vertical-align:top"><p><em>Uncommon: </em><strong>Thrombocytopenia</strong></p></td><td style="vertical-align:top"><p><em>Common:</em><strong>&nbsp; Thrombocytosis<sup>&beta;</sup> Thrombocytopenia</strong></p><p><em>Very rare:&nbsp;&nbsp;&nbsp;&nbsp; </em><strong>Immuno-allergic thrombocytopenia</strong></p></td></tr></tbody></table><p><strong><sup>&beta;</sup></strong>: Platelet increased &gt;400 G/L</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of enoxaparin sodium in children have not been established (see section 4.2).</p><p>&nbsp;</p><p><u>To report any side effects</u><u> </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via The National Pharmacovigilance and Drug Safety Centre (NPC).</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and symptoms</u></p><p>Accidental overdose with enoxaparin sodium after IV, extracorporeal or SC administration may lead to haemorrhagic complications. Following oral administration of even large doses, it is unlikely that enoxaparin sodium will be absorbed.</p><p>&nbsp;</p><p><u>Management</u></p><p>The anticoagulant effects can be largely neutralized by the slow IV injection of protamine. The dose of protamine depends on the dose of enoxaparin sodium injected; 1&nbsp;mg protamine neutralizes the anticoagulant effect of 100&nbsp;IU (1&nbsp;mg) of enoxaparin sodium, if enoxaparin sodium was administered in the previous 8&nbsp;hours. An infusion of 0.5&nbsp;mg protamine per 100 IU (1&nbsp;mg) of enoxaparin sodium may be administered if enoxaparin sodium was administered greater than 8&nbsp;hours previous to the protamine administration, or if it has been determined that a second dose of protamine is required. After 12&nbsp;hours of the enoxaparin sodium injection, protamine administration may not be required. However, even with high doses of protamine, the anti-Xa activity of enoxaparin sodium is never completely neutralized (maximum about 60%) (see the prescribing information for protamine salts).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, heparin group. ATC code: B01A B05</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Enoxaparin is a LMWH with a mean molecular weight of approximately 4,500&nbsp;daltons, in which the antithrombotic and anticoagulant activities of standard heparin have been dissociated. The drug substance is the sodium salt.</p><p>&nbsp;</p><p>In the <em>in vitro</em> purified system, enoxaparin sodium has a high anti-Xa activity (approximately 100&nbsp;IU/mg) and low anti-IIa or anti thrombin activity (approximately 28&nbsp;IU/mg), with a ratio of 3.6. These anticoagulant activities are mediated through anti-thrombin III (ATIII) resulting in anti-thrombotic activities in humans.</p><p>&nbsp;</p><p>Beyond its anti-Xa/IIa activity, further antithrombotic and anti-inflammatory properties of enoxaparin have been identified in healthy subjects and patients as well as in non-clinical models.<br />These include ATIII-dependent inhibition of other coagulation factors like factor VIIa, induction of endogenous Tissue Factor Pathway Inhibitor (TFPI) release as well as a reduced release of von Willebrand factor (vWF) from the vascular endothelium into the blood circulation. These factors are known to contribute to the overall antithrombotic effect of enoxaparin sodium.</p><p>When used as prophylactic treatment, enoxaparin sodium does not significantly affect the aPTT. When used as curative treatment, aPTT can be prolonged by 1.5-2.2 times the control time at peak activity.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Prevention of </em><em>venous thromboembolic disease</em><em> associated with surgery</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extended prophylaxis of VTE following orthopaedic surgery</p><p>In a double blind study of extended prophylaxis for patients undergoing hip replacement surgery, 179 patients with no venous thromboembolic disease initially treated, while hospitalized, with enoxaparin sodium 4,000&nbsp;IU (40&nbsp;mg) SC, were randomized to a post-discharge regimen of either enoxaparin sodium 4,000&nbsp;IU (40&nbsp;mg) (n=90) once a&nbsp;day SC or to placebo (n=89) for 3 weeks. The incidence of DVT during extended prophylaxis was significantly lower for enoxaparin sodium compared to placebo, no PE was reported. No major bleeding occurred.</p><p>The efficacy data are provided in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Enoxaparin sodium<br />4,000&nbsp;IU (40&nbsp;mg) once a day SC<br />n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo<br />once a day SC<br />n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Treated Extended Prophylaxis Patients</strong></p></td><td style="vertical-align:top"><p>90 (100)</p></td><td style="vertical-align:top"><p>89 (100)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Total VTE</strong></p></td><td><p>6 (6.6)</p></td><td><p>18 (20.2)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total DVT (%)</p></td><td style="vertical-align:top"><p>6 (6.6)*</p></td><td style="vertical-align:top"><p>18 (20.2)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proximal DVT (%)</p></td><td style="vertical-align:top"><p>5 (5.6)<sup># </sup></p></td><td style="vertical-align:top"><p>7 (8.8)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*p value versus placebo =0.008</p><p>#p value versus placebo =0.537</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>In a second double-blind study, 262 patients without VTE disease and undergoing hip replacement surgery initially treated, while hospitalized, with enoxaparin sodium 4,000&nbsp;IU (40&nbsp;mg) SC were randomized to a post-discharge regimen of either enoxaparin sodium 4,000&nbsp;IU (40&nbsp;mg) (n=131) once a&nbsp;day SC or to placebo (n=131) for 3 weeks. Similar to the first study the incidence of VTE during extended prophylaxis was significantly lower for enoxaparin sodium compared to placebo for both total VTE (enoxaparin sodium 21 [16%] versus placebo 45 [34.4%]; p=0.001) and proximal DVT (enoxaparin sodium 8 [6.1%] versus placebo 28 [21.4%]; p=&lt;0.001). No difference in major bleeding was found between the enoxaparin sodium and the placebo group.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extended prophylaxis of DVT following cancer surgery</p><p>A double-blind, multicenter trial, compared a four-week and a one-week regimen of enoxaparin sodium prophylaxis in terms of safety and efficacy in 332 patients undergoing elective surgery for abdominal or pelvic cancer. Patients received enoxaparin sodium (4,000&nbsp;IU (40&nbsp;mg) SC) daily for 6 to 10&nbsp;days and were then randomly assigned to receive either enoxaparin sodium or placebo for another 21&nbsp;days. Bilateral venography was performed between&nbsp;days 25 and 31, or sooner if symptoms of venous thromboembolism occurred. The patients were followed for three months. Enoxaparin sodium prophylaxis for four weeks after surgery for abdominal or pelvic cancer significantly reduced the incidence of venographically demonstrated thrombosis, as compared with enoxaparin sodium prophylaxis for one week. The rates of venous thromboembolism at the end of the double-blind phase were 12.0 % (n=20) in the placebo group and 4.8% (n=8) in the enoxaparin sodium group; p=0.02. This difference persisted at three months [13.8% vs. 5.5% (n=23 vs 9), p=0.01]. There were no differences in the rates of bleeding or other complications during the double-blind or follow-up periods.</p><p>&nbsp;</p><p><em>Prophylaxis of venous thromboembolic disease in medical patients with an acute illness expected to induce limitation of mobility</em></p><p>In a double blind multicenter, parallel group study, enoxaparin sodium 2,000&nbsp;IU (20&nbsp;mg) or 4,000&nbsp;IU (40&nbsp;mg) once a&nbsp;day SC was compared to placebo in the prophylaxis of DVT in medical patients with severely restricted mobility during acute illness (defined as walking distance of &lt;10 meters for &le;3&nbsp;days). This study included patients with heart failure (NYHA Class III or IV); acute respiratory failure or complicated chronic respiratory insufficiency, and acute infection or acute rheumatic; if associated with at least one VTE risk factor (age &ge;75 years, cancer, previous VTE, obesity, varicose veins, hormone therapy, and chronic heart or respiratory failure).</p><p>A total of 1,102 patients were enrolled in the study, and 1,073 patients were treated. Treatment continued for 6 to 14&nbsp;days (median duration 7&nbsp;days). When given at a dose of 4,000&nbsp;IU (40&nbsp;mg) once a&nbsp;day SC, enoxaparin sodium significantly reduced the incidence of VTE as compared to placebo. The efficacy data are provided in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Enoxaparin sodium<br />2,000 IU (20&nbsp;mg) once a day SC<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Enoxaparin sodium<br />4,000 IU (40&nbsp;mg) once a day SC<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<br /><br />n (%)</strong></p></td></tr><tr><td><p><strong>All Treated Medical Patients During Acute Illness</strong></p></td><td style="vertical-align:top"><p>287 (100)</p></td><td style="vertical-align:top"><p>291(100)</p></td><td style="vertical-align:top"><p>288 (100)</p></td></tr><tr><td><p><strong>Total VTE (%)</strong></p></td><td><p>43 (15.0)</p></td><td><p>16 (5.5)*</p></td><td><p>43 (14.9)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total DVT (%)</p></td><td><p>43 (15.0)</p></td><td><p>16 (5.5)</p></td><td><p>40 (13.9)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proximal DVT (%)</p></td><td><p>13 (4.5)</p></td><td><p>5 (1.7)</p></td><td><p>14 (4.9)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin</p><p>* p value versus placebo =0.0002</p></td></tr></tbody></table><p>&nbsp;</p><p>At approximately 3 months following enrolment, the incidence of VTE remained significantly lower in the enoxaparin sodium 4,000&nbsp;IU (40&nbsp;mg) treatment group versus the placebo treatment group.</p><p>The occurrence of total and major bleeding were respectively 8.6% and 1.1% in the placebo group, 11.7% and 0.3% in the enoxaparin sodium 2,000&nbsp;IU (20 mg) group and 12.6% and 1.7% in the enoxaparin sodium 4,000&nbsp;IU (40 mg) group.</p><p><em>&nbsp;</em></p><p><em>Treatment of deep vein thrombosis with or without pulmonary embolism </em></p><p>In a multicenter, parallel group study, 900 patients with acute lower extremity DVT with or without PE were randomized to an inpatient (hospital) treatment of either (i) enoxaparin sodium 150&nbsp;IU/kg (1.5&nbsp;mg/kg) once a&nbsp;day SC, (ii) enoxaparin sodium 100&nbsp;IU/kg (1&nbsp;mg/kg) every 12&nbsp;hours SC, or (iii) heparin IV bolus (5,000&nbsp;IU) followed by a continuous infusion (administered to achieve an aPTT of 55 to 85 seconds). A total of 900 patients were randomized in the study and all patients were treated. All patients also received warfarin sodium (dose adjusted according to prothrombin time to achieve an INR of 2.0 to 3.0), commencing within 72&nbsp;hours of initiation of enoxaparin sodium or standard heparin therapy, and continuing for 90&nbsp;days. Enoxaparin sodium or standard heparin therapy was administered for a minimum of 5&nbsp;days and until the targeted warfarin sodium INR was achieved. &nbsp;Both enoxaparin sodium regimens were equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism (DVT and/or PE). The efficacy data are provided in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Enoxaparin sodium<br />150&nbsp;IU/kg (1.5&nbsp;mg/kg) once a day SC<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Enoxaparin sodium<br />100&nbsp;IU/kg (1&nbsp;mg/kg) twice a day SC<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Heparin<br />aPTT Adjusted IV Therapy<br />n (%)</strong></p></td></tr><tr><td><p><strong>All Treated DVT Patients with or without PE</strong></p></td><td style="vertical-align:top"><p>298 (100)</p></td><td style="vertical-align:top"><p>312 (100)</p></td><td style="vertical-align:top"><p>290 (100)</p></td></tr><tr><td><p><strong>Total VTE (%)</strong></p></td><td><p>13 (4.4)*</p></td><td><p>9 (2.9)*</p></td><td><p>12 (4.1)</p></td></tr><tr><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DVT Only (%)</p></td><td><p>11 (3.7)</p></td><td><p>7 (2.2)</p></td><td><p>8 (2.8)</p></td></tr><tr><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proximal DVT (%)</p></td><td><p>9 (3.0)</p></td><td><p>6 (1.9)</p></td><td><p>7 (2.4)</p></td></tr><tr><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PE (%)</p></td><td><p>2 (0.7)</p></td><td><p>2 (0.6)</p></td><td><p>4 (1.4)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>VTE = venous thromboembolic event (DVT and/or PE)</p><p>*The 95% Confidence Intervals for the treatment differences for total VTE were:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; enoxaparin sodium once a&nbsp;day versus heparin (-3.0 to 3.5)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; enoxaparin sodium every 12&nbsp;hours versus heparin (-4.2 to 1.7).</p></td></tr></tbody></table><p>&nbsp;</p><p>Major bleeding were respectively 1.7% in the enoxaparin sodium 150&nbsp;IU/kg (1.5&nbsp;mg/kg) once a day group, 1.3% in the enoxaparin sodium 100&nbsp;IU/kg (1 mg/kg) twice a day group and 2.1% in the heparin group.</p><p><em>&nbsp;</em></p><p><em>Treatment of unstable angina and non ST elevation myocardial infarction</em></p><p>In a large multicenter study, 3,171 patients enrolled at the acute phase of unstable angina or non-Q-wave myocardial infarction were randomized to receive in association with acetylsalicylic acid (100 to 325&nbsp;mg once daily), either SC enoxaparin sodium 100&nbsp;IU/kg (1&nbsp;mg/kg) every 12&nbsp;hours or IV unfractionated heparin adjusted based on aPTT. Patients had to be treated in hospital for a minimum of 2&nbsp;days and a maximum of 8&nbsp;days, until clinical stabilization, revascularization procedures or hospital discharge. The patients had to be followed up to 30&nbsp;days. In comparison with heparin, enoxaparin sodium significantly reduced the combined incidence of angina pectoris, myocardial infarction and death, with a decrease of 19.8 to 16.6% (relative risk reduction of 16.2%) on day 14. This reduction in the combined incidence was maintained after 30 days (from 23.3 to 19.8%; relative risk reduction of 15%).</p><p>There were no significant differences in major haemorrhages, although a haemorrhage at the site of the SC injection was more frequent.</p><p>&nbsp;</p><p><em>Treatment of acute ST-segment elevation myocardial infarction</em></p><p>In a large multicenter study, 20,479 patients with STEMI eligible to receive fibrinolytic therapy were randomized to receive either enoxaparin sodium in a single 3,000&nbsp;IU (30&nbsp;mg) IV bolus plus a 100&nbsp;IU/kg (1&nbsp;mg/kg) SC dose followed by an SC injection of 100&nbsp;IU/kg (1&nbsp;mg/kg) every 12&nbsp;hours or IV unfractionated heparin adjusted based on aPTT for 48&nbsp;hours. All patients were also treated with&nbsp; acetylsalicylic acid for a minimum of 30&nbsp;days. The enoxaparin sodium dosing strategy was adjusted for severe renally impaired patients and for the elderly of at least 75&nbsp;years of age. The SC injections of enoxaparin sodium were given until hospital discharge or for a maximum of eight&nbsp;days (whichever came first).</p><p>4,716 patients underwent percutaneous coronary intervention receiving antithrombotic support with blinded study drug. Therefore, for patients on enoxaparin sodium, the PCI was to be performed on enoxaparin sodium (no switch) using the regimen established in previous studies i.e. no additional dosing, if last SC administration given less than 8&nbsp;hours before balloon inflation, IV bolus of 30&nbsp;IU/ kg (0.3&nbsp;mg/kg) enoxaparin sodium, if the last SC administration given more than 8&nbsp;hours before balloon inflation.</p><p>Enoxaparin sodium compared to unfractionated heparin significantly decreased the incidence of&nbsp; the primary end point, a composite of death from any cause or myocardial re-infarction in the first 30&nbsp;days after randomization [9.9&nbsp;percent in the enoxaparin sodium group, as compared with 12.0&nbsp;percent in the unfractionated heparin group] with a 17&nbsp;percent relative risk reduction (p&lt;0.001).</p><p>The treatment benefits of enoxaparin sodium, evident for a number of efficacy outcomes, emerged at 48&nbsp;hours, at which time there was a 35&nbsp;percent reduction in the relative risk of myocardial re-infarction, as compared with treatment with unfractionated heparin (p&lt;0.001).</p><p>The beneficial effect of enoxaparin sodium on the primary end point was consistent across key subgroups including age, gender, infarct location, history of diabetes, history of prior myocardial infarction, type of fibrinolytic administered, and time to treatment with study drug.</p><p>There was a significant treatment benefit of enoxaparin sodium, as compared with unfractionated heparin, in patients who underwent percutaneous coronary intervention within 30&nbsp;days after randomization (23&nbsp;percent reduction in relative risk) or who were treated medically (15&nbsp;percent reduction in relative risk, p=0.27 for interaction).</p><p>The rate of the 30&nbsp;day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p&lt;0.0001) in the enoxaparin sodium group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.</p><p>The incidence of major bleeding at 30 days was significantly higher (p&lt;0.0001) in the enoxaparin sodium group (2.1%) versus the heparin group (1.4%). There was a higher incidence of gastrointestinal bleeding in the enoxaparin sodium group (0.5%) versus the heparin group (0.1%), while the incidence of intracranial haemorrhage was similar in both groups (0.8% with enoxaparin sodium versus 0.7% with heparin).</p><p>The beneficial effect of enoxaparin sodium on the primary end point observed during the first 30&nbsp;days was maintained over a 12 month follow-up period.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Based on literature data the use of enoxaparin sodium 4,000 IU (40 mg) in cirrhotic patients (Child-Pugh class B-C) appears to be safe and effective in preventing portal vein thrombosis. It should be noted that the literature studies may have limitations. Caution should be used in patients with hepatic impairment as these patients have an increased potential for bleeding (see section 4.4) and no formal dose finding studies have been performed in cirrhotic patients (Child Pugh class A, B nor C).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General characteristics</u></p><p>The pharmacokinetic parameters of enoxaparin sodium have been studied primarily in terms of the time course of plasma anti-Xa activity and also by anti-IIa activity, at the recommended dosage ranges after single and repeated SC administration and after single IV administration. The quantitative determination of anti-Xa and anti-IIa pharmacokinetic activities was conducted by validated amidolytic methods.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>The absolute bioavailability of enoxaparin sodium after SC injection, based on anti-Xa activity, is close to 100%.</p><p>&nbsp;</p><p>Different doses and formulations and dosing regimens can be used.</p><p>The mean maximum plasma anti-Xa activity level is observed 3 to 5&nbsp;hours after SC injection and achieves approximately 0.2, 0.4, 1.0 and 1.3 anti-Xa&nbsp;IU/mL following single SC administration of 2,000 IU, 4,000&nbsp;IU, 100&nbsp;IU/kg and 150&nbsp;IU/kg (20&nbsp;mg, 40&nbsp;mg, 1&nbsp;mg/kg and 1.5&nbsp;mg/kg) doses, respectively.</p><p>&nbsp;</p><p>A 3,000&nbsp;IU (30&nbsp;mg) IV bolus immediately followed by a 100&nbsp;IU/kg (1&nbsp;mg/kg) SC every 12&nbsp;hours provided initial maximum anti-Xa activity level of 1.16&nbsp;IU/mL (n=16) and average exposure corresponding to 88% of steady-state levels. Steady-state is achieved on the second day of treatment.</p><p>&nbsp;</p><p>After repeated SC administration of 4,000&nbsp;IU (40&nbsp;mg) once daily and 150&nbsp;IU/kg (1.5&nbsp;mg/kg) once daily regimens in healthy volunteers, the steady-state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose. After repeated SC administration of the 100&nbsp;IU/kg (1&nbsp;mg/kg) twice daily regimen, the steady-state is reached from day 3 to 4 with mean exposure about 65% higher than after a single dose and mean maximum and trough anti-Xa activity levels of about 1.2 and 0.52&nbsp;IU/mL, respectively.</p><p>&nbsp;</p><p>Injection volume and dose concentration over the range 100-200 mg/mL does not affect pharmacokinetic parameters in healthy volunteers.</p><p>Enoxaparin sodium pharmacokinetics appears to be linear over the recommended dosage ranges.</p><p>Intra-patient and inter-patient variability is low. Following repeated SC administration no accumulation takes place.</p><p>&nbsp;</p><p>Plasma anti-IIa activity after SC administration is approximately ten-fold lower than anti-Xa activity. The mean maximum anti-IIa activity level is observed approximately 3 to 4&nbsp;hours following SC injection and reaches 0.13&nbsp;IU/mL and 0.19&nbsp;IU/mL following repeated administration of 100&nbsp;IU/kg (1&nbsp;mg/kg) twice daily and 150&nbsp;IU/kg (1.5&nbsp;mg/kg) once daily, respectively.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution of enoxaparin sodium anti-Xa activity is about 4.3&nbsp;litres and is close to the blood volume.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Enoxaparin sodium is a low clearance drug with a mean anti-Xa plasma clearance of 0.74&nbsp;L/h after a 150&nbsp;IU /kg (1.5&nbsp;mg/kg) 6-hour IV infusion.</p><p>Elimination appears monophasic with a half-life of about 5&nbsp;hours after a single SC dose to about 7&nbsp;hours after repeated dosing.</p><p>Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>Based on the results of a population pharmacokinetic analysis, the enoxaparin sodium kinetic profile is not different in elderly subjects compared to younger subjects when renal function is normal.&nbsp; However, since renal function is known to decline with age, elderly patients may show reduced elimination of enoxaparin sodium (see sections 4.2 and 4.4).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>In a study conducted in patients with advanced cirrhosis treated with enoxaparin sodium 4,000&nbsp;IU (40&nbsp;mg) once daily, a decrease in maximum anti-Xa activity&nbsp;was associated with an increase in the severity of hepatic impairment (assessed by Child-Pugh categories). This decrease was mainly attributed to a decrease in ATIII level secondary to a reduced synthesis of ATIII in patients with hepatic impairment.</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>A linear relationship between anti-Xa plasma clearance and creatinine clearance at steady-state has been observed, which indicates decreased clearance of enoxaparin sodium in patients with reduced renal function. Anti-Xa exposure represented by AUC, at steady-state, is marginally increased in mild (creatinine clearance 50-80&nbsp;mL/min) and moderate (creatinine clearance 30-50&nbsp;mL/min) renal impairment after repeated SC 4,000&nbsp;IU (40&nbsp;mg) once daily doses. In patients with severe renal impairment (creatinine clearance &lt;30&nbsp;mL/min), the AUC at steady state is significantly increased on average by 65% after repeated SC 4,000&nbsp;IU (40&nbsp;mg) once daily doses (see sections 4.2 and 4.4).</p><p><em>&nbsp;</em></p><p><em>Haemodialysis</em></p><p>Enoxaparin sodium pharmacokinetics appeared similar than control population, after a single 25 IU, 50 IU or 100 IU/kg (0.25, 0.50 or 1.0 mg/kg) IV dose however, AUC was two-fold higher than control.</p><p>&nbsp;</p><p><em>Weight</em></p><p>After repeated SC 150&nbsp;IU/kg (1.5&nbsp;mg/kg) once daily dosing, mean AUC of anti-Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30-48&nbsp;kg/m<sup>2</sup>) compared to non-obese control subjects, while maximum plasma anti-Xa activity level is not increased. There is a lower weight-adjusted clearance in obese subjects with SC dosing.</p><p>&nbsp;</p><p>When non-weight adjusted dosing was administered, it was found after a single-SC 4,000&nbsp;IU (40&nbsp;mg) dose, that anti-Xa exposure is 52% higher in low-weight women (&lt;45&nbsp;kg) and 27% higher in low-weight men (&lt;57&nbsp;kg) when compared to normal weight control subjects (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p>No pharmacokinetic interactions were observed between enoxaparin sodium and thrombolytics when administered concomitantly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Besides the anticoagulant effects of enoxaparin sodium, there was no evidence of adverse effects at 15&nbsp;mg/kg/day in the 13-week SC toxicity studies both in rats and dogs and at&nbsp; 10&nbsp;mg/kg/day in the 26-week SC and IV toxicity studies both in rats, and monkeys.</p><p>&nbsp;</p><p>Enoxaparin sodium has shown no mutagenic activity based on <em>in vitro</em> tests, including the Ames test, mouse lymphoma cell forward mutation test, and <em>no clastogenic </em>activity based on an<em> in vitro </em>human lymphocyte chromosomal aberration test, and the <em>in vivo</em> rat bone marrow chromosomal aberration test.</p><p>&nbsp;</p><p>Studies conducted in pregnant rats and rabbits at SC doses of enoxaparin sodium up to 30&nbsp;mg/kg/day did not reveal any evidence of teratogenic effects or foetotoxicity. Enoxaparin sodium was found to have no effect on fertility or reproductive performance of male and female rats at SC doses up to 20&nbsp;mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>SC injection</u></p><p>Do not mix with other products.</p><p>&nbsp;</p><p><u>IV (Bolus) Injection</u> (for acute STEMI indication only):</p><p>Enoxaparin sodium may be safely administered with normal saline solution (0.9%) or 5% dextrose in water (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pre filled syringe
2 years

Diluted medicinal product with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose
The diluted solution must be used within 8 hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&nbsp;&deg;C. Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.8 mL of solution in a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a red polypropylene plunger rod.</p><p>&nbsp;</p><p>Packs of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 pre‑filled syringes</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>INSTRUCTIONS FOR USE: PRE-FILLED SYRINGE </strong></p><p>&nbsp;</p><p><u>How to give yourself an injection of Inhixa</u></p><p>If you are able to give this medicine to yourself, your doctor or nurse will show you how to do this. Do not try to inject yourself if you have not been trained how to do so. If you are not sure what to do, talk to your doctor or nurse immediately.</p><p><strong>&nbsp;</strong></p><p><strong><em>Before injecting yourself with Inhixa</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the expiry date on the medicine. Do not use if the date has passed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the syringe is not damaged and the medicine in it is a clear solution. If not, use another syringe.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice any change in the appearance of the product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure you know how much you are going to inject.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check your abdomen to see if the last injection caused any redness, change in skin colour, swelling, oozing or is still painful, if so talk to your doctor or nurse.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decide where you are going to inject the medicine. Change the place where you inject each time from the right to the left side of your stomach. This medicine should be injected just under the skin on your stomach, but not too near the belly button or any scar tissue (at least 5 cm away from these).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The pre-filled syringe is intended for single use only.</p><p>&nbsp;</p><p><strong><em>Instructions on injecting yourself with Inhixa</em></strong></p><p><strong>1)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands and the area that you will inject with soap and water. Dry them.</p><p><strong>2)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sit or lie in a comfortable position so you are relaxed. Make sure you can see the place you are going to inject. A lounge chair, recliner, or bed propped up with pillows is ideal.</p><p><strong>3)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose an area on the right or left side of your stomach. This should be at least 5&nbsp;cm away from your belly button and out towards your sides.</p><p><strong>&nbsp;</strong></p><p><strong>Remember:</strong> Do not inject yourself within 5&nbsp;cm of your belly button or around existing scars or bruises. Change the place where you inject between the left and right sides of your stomach, depending on the area you were last injected.</p><p><strong>&nbsp;</strong></p><p><strong>4)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully pull off the needle cap from the syringe. Throw away the cap. The syringe is pre-filled and ready to use.</p><p><img alt="" width="314" height="284" src="data:image/jpeg;base64,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" /></p><p><strong>Do not</strong> press on the plunger before injecting yourself to get rid of air bubbles. This can lead to a loss of the medicine. Once you have removed the cap, do not allow the needle to touch anything. This is to make sure the needle stays clean (sterile).</p><p>&nbsp;</p><p><strong>5)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the syringe in the hand you write with (like a pencil) and with your other hand, gently pinch the cleaned area of your abdomen between your forefinger and thumb to make a fold in the skin</p><p>&nbsp;</p><p>Make sure you <strong>hold the skin fold throughout the injection.</strong></p><p><strong>&nbsp;</strong></p><p><strong>6)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the syringe so that the needle is pointing downwards (vertically at a 90&ordm; angle). Insert the full length of the needle into the skin fold</p><p><img alt="" width="381" height="303" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>7)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press down on the plunger with your finger. This will send the medicine into the fatty tissue of the stomach. Make sure you hold the skin fold throughout the injection</p><p>&nbsp;</p><p><strong>8)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the needle by pulling it straight out.</p><p><img alt="" width="393" height="386" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEA3ADcAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAGCAYkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK4f4mfGzwJ8HNPW78aeKtN8PpJ/qorqYefMfSKEZeQ+yqTQB3FFfOn/DU/ifxh83w6+C3izxHaHlNU8RSReH7OQHoyeeTMynrnyelMbVP2mfFB+WP4a+AraT1N7rd1GDj2t4yRz6jinYD6OrF8T+MtA8E6a+oeItc07QLBeWutTu47aIY65ZyBXgr/AH4geKP+Rz+PXi+9jPW18LW1roUJ9RujRpsf9tc+9aHh39j/wCEfh7UU1OXwfb+IdYBBOqeJp5dWuSR333LSEH6YosAl5+2p4N1ieSz+HOj+Ifi1qQJQDwrpzNZI3QeZezbLdR7hz9Kyrvw/wDHX40DZ4l8QWfwd8MS/f0jwjP9t1mVT1WS/ZQkJ94UJHZu9e7W9tFZwJBbxJBBGAqxxqFVQOgAHAA9BUlFgOM+F3wd8IfBrRJNM8JaPFpsc8hmurlmaW5vJTkmSeZiXlckk5YkjOBgcV2dFFUAUquY2ypIPqDSUUAXYdSZcLIN4/vDirH9pQ/7X5VlUUrAdBRRRUgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeOfHD49TfD3U9M8HeEdIHi/wCJutxtLp2hiXy4beAHa15dyAHyrdTxn7zt8qgnJAB6V4o8XaL4H0S51nxFq9loek2w3TX2oXCQQoPd2IA/OvC5v2vZfG7GH4Q/DvxB8SFJwutzKNI0X0JF1cANIAf+eUbg9jUHhX9mODWtatvFvxe1X/hZ/jOM+bCl9HjSNLY87bKyOUXHAEjhpCQCWBOK9yVAihVAVVAAVRgADsKdgPC5PAvx0+Jmf+Ex+JNh8P8ASpOG0f4eWebllPOG1C6DMG7ExxJ04I611Hw5/Zt+Hnwv1BtV0jQEvPEcvM/iHWZXv9TmbuWuZizjPcKQPQCvTicDJ4HUk01WEihlIZWAIZTkEHoRVAOooooAKKKKACiiigAooooAKKKKACiiigDoKKKKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivP/jL8aPD3wP8Lrq+uPNc3V1KLXTNHsU8291O6b7kFvEOXYnGT0UckgDNAFf46fGjTfgj4KOrXFtLq2tXsy2Oi6FanNzql8/EcEY9zyzdFUEnpg8b8AfhHqHgWx1XxP4vuYtW+JnimUXuv6lGMohAxHaQE8iCFcIozyQWPLYGV8J/hX4j8ReM/wDhbHxVEL+NpoWg0fQYJPNtPDFo+CYYz0kuHGPNmxkkbVwo59vpgFFFFUBkeLtQOk+F9Vu1Xe8du+xf7zEEKPxJA/GtGzh+z2sEX/PNFX8gBWT4oH2r+y7ADP2q9jLD/ZjzKSfYmMD/AIEPWtygAooooAKKKKACiiigAopWXCg+tJQAUUUUAFFeefHT4tRfB3wHLqsVk2sa/ezx6boeixH97qOoSnbDAvoCeWP8Kqx7V86/8Ke/bb/6Kl4N/wDAE/8AxFAH3bRRRUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFfFuoeCvEH7cll4o1y68eeI/BPw8W8uNM8K2fhm7+zG7WCQxSahdEDMyySI4SMkKEUH7zbq8usfgH8W/hPG2n2el/Ee9ksWYL4k8CePlWC+jGdkj6dqMz4kwcMgyuclTggB2A/SOivzui+Nv7UPh3/RfDmmeL/GF0PljtPGngK1thkYADXltexR4/wBsqc9ea9z03w3+0j4/0ezPir4h+Gvh158KtdWXg3QzcXUZIBaMXF1LIisMkblQ8jIJ4NFgPQ/jn+0Ro3wZhtdMgtJvFHjvVVK6N4T00g3V23Te55EMKnlpnwqgHGSMHjfg98Hb1vEsnxJ+I+qW3iv4mXURiRrfP2HQYG5NpZRnJUY4aQ/O5BJIBxXU/Cn4D+FvhDJf3ulx3mqeI9TIOp+JNbumvNSviOnmTtztGBhFCqMcKK7a4ju0voZYhDLATtkVlw6KR1DZ5GcZBH40wL1FFFMAqO5uYrO3knmkWKCNS7yOQFUAZJJPAAHenswVck4AGSSeMV59Y38nxO8QGSL/AJFDTZcBu2o3Cnj6xIefRmA6gcAG/wCH/M13UZdelWSO2aPyLCKRSpERILSEHkGQgEA8hVXoSRXR0UUAFFFFABUVzdRWdvJPcSpBBGpZ5JGCqoHJJJ4AHqawfFPji08NywWaQzanrFwM2+m2gDSuOm49lUd2OAMHriqMPhO98UTQXvito3jjIki0W3Ym2jI5BkJx5rD3AUHoD1oA39A1ga/pq3yQSQW8rEwGQYaSMHAfGMgN1APOCCcE4GlQOOlFAC7vlx75FJRRQAU13WNC7kIigksx4AHUk06vBv2jdY1H4ga3oXwQ8MXUlrq/iyN7jXb+3OH0vQo2C3EuR915iRBHkcl2PG3NAEHwTs2/aJ+Ll38Yr9DJ4M8PtPpHgW3cfJOclLvVcHqZGBhiP9xGOAWzX1BWZ4b8Pad4R8P6domkWkdhpWnW8dpaWsIwkUSKFRQPQAAfhWnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMkTzEZTwGBFPooA+ZP2Mbg6H8J5/h3e4i1/wCH+p3Xh6/hbglVlaS3nAPJWWB43BPUk+hr3uvJvjD8GPE9v46X4o/Cu5s7Xxstslnq2iakxSw8RWsZJSOVwCYp0yRHNg4ztYFTx8gXH/BVXUdSujLZeGNK8OWe9oxFrQvLlyVJVj5kMQjxkHGC2B1PancD9GKK+Rvht/wUI0DX7OGfxPpUFlZscSap4f1BNSgh5wWmhAWeEcjqjYyMkA19V6Jrmn+JNItNU0q9g1DTruMSwXVtIHjkU8ggjgiqAvUUUUAFVtS1K00eyku725itLaMZaaZgqj8T6+nesS+8aRnz00fT7rX7iFtjLZ7VjVh1UyMQuR0IBJHcV5X4z0jxfrGtWmr+KtHmn8PQfMun6HdkzWh4IkOAC7DuRwB0x3AOy1KbU/ilJ/Z9ilzpHhUnF1fyoYpr1e8cSkAqhHViBkHAGM577TtPttJsYLOzgW3tYECRxoMBQOgFed+GPDuieJLcXOgeN/EDoOWjTUt7IfRkkQkH2Irpf+ENuYoznxXruAOWaSD8/wDVUAdPVHUtb07R499/f21knXdcTKg/UivN/EGj+cxgj1zxtrLnj7PYlYUPsZPLRQP+BVV0f4G22qTJPrFnFptn1+wQTGe4lPrNcNyc91TA9zQB1zfFvwxLc/ZrC9k1i87W+mQPOx/FRtA9yQKnZ/EviNcRovhiybrJIVnvGHsoykZ9yWI9Aa3dH0PT/D9oLbTbKCyt16RwRhR9Tjqfc81eoAx/D/hXTvDaym0iZ7mY5nu7hjJPMfV3PJ9hwB2ArYoooAKKKKACsvxN4p0fwXod3rOv6pZ6NpFqu+e+v51hhjHTJdiAMngc8kgDmqPxA8faH8L/AAbqnijxJfJp2jabEZZ52BJ6gBVA5ZmJCqoySSABk15H8O/g/rXx61/T/iV8YNOa206BhceF/h7dYaDTEP3bq9XpLdsCCFIKwg4A3ZIQCN+0prPxUkGn/A/wfdeMHkyG8Wa5DLpugWo6FvNdBJckH+GFTkc7gOa9D+BvwRu/hpeeIvEvibXv+Et8f+JZIX1XWBai2iSOJdsNrbxAny4Y8uQCSWZ2YnJwPWVRY1CqAqgYAAwBT6kAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvzR+LHhWDUfHnxNufh7cWL+CtDvhb32m6lai60/7cUDXAt3yGjkEkoG1SUBDZXgAfRfxs+KWvfFjxJ4h+HHgDVZdC8PaBEx8beNbU/vLMbCx0+ybp9qZfvydIQR/GQBwGlfD7TvCvwR8HeBNKs1sYdWlWRreMnIEr7iSTklghJJJJJXJJPNNK4j5xH7NeteJNK8NB/BUg1fVwX07VtL1GCKblS+7JKOgCjODlemRzivsn9kP4X+N/gL8GY9F8WQf2zq1zfTX7W+nzxkWiyBQIgGKpn5CzbCV3SNjI5PYeFdESb4n2qQoBYeHdIEUC/wBySZgo/wDHIiPxNer1Ww73RzMniLXZ1xZ+FrhW7NfXcMS/jtZz+lV18O674gY/8JBqMMFkeum6SGRXHpJMcMw9QoUHvkcV11FAGawfRoYYLPT0NhGoUR2xCtGB2CYAI+hz7Glt/EGn3EvlC5SOfvDNmN/++Wx/KtGqt9ptpqcPlXdvHcJ2WRQcfT0+ooA5nxR8LdE8S3Qv1SXStXU5XUdNfyZs+pI+9+IJ9xUMOk+N9DtPLttb0/XQv3f7StWilx6b42wT9VBPc1rR+FX0w79J1Ce0A5FvMxlh+mDyPqDmrtnrG6Zba9j+x3h4Ck5ST3Ru/rjgjuO9AFbTYNXvo1lvL9rRs4NvDaohBHYlmkBHuDj+VbSKVQAsXIGCzYyfrgAfkKdRQAUUUUAFFFFABTJpo7eF5ZnWKKNSzu5AVQBkkk8AAckmo72+t9Ns57u7nitbWBDJLPO4SONQCSzMSAAACSSQABXziv279tjWpbKxuLvTPgHYSGO81C3ZoZvF8ynDQQsMMtipBDyAgynKqdoJoAteCrc/tcfFOz8YzxmT4O+Dbtm8PxyKdniHVUJVr4g/et4DlYuMM+5skKBX1XVLSdJstA0u00zTbSGw0+0iWC2tbaMJHFGoAVFUDAAAAAHQCrtQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzp8WvjTr/jzxZf/AAq+EMyHxFDiPxF4uZd9n4ajYcqD0lvCM7YgcLwzkAYqp8evjBrvi3xFqfwt+G19Jp+oWNr9p8XeLoE80eHrQoWEUI6PeyqDsX+AfMR0xm/Br4heDvh38O9L0nwf8PvFsPh5VMkd3b2cd01y7HLzSukrM8rHJYkE5yDjAAYG3rHw30b4T/B3Svh54aSSKHUrtLOS4mkL3Fy0jGS5uJn6vI4VyzHqWwMDAFWGBdb+KsWxR9k0e3YqoHAbGxcfTMn5Vj+KPjz4W1L4gabcajLfaJZaTYzSRrq2nzW265kIXGWTHCKec4+birvgDXLOTwv4g8SWl3b6g8m5la3lV921SQuQTyWJAHqaonqenfDO38631nVSOb6+dY2/6ZxYiA+m5HI/3q7Ssvwto/8Awj/hvTNOJ3PbW6Ru395gBuJ9ycn8a1KCgooooAKKK8P+LX7V3h74e6pqOgaFYTeNfFOnxedf2VjcR29npadQ9/eyERWqn0YljxhTkUAe4VDdWcF9A0NxEssTdVYZH19j7jkV8weA/j/8XviJptxr/hXS/hZ480y2b/SNF8M+K5ZL6MHJ2iZoREXx0DBQcHDYOa9n+EXxo0L4x6ZfyadHeaVrOlzC11fQNVi8i+02cjISaPJ4I5VlJVhyCcHABvywaroXz2hbVbIdbeVsTIP9hz94D0PPvWhpWuWmsI5gdhKhxJBICskZ9Cp5H16e9aCnHB6d6p6hosF8yS4Mdwg/d3ER2uv49x7HIPcUAW6KwYvEDabfpp+r7YpJOILoDEU3sf7reoJx6HkCt6gArD8beN9C+HPhfUPEfiXVLfRtEsIzLcXd021VA6ADqWJwAoBJJAAJIFc38Xvjd4a+DOm20mryT3+s6g/kaV4f0yMz6jqc3aOCEcsckZY4VQckgVx/w9+A+vfEzxNZfET42RQz6pbSC40HwNDL52m6AP4JJP4bm7weZCCqnIQDANIDD8N/DnXP2tr6DxT8SdPvNC+FcbCXQ/AdyTFNqgBBS71RQeVOAUticAYL5PB+o7Gxt9Ms4LSzt4rW1gQRRQQIEjjQAAKqgYAA4AAwMVZoqQCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8k/aW+K2pfCv4dJ/wjkMd5428Q3sOg+HLWblHvpyQsjj+5EoeVv9mMjvXrdfOfxUUat+2P8H7G8OLPTvD+u6rZq3R7staW5IH95YppMegc0Adj8FPhDp/wa8B22g2csmoX0kjXmq6tcc3GpX0h3TXMpOSWZsnknAAA4Arivix4bn+D9hqnjzwULa2kUBtQ8P3BZbLUXZgqFQoJimLFRuUYbPIPJPuKsV6V5J8ebo6tq3gjwvFy2oaoL6ZexithvAI9DK0IqwPN9Y8WfF3RdPa/1n4d+FtRtb58C307xKyTEAcAedbhDwM8sBz1Gazrjxr8M9Ym+weMNEm+G3iSxhN3Lb65B9gumhjwd9tdQnbOqsFwEcnjlcZr07x5fLqfiTS9LtCssNlHuYKcgADJB+ioOPevNv2gPFWgeHfG2meI/E9n/btp4J0ibXPs0iCRpb24ZLe1hjUggOztheOCQe2aBaljwp8UPjRfTSyeD/CTeKfCjr/oeoeOLpdJuGHZlMaPI6EcgvEpIIO49+mm+O3xX8Jr9o8V/BKe802MZluvBuuxanKg7kW0iQyNj0XcfQGqn7PPxl8XeNPEninwl8RNN0nRvFulxWmpwW2lM5iksblCRguSWaKVJI3YYUkKQBkZ9zoDUz/ht8TPDnxb8K2/iHwtqK6jpkrtExKsksMqnDxSxsA0cingqwBB7YIJ6dmCqSTgAZJJwMV8iy/FvQP2eP2qPiJpV5aapev4w0nS9b0/Q/D+nS3l1d3im4t5zHFGCASkMRZmKj5QSc11kngXx3+07f8AmfEGwvvh98MI+YvBsV6BqOsk/wAWoSwsRHDjpbxsSxJ3tgAUDF8RfEnxH+0Z4gvvB3wr1STRvB1jKbfxD8Q7cAncDh7PTSQVebGQ0/KxZ4y2MeRfDz4c+H/ixJHFpOlxaZ8EPD+oSf2No4yzeJr6Jysmp3ztlp0EisI1cncV3tkbQPs6LwjYaP4Mfw5oFpbaHp8dm1paW9lEI4rYFCFCKoAABOeK+Tf2bfiJ4c8M/CPR/B+u6lYeGvE/g+1XSNZ0nUbhLeW2mhGwyEMRlJABIsgyrBgQSc4BM6jx78GRfaxaeMPAl3D4L+Immri01a2hAhuo+9reRrgTQtgAg/MpwykEYPEXH7QGi6b42+FXxo18Wvge41C71XwH41jMu6DzbeOWSM7wP3gSe3IjbG7bOV65FXPFfx0ufiFpmqwfDbULSw8OWKN/bXxN1T5dG0mMcObdjgXU4HCqhKAldzc4PiHgGzvvj98RPDulfCu81DwV8PPhLFJPpniDWLBbi61bWLkbzdTQzDDbwxk5AYCQEbTIoUBH6JfDf4z+BPjBazz+DvFeleIxAQJ0sLpXkhJ6B487kJ7bgM12O4xtjtXwx4uvdR8aawLHxP4btvAfx+02wudR8K+OfDrD7FrjWyCR4Gbh9rKMPbzBgFLFScV9dfCfx2nxQ+F3hHxekP2ca5pVtqPk5z5ZliVyue+CSM+1AzpdU0u01izeC7hWaJ+qsO/qD1BHqK8D8U/Ebxre+Obr4SfDBrHUPEtvEtzqPiPUgZbTw5aSf6szIMGa5bBMcORkDcxC8HR+K3xX8SeJfFl18K/hNFFd+NzAj6v4gnw1j4Yt5MhZZf8AnpcMMmOAcnAZsKDn1P4M/Bnw/wDA/wAHpoWhJLPLLIbrUdVvH8281K7bmS4uJDy7seeeAMAAAAVN7aAYXwf/AGb/AA58KdRufENxc3ni/wAe3ybL/wAXa84mvZh1McfAWCEHpFEFUADOcZr1uiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5B+0F8H9X+Ilt4c8R+D9RttH+IPhK7e+0W6vkZrWYSIY57S4C/N5MyYBK/MpVWHIwfX6KAPmWH9o7xpp8P9naz8A/iCnilf3ZttKhtbvTpH7FL3zlQIeuXCkDqueDyfw51Dxz8TPjl4h1Xx3pNh4X/AOEftY9OttF029N2YvMUTOJrgAKZQXhyIxtG0DJIJP1/d3UVjaz3M7iOCFGkkduiqASSfoM18qfCfVJW+HGu+L7gGO98SX1zqeG6qJXJjA9gjRj/AIBjtTV2JnXeB7WLWvE2s3gRVttpgjC8DDcDHvtH614Hf6T/AMNCaL8YU8L6haXXjfw/4h057HT7iQBS2nNHPbpICeEmIdQx4zk5+U17lp+qR+Bvhbq+uTEL5NtNdkk+ikL+oB/GsXwp+x34f8UfDnwVrv8AaOteCPiLHpqyy+JvDVyLa7czsZ3hnVlZJ0DyEbZFOMcEU3oCPBPH/wAavA/iSfR/FNt4ytPhN8XvDYdI7HxUrWrgNgzWN3GwBmgcgfMhOCA6nIIPsfwn/bX8FeNfhbqvjDxRNH4Lg0Wf7Hfz3Uwlsp5gCc2Uyj/SVIGQFG8ZAKgkE9Befsn/ABI1KVEv/wBoXW7m1X5Qf+EX0oXAX0EvknB6chc10ngz9if4ZeGb59U1uzvviH4ieNoTrXjS6OozojAgrGhAiiHJ/wBWinmlcLHD/sywXnxa+JHir463enSaZouuafbaL4Uhu123MmmRM8j3TL/CJpX3Kp52qpPUE/SlfMfwJ8af8M56la/Aj4h3A019PZofBviC7IS11zTtxMMQkOFW5iUiNoyQSFUrkHJ+m6oYteK/tLah8F/h/wCFpPHPxZ0Dw9qEdkvl20mpaZBdXc78lYYQ6lmYnOACAOSSACRsfGD9orwp8IGt9MuJJvEHjC/OzTPCeir9o1K+kPQLGOVXuZHwoAJzkYPyr+0H+z/r/j638A+IfjRMja/418Yad4eXQrGcmy8N6VIZJZLaGQfeuZvJRJLjqdxVMKOUBo/s43+qft3eJW8a+KtAi0L4LeF7hYvDPg5APIvrxMH7RcgALIIgQAgGwMxABKsW0PgX8Q/CngDR/GmkeLPEGmeHPFtp4n1a61u21a7jtpi0l1I8cwDkFkaEwlWGQVAAPGK+xPCPhHRvAfhvTvD/AIe0230jRtPiEFrZWqbY4lHYDuSSSSckkkkkkmqfiH4b+EvF2oQX+u+FtF1q9gA8q51DT4p5Y8dNrspIxk9CKYHxD4k8San4+h1P4mafBLJJqjN4H+FtjOjJ9pubtTHdasVIyECB9rEACOFjgbwa9sbVfEMLaN+z/wDBieG2u/DOk2llr/jK7iEsGgwCJVjVI84mvJFXcqEhVBDNkHFec/F74vXeuftdf8I34O05fEfjDwjo50zw1o6j/R4dVvFDXN9cMOI4La2EKknkmYqoJJx9a/Aj4P2XwR+HttoMV0+q6rPK9/rOsTL++1K/lO6e4c9csxwBk7VCqOBUgXPg/wDB3w98EvCKaF4fimcyStc3+pXrmW81G5bmS4uJTzJIx5JPA4AAAAruqKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeT/tReIpPD/wT1+K2fZfauI9HtsHkvcOIiR7hGdv+A15prdqui+FtA8PWw2COJECAYIwBgH6FiPwrZ/aPvR4l+KXw38Hg77e3kn8QXsfosa+VET9TJMR7rWVJMdY8cBicpbjJ9Mjn/wBCP6VaEyn8Y7Mat4b8L+B4D/yMerWmmOF6i3DBpj9Agcn6V9ULGI1CqAFAwAB0r5s8K2v/AAl37TmlRn57Xwpost6zdQLi4PlID6Ha03/fNfS1SwQUUUUhnN+PPh54Z+KHhy40DxdoVh4i0efl7PUIFlTI6MM/dYdmGCOxFeLL+wv4IswLbSfFXxG0HRhx/Yum+NL+Oz2/3QpkLAdsBhX0bRQB5z8KP2evh58EluD4N8L2ek3d0MXOosXuL257/vbiUtK4zzhmIp/x2+D9l8cvhvqHhe6vptJu2kivNO1a2GZtPvYXEkFwgyMlXUcZGQSMjOa9DooA+UNN/ae1b4QQrovx88O3vhXULYeWPGOl2Ut3oGpAcCVZY1Y27NjJjlVdvODjAE2tftwfD/Vbc6d8Mp5viv4zuV22OheHIJJQznhWnmKiOCIHBZ3YYAJwSMV9U1FFDHCpWONYwSWIUADJ6n607geDfsp/szp8EbHXvE/iKWHV/ih4xum1LxHq0eSiyOxcWsGeRDGWIHdiMngKF9+oopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVj+LfEVv4R8Laxrt2cWumWc15L2+WNC5/QUAfLs3iS38RfHz4i+IJZ1MWnCPQLHcecQjM2PbzHlHvke9a3gdRNNc3kxwJHwzegHzMfyOfwr8uta/bL8f+AvGmr2lharqGnLcNPcW2qWi+ZHdSHfcZaPa4Hms+AzHgA9DivV/hl/wUCuPGtxLo8nhy6h1Ka3lJmsbgbdqxkuzI2MKFBJ+ckjgAnAN6WsLU/RP9lG0fWW8feNJlxJrWtNawt1HkWw2DB9PNab8q9/rgPgL4RfwL8G/CGjzJsuorCOW6U9ftEo82b/yI7V39QMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvnr9ubxBe6f8Br7Q9LsrjUtU8SXcOlQ2dpKI5pUJMswRiRgmKJxnIxu4OcV9C18wfHjVv8AhIfj74b0lTut/DWkTalLjoLi5byowfcRxyH/AIH70wPwm17S9Yj1y9k1nT7v+1TO7XDiVxcmYsd5dXy27Oc5AOc5r6G/YZ+Fr/Ev4v6Ql3DLfWr39vYlrk7JoSW82Y4BJZTbxTA5IA3DgnBH6MeLPgl4A8fat/afiDwppup6hgK1xLFhnA4AcgjcAOBuzgcdKvfs2/Dnw7b/ALRmoXHh7QNO0fTfDWkn5dOtUgX7ROxiQMFAyQsVxgnJw/vRsI+zKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/OeH40a94s+LHxW1rQ/hn4r8ULD4km0eW8tBaxQxpZqsCovmzKxbhnIA48wZOSa/QjXtatfDeh6jq18/lWVhbyXU8n92NFLMfyBr40/ZRW9t/gdour6gmzV/E8tz4lvdx5eS9me4BB4OQsiD8BxTQmYGh/tC+HL3Vk0bWLXVfBviGRSYNJ8TWTWktwQOkLkmOU9gEck+le6fsY6KzeC/Eniub5pvEOsTNHL/AH7e3xboR7F0mb/gVeO/tdbPEXwhk8MHT7TUdZ8T6lZ6BpIvIFkMV3cyqglUkZDRp5jgjkbM8V9hfDnwLp/wx8B6D4T0oyyafo9pHZwyXDbpZAoALuQBlmOWJAGST0oYI6aiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoryzx1+0x8Ofh3q91per6+0l9YoZb+HS7G4vzp8YGS9yYI3EAA5/eFTjkDFejaXqlprmmWmo6fcxX1hdxLPb3Nu4eOWNgCrqw4IIIII9aALtFFFABRVDWNc07w7p8t/quoWumWUYzJc3kywxJ7lmIA/E15Xe/tYfDzzTFod7qPjJ843eF9LuNQgyP+niNDAPxkFAHsdFefeAfjb4b+IWsSaNbC/0jxBHb/bG0fWbRra5MAYKZEBysihiASjMFLAHGRn0GgAooooAw/GnhHT/H3g/XPDGrpJJpWs2M2n3iQyGNzDLGY3CsOQSrHkdK/PT4Gf8AC7m+GtlqPhWXw3468Fi4urbRbTXp3sNUWxhnkhtyZ4ozFJujjVssgPI5PWvuL9onxhJ8P/gL8Q/EcJK3Om6Be3Fvt6mYQt5YHuXKj8a+fNdvo/2dv2b9G07TrT7TqdnY2Og6XYwnDXF9L5dvEo9SZH3E+gY9qaEzF+Bfh74g/tAfFjwH438UeDrXwt4K8IT6lcQsurpejUNRXNpGUUIpCx5uCGIwSAR2z9xV45rXj7wJ+x78ENDHjHXYtL0zSrOO0WQoXmvZwoLmONQWd3YljgYBYkkDmvlr4L/8FYdI+L/7SumeDH8Or4c8EasGsdP1G+lzdveEjyTKAdkaPgoFG4hmUlsZANxn6EUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis3xB4h0zwnot7rGtahb6VpVlE09zeXkojihjAyWZiQAB6mgDSr5z+NnxW8SeMrjUfBPwqjmv7izmEHiPXrC4jhawUg5tbaSQhDdHjccnyVJJBcqtfMnxa/4KKyfFSTWLP4daJ4t1zwfYySRTnwrYTxXl+iA7mlvShFlAwyQYlaUryWi5FdH4N+H/7VXjrRbLTtO/4Q/wDZ18IQrsg0/T7ZdS1FIycnIO6Pcckk5RiSSRkk0wPVvh1+z2lpb6f/AMJJaWNlpVhKLiz8LaZK81qs2d32i7mcBrubd8wLKFDHJDsA47v4N/EDw94H+G+s3PiDxBpegaNa+JdZgtZtSvI7eNY1vpgUBcgYDbwAOgAA4xXz54j/AGbfDOjTRaf8Tv2hfiN4w1uVQ/8Awj2maq0L3I4BKWFqjTMORyMgZySOtdJ8NU+F/wALrlNF8E/DbQ9G1C0B2y+K9dsodRwWLEnfJPcqCxJw6qQSflBNPcD3D/hoceLI2X4ceE9V8aZ4XVLlW0vSc+v2mZN0i/7UEUoqk3hn4seLudf8f2XhK1brp/gvTVaYD+613diTd6ZWGM+mDzVuLxd491GHfpnhrwndjs3/AAlcuMc45Wxb2pZvEXxRjT934G8NSyHP3fFUwXPbJNgDj8KLAeba9+yL53idtbstftvEF2+0iX4gWk+vS2zAAE27tcRiJTjJUKOScEDAHV2PwH1q6Vf7b+IurOBgG10CxttPtseg3JNMB9JQR61haheftCeJvGkmgI3g3wJo5sxd/wBtWlvda1LnftMSmQW8YfGG+ZWGDkA84vt+zn4h8QY/4S340+PNajPDWulzWujQMO4zawpJj/tpn3pgc7dN8Mvgb+0F4enfUBa6rBoF815Ld3U+o6ndefNbi3hRSZJpATDcMEQEL5ecDIz3d7+0B4o15ivhPwDNb254XUfFl4LFT6MlvEssrf7sgiNcrov7Efw88J32o3fhq98VeG5dRcSXbWOv3DPMwGMvJKXcn6sefStiP9knwNKoXVL3xdryAkmPUvFupNG2ezRrOqMPYgj2pWA6b4Y/Gi71jxm3gjxZNo6+KJLKTUbR9JdliuII2RZAYXdnjZDInViHBJBG1gPYq+Xbj4a+CvAP7QHwe0fwR4Y0rQtVjm1PVL9tMtEjkOnrYyQM0zgbmDXFxagFiSSOOhx9RUgPJ/2pfBuq+P8A9n/xroeiW327VLizDw2m8J9o8uRJDECeAXVCozxlhkjrXi/w9gu/2mvjN4U8Tw6RqFl8L/BYOqWt3qVs0A1jVnjMcRiRwGaK3VpG34AMhUDO0mvff2gPFdz4L+DPi3VLFd+pixe2sY84L3UuIoVHuZHQfjXSeA/Cdv4D8EeH/DVo2+20ewgsI2IwWWKNUBPucZ/GgDT1KC0nsZkvooZbPYTKs6hk2gc5BGCMZ61+cX7LH7HPwz/au8JePPih4q0GWwfxF4uvp/Dtxo072LWNjE4WPy1TCZ3hwcqRlAR1NfWP7cvxKb4U/sq/ELWYJDHf3GnnTLPafm865IgUr7r5hb/gJrrP2afhqvwf+AfgPwf5Yin0vSYEuVHT7Qy75j+MrufxpAd7o9jJpek2VlNeXGoyW0CQteXW0zTlVAMj7QF3NjJwAMk4AHFX6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5f4kfETQfhL4E1vxh4nvRp+haRbtc3M5GTgcBVHVmYkKoHJJAHWgDz39o/9qzwb+zXplgutzrqPiXVpFh0nw7b3EUdxduTtDM0jBYogfvSuQoxxk8H5z8S/ESw/abvLa18VaRffEyy0+Rbn/hAvhzIL3RoJhyn9o6o7xQXMq9RErqikElX4auZ+Bv7Kcf7WHj7xB8fvjjokt3beIZg/hjwrfSOotNPU4gaZVIBygGEPByzEEsMfduh6DpnhfSbXS9H0+10rTLZRHBZ2UKwwxqOgVFAAHsBTA8F0vVvjVdaOmi+HPgv4M8DeH44vJhs/EGvq6pH02/Z7OB0AwT8ocj3rC+IFj4p8NaBP4h+OnxmXw/oDOIovDfgC3fTzdSHhYUuCWu5nboFiKE9emSO28eftF3Fz4nvfA3wq0P/AIT3xzbER3spkMWkaKx6G9uRkBh18mMNIcEEL1qz8Mf2dI9D8Tp478f6y/j/AOI7IVTVLqMJaaYp6xWFvkrAo6FuXbkluSKoDzv4W/AXUfGGmyOdDk+Dfw/vT5p8OaTIYtf1lT0fVL4EyJuHJhRy+CQ0nBWvbdO+APwz0rQ4tGtvh/4aTTIzkWz6VBIpPdm3ISzHuxJJPJJNd9RQB5XqH7Knwb1J/Ml+F3hKObp51to8EEmOuN8ahse2ar/8Ml/CPPHgixX0VZJQPyD4r1yigDx+T9kr4Wf8u/hy4045yG03V720bPrmKZeeKjH7Ot7oUnmeEvin478Pbfu215qa6zb/AEK3ySvj2Vx7EV7JVC712wsdWsNMmuAt/fiRra3ClmdYwC7cA4VdygscDLKM5YAgHhXgk/tMWGlSvrjeA9cube7ng+z3UVxp73EKSMIpkmhedR5iBW2tEpUkgjjJ5/4rftfeO/g3Jplt4g+BuqPc6lOLa1vbHW4JtOkkIJCGcJvVyRhVaIFycKCeD9SVwPxi8efDrwl4Xns/iPqej2+kaihgOn6oFlN4D1RIMFpT04VSc44oA+X/AIG/Fb4t3vjbxF4kn8E+E9Z8fa2FgNnqXi9tPn0+wiZmhtYrNrQyogLszM2S7sSTgAL7qnj79pCbJ/4Vz8PrbH8Mniu6cn8rIYxXzd4p0fxPr9v9m+DXgfxx4j0LIaPS/iFpkC6Nt7GGS9mivYxjpjcFGMKAMV6p8KvEX7SngvwVYaNrHwp0PW5bVpAl1ceNwswhMjNHESbeQsY0KpuZyWCgkkkkzYCP4oeJvj14s8Q+CvDGoeE/AUN3LqkeuQWtvrt46SLYkSnznNqCiCUw4KqxLFQQBk16EfHn7SEalv8AhXvw8nx/Anim7Un8TZVwNv8AEj4j6D8Xrrxl47+C/iO10mLRo9JsD4XurXWvs5adpbqR0jkWYhwlsAFiJAjORzXt3w3+NXgr4srcL4Y12G9vbXi602ZGt721PTEtvKFkj54+ZQCehNFgPJ/iBJ8Xviho9vpPjL4DeC/EenW13FfxQDxvKqrPESUcA2anIJPBJByQQRXUj44fG+33faP2fVnA/isPGtkxP0EiR/qRXs9FFgPGR+034508D+2P2efHcHPP9m3ul3wH/fN0Cfypy/tlaVaH/ib/AAv+KuiqD80k3hCe4jX6tbmQYr2SiiwHkEP7d3wR3Kl/4yk0CQ8FNe0i907aenJnhQD88V3vhf8AaE+F3jYoNA+I3hTWJG6R2WtW8r/QqHJB9iK35YknRkkVZEIxtYAjH0NcN4m+Anw08ab/AO3fh/4Z1Z3+9Jd6RA78/wC0Uz+OaLAesxyJMgdGDowyGU5B/Gn180N+xR8LLF2l8N2Gs+B7k5In8K6/e6dtJ7hI5Qn4FSPanr8C/ib4X58I/H3xMkY5Fr4u0601qM+xcpFLjoM7yfc0WYH0pRXzgnjL9pHwZzqPhHwN8SLReN+g6nPo14R3JiuFljJ9hKB9Knj/AG0vD/h1hH8RfBfjX4ZOvyyXWs6O11YBva7tDNHj3Yr68DmkB9EUVyvgP4peD/ihp/27wj4o0jxLaYBMml3sdwFz2YKSVPscV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8jeLJI/2xPjVc+GZLcz/B/wCHeog6m7cxa/rcfS2I/igticuDwzkAggZrt/j98UdZ8QeJYvgz8OtQWz8cataNcarraKXXw5pp+U3BAI/fvnbEmQckscBRnuPhf8NdD+EPgPR/CPhy3NvpWmQiKPedzyMSS8kjfxO7FmYnqWJ46U0B1CqI1AACqowABgACvn/xd408T/tAaxdeDvhpfzaH4St5Wt9f8fwgZ4JD2mmE8STZBVpxlIuQCzjA9i8Y+EY/G2nppt7e3MGkSE/bLW1cxtdrxiJpAQyoedwUgsMAnaWVtbTNLs9F062sNPtYbCwto1igtraMRxRIowFVQAAAAAAAABVAYvw8+HPh74VeE7Lw34X0yHStJtAQsUYJZ2PLSOxyzuxyWZiSSSSTXSUUUAFFFcN4q8SajresyeFPCs6wakoVtT1baHTSomGQADkNcOOUQghQd7AjasgBc1L4n6NpurXmnJFquo3Nmypc/wBl6Tc3aQOyhgjvFGyhtrKxXOQGUkAEZq/8LIv7r/kG+BvE1+D0kkit7RfxE80bAfRSfauj8M+GdP8ACOiwaZpkTRW0ZZi0jl5JJGJZ5JHJJZ2YlmYkkkkkkmtSgDhLi4+IuuW8sVvZaD4WEikJdzXUmozJkEAmERxICOD/AKxhkcgjrgeGfhj478L391qj+MdE8Qa3dKsc+o6poUoneNSSsSmO7CRICScRoASSSCSSfWqjuI3mt5I0kMTshUSKASpIwCM8ZHXmgDyFfEnxL8darqPh7TbbRvDdjaMIbrxfZ3T3vzjIkitreWFFMynALM0kaEkEOysg6bwL8EPCHgDUJdWs9OOo+JLgf6T4i1eQ3epTnvunfLBfRE2oOgUDArtNP0+30mxgs7SIQW0KhI416AD3PJPck8k5J5qxQAUUUUAFcT8QPg74W+JMltd6rYGDW7Pmx13T3NtqNm3YxXCYYD1Ukqw4ZSCQe2ooA888J654i8JapB4a8Z3CaoJjs0vxNFEIlvSBkRXEY+WO4ABIK4SQAlQpBQeh1V1TS7bWbCWzvIhNbygBlJIOQQQQRyCCAQQQQQCCCAamt43ht443kaZ1UKZGABYgYyQOMnqcADPYUASUUUUAFFFFABRRRQAUjAMCCMgjBBFLRQB5P44/ZW+F3j3UP7UvfCdrpmuglk1vQmfTb9G/vCeAo5I/2iR6g1gR/Df41fDD5/AvxOj8b6XH93QfiNb+dJjuF1GALKD2BkST3zXu9FAHitj+2DaeEbiKw+MHg7WPhTdMwjGq3WL/AESRug238IKpn0mWMjvXveja1p/iLS7fUdJvrbU9PuFEkN3ZzLLFIp6FXUkEfQ1k3VrDe28lvcRRzwSqUkhkUMrKRggg8EEdQa8O1T9le08L6lca78H/ABFefCbXZXMs1rpiCbRb1u/n6e58vnkbovLYZyDmpsB9LUV84aT+1Hqvw31C30T46+HovBcs0ggtvGOmO9x4evHJwA0pG+0Y9lmAHBw5r6ItbiK8t4riCVJoJVDpJGwZXUjIII4IIwQRSAnooooAKKKKACiiigAooooAKKKKACiiigAooooAK81/aC+LD/B34ZX2t2VmNU1+5lh0zRNMzj7ZqFw4jt4vpuO5j2VWPavSq+fP2rFS38TfAa9nUy2kPxBt4nhxkb5bC9SJyP8AZcqfxoA3fgb8IYvhL4VlS8uzrPi3WJjqPiLX5R++1G9YfOxPUIv3UQYCooAHUn0aiirAKKKKACq9/qFtpVlPeXtzDZ2cCGSW4uJAiRqBkszEgAAckkgCrFefeObo+NNctfBmnJ5ogubTUNZuyMx2kMcqzxxZ6GWUxgBRyqFnJHyBwBs3izWviCgtvB8E+maVLxJ4ovoNq7O5tIX+aVj/AAyOoiAIYGUDaet8L+F9P8H6SmnabE0cIZpJJJHLyzSMcvJI5JLuxJJYkkk1rUUAFFFFABRRRQAUUyaaO3heWV1iiRSzO5AVQBkkk8AAdzXEr8WrLVSf+EY0fVvGEYODdaTFGtqfdLid44pBng+WzY7igDuaK4lde8f3PzweENGt4j0TUPEDpN+Kx2sij8HNRSfEu58Nso8Y6DN4etyQDq1vOLzTVJ6B5gFeIerSxIg4G7JAoA7uimq4kUOhDIwBDKcg56EGnUAFFV7rULaxaBJ50heeQRRKxw0jEE4UdScAkgdACTwCasUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdS0yz1rT7ix1C0hvrK5jMU9tcxiSKRCMFWUgggjgggg14DJ8KfGf7N1xLrHwZLa54P3GW9+GepXJEKgklm0uZiTbv1PksTExJxtOK+iKKAMH4QfGnwx8bvDkmq+HLqUTWspttR0q+jMF9ptwPvQXEJ+aNwQevB6gkc131cn4f8ABeg6d4r1XxLa6PZ2/iDUYIra81KOELPPHGWKK7AZIG44z7DsK6yoAKKKKACiiigAooooAKKKKACiiigAooooAK8A/a9It7D4TX8o/wBGs/iJo7zMeihzLCp/77lT869/rwH9uy1ll/ZX8b6hbj/StFW11uBx1R7S6huMj8Ij+BoA9eoqCyukvrOC5iOY5o1kU+xAI/Q1PVgFFFFABXEfDJVjuvGkUg/09PEFwbpz1bdFE8JP0geBR7KB2rt68zh8WaX4B8eeL/7fnk0ex1O5trqDULyCRLNiLaOJs3BXy1OYlG1mBz2wQSAemUVFa3UN7bxz28sc8EihkkjcMrA9CCOCD6ipaACiiigArm/F3jq18LyW1lHbzavrt6CbPSLIAzzAYy5JIWONSRukchQSBkkgGr408Zz6VeW2haFbx6l4qvkLwW0hIitogcG5uCOViU8ADl2wq85K2vBvgm38Jx3NxLcSarrt8VbUNWuQPOuWGcAAcJGuSFjXCqCcAksSAYtv8PLvxZPHf+O54dUKsJIPD9sSdNtiDkFwQDcuDj55AFBAKxock96qhVAAAAGAAMDFLVWz1Sz1GS7jtLuG5ktJTb3CxSBjDIFVtjgH5W2upwcHDA9CKALVYfi7xfofg3S/tOvX0NpbSnykjkBd52IP7uOMAtIxGcKoJPYGsP4l+Ob7wy2maTolvBca/qvmtA13kwW0MQXzJ5ACCwUyRqEBBZpFGVAZh4x4k8VeFPhZdHWfFmutqfii7XYtxcATX0wJAEdvCo/dxbsAKgVc4LEsSxBGXH8dPGXw68fad4M8H/C6fW9A8RefP4et9V1qHTWtGij8yeAKUkKQkYeNGwygsoUKqqvpFmvx98YMovT4K+HFg/3jZtPrl8o9FLCCFW9ysgH901yvw78LeM/id8VPC/jfW/D0ng3wv4eju5LG01GQHUL6WaMRBpIwMQqqknBJYkDqDkfStAzk/Bvw4svCMz3s9/qHiHXZU2Ta1rMwluGBOSqBQscKEgEpEiKSASCea6yiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAvaV96T8P61pVm6V96T8P61pVLAKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFecftIaP8A8JD+z38TdM272uvDOpRKv+0bWTH64r0eqWtWUWpaPfWlwN1vcQSRSKe6spB/QmgDzT4F65/wkvwS+H+r795vvD+n3JY9ctbxsc++Sa7ivF/2L/M/4ZV+GCSuZDHokMas3UooKp/46BXtFWAUUUUAFIyhlIIBBGCCMjFLRQBxN38IfDwuJLvRoZ/CeouSzXfh+T7IXY/xSRgGKY/9dUYe1U5vE3iH4drv8VGHW/DqnDeILKLyprRem66gBI2D+KaIgDJLRooLD0KkIDAhhkEYINAGJJ488NQ2f2t/EOlJagZM7XsQTHru3Y/WucuvicfEoNn4Dtl8R3TnadWORpVsP77zjiYjn93CWYkAMYwSw6WPwT4dhvftiaBpaXnX7QtlGH/76xn9a2hwMDgdABQBzvg3wbD4Tt7mSS5k1TWL5xNqGqXAAluZAMDgcKijhUHCjgZJJPRUUUAYl74iltPGWkaINPllgvrK7umvlPyQtC9uqxkY5LidiDkYER4OeOXtdC1Xwx8Z7/UbHSpLvw94ns4TfXUM0aizvrdXVZZEZgzCWExx7kDEGBAQAdw9BkkSONndgiKCWZjgADkknsBXntvrGv8AxQXzdCvG8OeE2/1esLGr3uoL/et1cFIojxiR1ZnBJVVG12AMj4xaVH4/1rS/DWh3Mtt4rtw08mqWshUaTaSDa7S4+95pACREgsybwQIiw0fhn+z74O+F05v7Cyk1PX5OZ9d1aT7TeyMRgtvIwpI4O0DIAznrXZeF/Cel+DtONnpVt5CPIZZpZJGlmnkOMySSMS0jnAyzEkgAZwABsUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAXtK+9J+H9a0qzdK+9J+H9a0qlgFFFFIAooooAKKKKACiiigAooooAKKKKACs7xFMbbw/qcq8mO1lYD6ITWjVLWLb7bpN9b4z50EkePqpH9aAPDP2PbU2f7K/wnjc5Y+G7GQkerQq39a9grxn9jPUDqX7K3wudyC8OhW9qxHrEvlH9UNezVYBRRRQAUUUUAFFFFABRRRQAU1mCKWYgKASWbgYHc1X1TVLPQ9NutQ1G6hsrC1jMs9zcOESNAMlmY4AAAySa4FdOv/jAwn1a3n0vwRnMWk3CmOfVh2e6U4McB6iA4ZxjzAATGQCO6uH+NUn2K0DJ4ARsXd70/trB/wBRF62xPDydJANq5Usx9KVQihVACgYCgcY9BRHGkMaIiBI1AVVUYAA4AA7AelOoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAL2lfek/D+taVZulfek/D+taVSwCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABSUtZfifUF0nw3q165wttaSzH6KhP9KAPn/9iAo37L/gwxf6rdfeXn+59uuNv6Y6cV7pXi/7GFi2n/so/CqN12vJoFtOwwBzIokJ49S5PvmvaKsAooooAKKKKACiiigAqrqmq2eh6bd6jqFzFZ2FrE089xOwWONFBLMxPAAAJJq1Xnl1GPiV43ezf954X8Nzq1wv8F7qQwyIezJACrEcgyso4MRBAE0bRbv4k6lbeIvENtJbaJBIs2jaBcIVOQQUu7pD1lJAMcbDEQwSPM+56JRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAF7SvvSfh/WtKs3SvvSfh/WtKpYBRRRSAKKKKACiiigAooooAKKKKACiiigAryX9rDxV/whf7M/xQ1gPslg8O3qQt3814Wjjx77mXFetV82/tmTL40tPh98I4SJLnxx4ht2vYe40uyZbu7c+gPlwx88EygUAelfCvw2vg74Y+ENAQbV0vSLSyAA/55won/stdRSUtWAUUUUAFFFFABRRXO+LvHFn4TW2gMU2p6xellsdJswGuLkjGSASAiLkbpGIRQRkjIBAKfxC8T3mlW9po2hmN/FGsM0Fgsi7lgUAeZdSDvHEpBIJAZjGmQXBrY8LeG7Pwh4fs9IsPMNvbLgyStullcks8kjfxO7FmZjyWYk8msfwT4TvNPuLzX9flhufE+pKqzm3JMNpCpJS1hJAOxSSSxALsWYgAqq9dQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBe0r70n4f1rSrN0r70n4f1rSqWAUUUUgCiiigAooooAKKKKACiiigAooooASvlz4NSJ8Zvj98QPi6XW60LTh/whvhaReUaCB919cIehElz8gYdVg7giuo/au8Varc6V4d+F3he+fT/FHxAvG083kB/e6fpka77+7X0ZYv3anj55kwcivQ/B3hDSPAHhXS/DmgWUenaNplutra2sQwqIowB6knqSckkkkkkmmgNmiiiqAKKKKACiiuM8da9qEt9Y+FvD8/2bXNTVpZb4IG/s60UgSXGCCC5JCRqwILtkhlRhQA/xT48ez1I+H/Dtomt+KWQMbYsVgskbOJbqQA+WpwcKAXfBCqQGZbXg7wPF4Za5v7u5bV/EN8Ab7Vp1AeXGSsaLkiOFcnbGpwMkkszMzXvC/hPTPBuliw0u38mLcZJZHYvLPIcbpJJGJaR2xksxJPc1sUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAF7SvvSfh/WtKs3SvvSfh/WtKpYBRRRSAKKKKACiiigAooooAKKKKACiiigD5XuGaf/go3dLITItv8MYzCGORGX1I79vpnaucdcD0r6IooqkAUUUUwCiiigArgPBv7z4o/EiVvmkjmsIEc8lYxbBwgPZQ0jtjpl2PUmiigDv6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC9pX3pPw/rWlRRUsAooopAFFFFABRRRQAUUUUAf/9k=" /></p><p><strong>To avoid bruising, do not rub the injection site after you have injected yourself.</strong></p><p>&nbsp;</p><p><strong>9)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drop the used syringe with its protective sleeve into the sharps bin. Close the container lid tightly and place the container out of reach of children.</p><p><strong>&nbsp;</strong></p><p><strong>When the container is full, give it to your doctor or home care nurse for disposal. Do not put it in the household rubbish.</strong></p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Techdow Europe AB 
Kåbovägen 32
75236 Uppsala 
Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>